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Abstract 
Abdominal aortic aneurysms (AAA) are dilatations of the abdominal aorta that are 
prone to rupture with fatal consequences. AAAs (diameter >3cm) are present in 
~4% of men aged >65years.  
AAA formation is initiated with the loss of medial elastin. Responses to this include 
synthesis of tropoelastin and deposition of collagen. Dilatation occurs following 
degradation of this collagen, secondary to release and activation of matrix 
metalloproteinases (MMPs) by invading macrophages. Elastin is strengthened and 
protected from proteolysis by cross-linking. 
Transglutaminases (TGs) introduce cross-links between protein chains and have 
been implicated in arterial repair; TG2 has been shown to be induced early in 
experimental aneurysm development. The literature suggests that TG2 and the 
homologous enzyme FXIII-A may act cooperatively or may compensate for each 
other in the face of deficiency. 
We have bred TG2-/-, FXIII-A-/- and TG2-/-.FXIII-A-/- double knockout (DKO) mice to 
characterise their basal vessel structure and function and investigate their 
susceptibility to aneurysm formation.  
This work has shown that both FXIII-A and TG2 are involved in the maintenance of 
basal vessel integrity and that aortic permeability is increased in mice lacking FXIII-
A. In the absence of the repair function of TG2, the DKO mice develop extensive 
cardiovascular fibrosis and exhibit decreased vessel tension.  
We have not seen evidence of a clear protective effect of TG2, however our DKO 
animals showed an (unexpected) decreased propensity to aneurysm formation. In 
an extended model there is evidence that aneurysm initiation and progression occur 
by different mechanisms and that TG2 plays a role in prevention of the latter. This 
thesis has also shown that TG2 and/or FXIII-A are not essential for vascular 
calcification.  
The results presented here help to define the common and distinct functions of 
FXIII-A and TG2 in arterial structure and function, and provide evidence in their 
evaluation as potential therapeutic targets. 
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Chapter 1: General Introduction 
This chapter discusses normal aortic physiology and elastogenesis and the 
pathology of aneurysmal disease. The various animal models of aneurysms are 
introduced and compared and an introduction is given to the key enzyme families 
related to this thesis; the transglutaminases (TGs) and the matrix 
metalloproteinases (MMPs).  
The primary focus of this work pertains to the vascular biology and development of 
abdominal aortic aneurysms (AAA), which are discussed in detail in section 1.3. 
However, in summary, a AAA is a focal dilatation of the abdominal aorta to 1.5 
times the normal diameter, or approximately 3.0 cm. The UK prevalence of AAA is 
~4% in men and ~1% in women over the age of 65 (England, 2013) and the natural 
history of AAAs is to expand and eventually rupture. AAA rupture accounts for 
~6000 deaths per year (Earnshaw et al., 2004) in the UK and mortality rates 
approach 90% if rupture occurs out of hospital and remain high (~41%) (Bown et 
al., 2002) even if the patient is transferred into a tertiary Vascular Surgery centre 
and intervention is undertaken.  
Current guidelines recommend aneurysm screening, and all men in the UK are 
invited for a “one-off” abdominal ultrasound scan when they reach 65 years of age. 
Detection of aortic dilatation (diameter >3.0cm) by ultrasound (or by imaging for 
another reason) prompts regular surveillance and/or review by a Vascular Surgeon 
with the ultimate aim of repair at a threshold diameter of 5.5cm,(Moll et al., 2011) or 
when risk of intervention is balanced by risk of rupture. Repair is either by surgical 
replacement of the aneurysmal segment of vessel (using a prosthetic graft) or by 
endovascular insertion of a stent-graft, usually via a femoral approach. Both of 
these options have considerable potential complications and side effects, and 
patients with AAA have increased cardiovascular risk when compared with the 
normal population. It is obvious therefore, that medical treatments to prevent AAA 
development and/or slow progression would be of great therapeutic benefit to this 
high-risk patient population and are, at present, woefully lacking. This thesis will 
investigate the role of two transglutaminases (transglutaminase 2 (TG2) and 
(F)actor XIII-A) in the development of AAA and will discuss novel insights into AAA 
pathophysiology as well as directions for future research. 
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1.1 Aorta structure and function 
1.1.1 Layers of the aortic wall 
The human aorta is an elastic artery, with a large lumen relative to wall thickness, 
which acts as a conduit of blood from the heart to the muscular arteries. Its 
structure consists of three distinct layers (tunica adventitia, media and intima) with 
two elastic lamina (internal (IEL) and external (EEL)) which are differentially present 
and delineate the media from the intima and adventitia respectively (see Figure 1). 
The tunica adventitia, or outermost layer, is composed of loose, irregularly 
organised connective tissue (collagen and elastin) with scattered fibroblasts and 
smooth muscle cells (SMCs). The adventitia is the location of the vasa vasorum; 
the network of small blood vessels that supply the aorta itself. This network is 
notably absent in the abdominal portion of the aorta which is comparatively thinner 
than the thoracic component and is reliant on the diffusion of nutrients for its 
metabolic needs.  
In contrast to the irregularly organised adventitia, the aortic tunica media (0.5-2mm 
thick) contains abundant elastic fibres arranged into distinct fenestrated concentric 
lamellae interspersed with contractile SMCs; the so-called “lamellar unit”. In new 
born humans the aorta contains approximately 25 lamellar units, with this number 
rapidly increasing to 50-75 units as elastin is synthesised in response to changes in 
haemodynamic stress. This elastin structure, which comprises up to 50% of the dry 
weight of the aorta,(Rosenbloom et al., 1993) is complemented by an extracellular 
matrix (ECM) containing large amounts of collagen I and II as well as proteoglycans 
which impart strength and stiffness to the vessel. Indeed, these collagen fibres have 
been shown to be the main ECM component imparting tensile strength to the aortic 
wall.(Wagenseil and Mecham, 2009)  
The tunica intima is separated from the media by the IEL and comprises an 
endothelial-cell lined luminal surface supported by a deeper connective tissue layer. 
The integrity of the luminal endothelial layer is particularly important to prevent the 
initiation of thrombus formation and atherosclerosis development but endothelial 
cells are also capable of synthesising elastin to contribute to the formation of the 
IEL. The sub-endothelial layer upon which the endothelium is situated is a 
supportive medium made up of collagen, elastin and an amorphous gelatinous 
structure known as “ground substance” which retains water and within which 
occasional fibroblasts and SMCs can be found.  
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Figure 1. Structure of the aorta 
Figure depicting the anatomy and structure of the aorta, highlighting the three 
distinct layers of the vessel wall; intima, media and adventitia. See text for further 
detail. 
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1.1.2 Elastin and the elastic fibre  
Elastin is the ECM protein responsible for the elasticity of connective tissues 
including blood vessels, skin, lung and ligaments. In arteries, elastin allows vessels 
to stretch and absorb the force generated by ventricular contraction in systole. This 
stored haemodynamic energy is released during diastole such that a relatively high 
diastolic blood pressure is maintained and end-organ blood flow is more constant 
and less pulsatile in nature.  
The elastin (ELN) gene is a single copy gene of 36 exons localised to chromosome 
7 in humans (chromosome 5 in mice), the product of which is the 70kDa soluble 
protein tropoelastin which has a highly conserved structure of hydrophobic domains 
alternating with lysine cross-linking motifs.(Wagenseil and Mecham, 2009) Various 
isoforms of tropoelastin are generated as a result of alternative splicing of the 
primary transcript and gene expression is controlled by factors including insulin-like 
growth factor-1 (IGF-1) and transforming growth factor-β (TGF-β). 
Occurring in the last third of foetal gestation in fibroblasts and SMCs, the process of 
elastin fibre formation, or elastogenesis (see Figure 2), is complex and begins with 
the binding of tropoelastin to a galactolectin chaperone protein called elastin 
binding protein (EBP) which prevents intracellular aggregation. Tropoelastin is then 
localised to the cell surface and is cross-linked following deamination and oxidation 
of its lysyl residues to allysine by lysyl-oxidase (Lox). This process is copper-
dependent and mice with abnormal copper metabolism (Brophy et al., 1988) (the so 
called “blotchy” mouse) or Lox-deficiency (Maki et al., 2002) are unable to cross-link 
elastin and collagen and demonstrate a propensity to AAA development and 
tortuous aortas with thickened vessel walls. Histologically the aortas of these mice 
show fragmentation of the elastin fibres as expected, however they are limited in 
their usefulness because of systemic pathologies (including emphysema) and 
vessel rupture which occurs before, or soon after, birth. 
The next stage of elastic fibre development requires the orientated immobilisation of 
tropoelastin onto a microfibril structure to facilitate the covalent cross-linking of 
tropoelastin to form the functional insoluble polymer. The highly cross-linked 
structure of elastin (15-20 cross-links per “unit”) results in its unique elastic recoil 
function and relative stability over the adult life span.(Wagenseil and Mecham, 
2009)  A number of proteins have been identified as components of this stabilising 
scaffold in arterial walls, including fibrillin-1 and microfibril-associated glycoprotein-1 
(MAGP-1), both of which are substrates for TG2. TG2 also cross links tropoelastin 
to protease-inhibitors such as elafin (an elastase specific inhibitor, absent in mice), 
thus helping to protect the ECM from degradation.  
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Human AAA tissue has been shown to contain greater amounts of tropoelastin than 
normal arteries, (Minion et al., 1994) however these novel elastin fibres are 
disorganised with frequent discontinuities and reduced cross-linking.This so called 
“maturation arrest” of elastin may therefore be a key trigger in aneurysm formation. 
It is reasonable to suppose that TG2 may be up-regulated in an attempt to restore 
normal elastin structure and Munezane et al (Munezane et al., 2010) have shown 
increased mRNA expression of TG2 in experimental aneurysm formation in rats, 
possibly in response to increased tumour necrosis factor-α (TNF-α) activity. Our 
previous work has shown that TG2 is present in striated deposits in human 
aneurysmal tissue, interspersed between cellular tissue (Figure 3), and this project 
aims to help delineate the role of TG2 in 1) normal aortic elastin formation and 2) 
the structural and functional response to aneurysm induction. 
Within the arterial wall, each layer of insoluble elastin is non-covalently associated 
with orientated collagen fibres and circumferentially arranged SMCs which together 
make up the lamellar unit. The importance of the lamellar unit structure was first 
recognised in 1967 (Wolinsky and Glagov, 1967) and the number of units found at a 
given anatomical site is directly proportional to the wall tension experienced at that 
site.(Clark and Glagov, 1985) Of note, there is a lower density of lamellar units 
found in the infra-renal segment (~25 units) of the human abdominal aorta when 
compared with the thoracic (55-60 units) and supra-renal regions,(Halloran et al., 
1995) perhaps contributing to the significant predisposition of this site to 
aneurysmal dilatation. 
Remodelling and fragmentation of elastin fibres occurs with increasing age,(Tsamis 
et al., 2013)  and in certain disease states, and eventually leads to arterial stiffening 
because of a compensatory increase in collagen production. Elastin fibre assembly 
is essentially “turned off” in adult animals and hence collagen (which is >100 times 
stiffer than elastin) is produced instead to reinforce the arterial wall, which ultimately 
results in vessel stiffening.(Wagenseil and Mecham, 2012) This can be measured in 
vivo as an increase in pulse wave velocity (PWV) and is an independent predictor 
of cardiovascular risk and mortality.(Blacher et al., 1999) Calcification of elastin 
fibres (which occurs with increasing age and in atherosclerosis) and elastin cross-
linking by advanced glycation end products (AGEs) (found with increasing age and 
in excess in Diabetes Mellitus) can also lead to arterial stiffening.(Aronson, 2003) 
Elastin-derived peptides (EDPs) (including those released within human 
aneurysmal tissue) have important chemotactic roles and have been shown to be 
involved in the recruitment of endothelial and smooth muscle cells and inflammatory 
monocyte/macrophages.(Hance et al., 2002) These degradation products promote 
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proliferation of arterial SMCs via a complex tyrosine kinase-cytokine signalling 
cascade triggered by binding to the cell-surface elastin receptor,(Mochizuki et al., 
2002) whilst in isolated SMC preparations proliferation is inhibited by the presence 
of soluble tropoelastin.(Karnik et al., 2003) Elastin is also required to maintain SMC 
quiescence and orientation (Li et al., 1998a) and eln-null mice die in utero or shortly 
after birth due to aortic obstruction secondary to excess SMC proliferation. These 
cells exhibit an abnormal  longitudinal, rather than circumferential orientation, yet 
the mice show no evidence of endothelial damage, inflammation, ECM disruption, 
or haemodynamic stress, suggesting that it is the absence of elastin itself that 
results in this fatal phenotype.  
The importance of elastin is further emphasised by study of the heterozygous eln+/- 
mice (Li et al., 1998b) which are viable with normal life expectancy, but have altered 
vessel morphology. These mice have approximately half the normal amount of 
elastin and as such their vessels show reduced compliance (i.e. are “stiffer”) with 
thinner elastic lamellae and a greater number of individual lamellar units. In order to 
maintain cardiac output in the face of increased vascular resistance these mice are 
hypertensive (Faury et al., 2003) and show varying degrees of cardiac hypertrophy 
and/or fatigue. The autosomal dominant condition Supravalvular Aortic Stenosis 
(SAS) is due to loss-of-function mutations in the elastin gene, elastin 
haploinsufficiency and decreased total elastin levels. Like the eln+/- mice, these 
patients are hypertensive with decreased aortic compliance and mortality from 
cardiac failure and, as in the mouse models, they reinforce the direct relationship 
between elastin quantity and phenotype severity.(Wagenseil and Mecham, 2012)  
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Figure 2. Elastogenesis 
Schematic diagram outlining the main steps in the process of elastogenesis 
as described in detail in section 1.1.2 (adapted from Mithieux et al.)(Mithieux 
and Weiss, 2005). EBP = Elastin binding protein 
 
 
Figure 3. TG2 localisation in AAA tissue 
Histological sections from human aneurysmal tissue. The DAB reaction 
product (brown) shows localisation of TG2 in striations (a) and capillaries (b) 
within the sample. 
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1.1.3 The microfibril 
Microfibrils are small (10-15nm) fibrillin-rich filaments which appear in developing 
embryonic tissues prior to tropoelastin and form a stabilising scaffold onto which 
tropoelastin is localised to enable polymerisation and elastic fibre formation. Long 
thought to be structural molecules only, microfibrils are now recognised as having a 
number of diverse facilitative roles in growth factor signalling and cell-matrix 
interactions (particularly through their interaction with members of the TGF-β family) 
and Mecham et al have recently proposed the idea of the “microfibrillar niche” within 
which cellular phenotype and behaviour can be altered.(Mecham and Gibson, 
2015) 
Fibrillins are the primary component of microfibrils and consist of three (two in the 
mouse) ancient homologous glycoproteins with epidermal growth factor (EGF)-like 
domains interspersed with 8-cysteine domains. Aside from their role in elastin fibre 
assembly, fibrillins regulate the availability and activation of latent TGF-β (Kaartinen 
and Warburton, 2003) and other growth factors which (via Smad signalling) are 
involved in a host of cellular and developmental processes.(Ramirez et al., 2007) 
The signalling pathways of TGF-β are summarised in Figure 4 but essentially TGF-
β is held in a latent form through binding to a latency associated peptide (LAP). 
Upon release, active TGF-β is able to bind its receptor, leading to receptor 
heterodimer formation, phosphorylation and downstream signalling through 
numerous “cross-talking” pathways. TGF-β availability is tightly regulated by 
components of the ECM and TGF-β signalling has been shown to inhibit the 
development of AAA and has been proposed as a potential therapeutic target (see 
(Wang et al., 2013b) for a review). 
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Figure 4. TGF-β Signalling 
The TGF-β family of growth factors consist of three TGF-β isoforms, at least 4 TGF-β activins, at least 10 bone-morphogenic proteins 
(BMPs) and several growth factors. The TGF-β isoforms are held in an inactive state by a “latency associated peptide” (LAP) and, when 
released, bind to the TGF-β-receptor II (TβRII) and cause heterodimerisation with TβRI and phosphorylation. Downstream signalling is 
effected via a number of pathways including Smad signalling (with receptor-specific Smad (R-Smad) recruiting a common-mediator Smad 
(Co-Smad) before translocation of these complex to the nucleus where it mediates gene transcription), the PI3/Akt pathway, the RAS/Erk 
pathway, the Rho pathway and via TGF-β activated kinase-1 (TAK-1) signalling through mitogen activated kinases (MAPK).  Through these 
various pathways (and their extensive crosstalk), TGF-β is able to influence cell survival, growth, migration and proliferation as well as 
multiple other cellular processes. TGF-β signalling has been shown to be downregulated in human AAA samples and TGF-β can inhibit AAA 
development and/or progression in various mouse models. See section 1.3.3 and Wang et al (Wang et al., 2013b) for further detail. 
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Due to its early and predominant expression in the developing mouse aorta it would 
seem that fibrillin-1 is the major player in elastic artery development and certainly 
Fbn1-/- mice die within a fortnight of birth from aortic aneurysms and complete 
diaphragmatic failure leading to impaired ventilation. In fibrillin-2 deficiency there is 
an absence of arterial pathology however Fbn1+/-.Fbn2 -/- results in a more severe 
phenotype than Fbn1 KO alone and dual deficiency results in death in utero with 
little or no evidence of elastic fibre production in the aorta, suggesting an 
overlapping, compensatory, role for these two proteins.(Wagenseil and Mecham, 
2009) In humans, missense mutations in the Fbn1 gene give rise to an excess of 
TGF-β and the spectrum of cardiovascular, musculoskeletal and ophthalmic defects 
of Marfan syndrome; which include aortic root dilatation and its associated aortic 
valve regurgitation, aneurysm formation and dissection.   
MAGP-1 is a small (20-30kDa) protein which is a component of almost all 
microfibrils, and is expressed in the aortic media at the surface of the elastic 
lamellae where it is able to facilitate cell-matrix interactions by binding various ECM 
molecules (including tropoelastin and collagen VI) as well as numerous growth 
factors. The MAGP-1 deficient mouse (Weinbaum et al., 2008) has revealed 
numerous potential functions of MAGP-1 including wound healing, haematopoiesis 
and fatty acid metabolism, although a number of reported phenotypes appear to be 
dependent on mouse genetic background and thus may not be truly reflective of the 
role of MAGP-1 in wild-type (WT) animals  
Despite the constitutive presence of MAGP-1 in elastic vessels, the KO mouse 
shows no cardiovascular defect and MAGP-1 appears not to be required for elastin 
fibre assembly in mice. Of interest though is the increased thrombotic occlusion 
time (following laser injury of the carotid artery) and increased venous bleeding time 
seen in the MAGP-1-/- line.(Werneck et al., 2008) This persistent phenotype was 
independent of platelet or coagulation function and the mice showed no defect in 
vascular structure or evidence of hypertension. Given that MAGP-1 is a substrate 
for transglutaminase reactions (via its conserved “amine acceptor” glutamine at 
position 20) Mecham et al (Mecham and Gibson, 2015) hypothesise that these 
findings may be evidence of impaired interaction between the developing fibrin 
thrombus and constituents of the vessel wall, analogous to the stabilisation of fibrin 
by transglutaminase FXIII-A. 
MAGP-2 is a 25kDa protein which is found exclusively in microfibrils and which 
shows similar matrix-binding properties to MAGP-1, although numerous studies 
have shown it to be a functionally distinct entity with important roles in 
angiogenesis,(Albig et al., 2008) tumour invasion and inflammation. Transgenic 
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mouse studies of MAGP-2 deficiency have not shown an essential role for this 
protein in elastic artery development despite recent genetic studies highlighting a 
loss-of-function mutation in the Mfap-5 gene (encoding MAGP-2) as a cause of 
hereditary thoracic aortic aneurysm and dissection (TAAD) in humans.(Barbier et 
al., 2014) MAGP-2 KO mice are phenotypically relatively normal, without the 
multiple abnormalities shown by MAGP-1-/- mice, although both lines do show 
haematopoietic disturbances.(Combs et al., 2013) Of particular interest for this work 
is the observation that in double knockout of both MAGP-1 and MAGP-2, mice 
display spontaneous aortic dilatation (site not reported) at 6 months of age. This 
dilatation is not due to hypertension and is not associated with aortic dissection 
however it is age-dependent and suggests that MAGP-1 and -2 have overlapping 
roles in the establishment of vascular integrity and/or vascular remodelling, which 
require further study. 
The fibulins are a group of 7 ECM proteins of which fibulins-1,2,4 and 5 are found in 
association with the (tropo)elastin core and/or the surrounding microfibril scaffold. 
Although their importance and function(s) are yet to be fully elucidated, mutations of 
the Fbln1 gene cause loss of fibulin-1 (normally located within the elastic core of the 
developing fibre), defects in the integrity of small blood vessel endothelium and 
bleeding which ultimately leads to death soon after birth.(Kostka et al., 2001) Loss 
of fibulin-4 or -5, (McLaughlin et al., 2006, Nakamura et al., 2002) in contrast, gives 
rise to tortuous large blood vessels with interrupted elastin fibres and visible 
aggregates of elastin within the media.   
EMILIN-1 or elastin microfibril interface located protein is a cysteine rich 
glycoprotein located at the interface between the supporting microfibril and the 
amorphous elastin core.(Wagenseil and Mecham, 2007) EMILIN-1 is expressed 
early in the development of the embryonic aorta and, in cell culture, antibodies to 
EMILIN-1 lead to the production of elastin aggregates rather than organised fibre 
formation.(Bressan et al., 1993) Insights from mouse models have revealed that 
EMILIN-1 is not essential for elastin fibre development, however KO mice display 
significant arterial hypertension when compared to WT littermates which is due to a 
generalised increased peripheral vascular resistance caused by arteries which are 
smaller in luminal diameter with thinner tunica media and irregular lamellae.  
Some authors have suggested that as EMILIN-1 can bind both tropoelastin and 
fibulin-5 it likely acts as a bridging molecule during elastin fibre formation. Whilst 
this may be true, work by Zacchigna et al (Zacchigna et al., 2006) has shown that 
EMILIN-1 may regulate the availability of TGF-β by inhibiting the conversion of pro-
TGF-β to the latent TGF-β complex; hence in the KO model excess TGF-β 
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signalling could lead to reduced cell proliferation and the impaired vessel growth 
exhibited by these animals. Further work is needed, but this example and others 
discussed above serve as a reminder that the ECM is not just a passive structural 
background but instead regulates growth factor availability and activation in ways 
that are only now being understood. As many of these ECM components are 
substrates for transglutaminase cross-linking, elucidating the role that TG2 (and 
other TGs) has in these various cellular processes will become increasingly 
important as new functions for the ECM are discovered.  
1.1.4 Vascular collagens  
Collagens are a group of 19 distinct proteins, 13 of which have been found within 
the vessel wall, that make up ~20% of the dry weight of the aorta and which are 
critical for vessel wall strength and integrity. Produced by vascular SMCs (VSMCs), 
as well as endothelial cells, macrophages and fibroblasts, collagens have a 
characteristic triple helical structure composed of 3 intertwined pro-collagen α-
chains and are broadly classified as 1) fibrillar collagens, 2) non-fibrillar collagens 
and 3) network forming collagens.  
Although a detailed discussion of collagen synthesis is beyond the scope of this 
work (see Prockop et al,(Prockop et al., 1979a, Prockop et al., 1979b) for an 
overview) there are many similarities with elastogenesis with a proline- and glycine-
rich “pro-collagen” structure formed initially, prior to hydroxylation of proline and 
lysine residues and extracellularisation as tropocollagen. Tropocollagen is then 
crosslinked in a lysyl-oxidase dependent manner to form collagen fibrils which are 
bound together (with various glycoproteins and proteoglycans) to produce collagen 
fibres. 
Within the aortic wall, type I collagen predominates and makes up 75% of the 
collagen content, with types III and IV (basement membrane collagen) also found in 
relative abundance.(Thompson et al., 2002) Collagen I and III form discrete bundles 
of fibrils 10-200nm in size which are found between the elastic lamellae and SMCs 
of the aortic media and as a loose mesh in the aortic adventitia. Biomechanical 
studies have shown that fewer than 10% of collagen fibres are circumferentially 
orientated at physiological pressures,(Wagenseil and Mecham, 2009) with this 
proportion rapidly increasing as pressures rise, more fibres are recruited, and the 
aorta becomes less distensible. This has particular relevance in AAA where the 
distended vessel is at the limit of mechanical strain that can be offset by elastin, 
and tensile strength is instead determined by the collagen contained within the 
vessel wall.(Thompson et al., 2002) The aged aorta contains a greater collagen 
concentration than that seen in developing or young vessels (~30% vs 20%) with 
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an increase in production occurring from middle age (Tsamis et al., 2013) and 
aneurysmal tissue contains greater amounts of collagen again (both in total and 
relative to diminished elastin) with increased turnover and synthesis.   
Transgenic mouse studies and various genetic human disease states illustrate the 
importance of the collagen structure for the vasculature, as well as in skin, bone 
and other organ systems.(Wagenseil and Mecham, 2009) Mice with Col1α1 
mutations, for example, die in utero from vessel rupture whilst mutations in human 
Col3α1 give rise to the autosomal dominant (type IV or vascular-type) Ehlers-
Danlos Syndrome (EDS) with patients showing joint laxity, propensity to bruising 
without trauma (ecchymosis) and abnormal scarring. Sadly, however, this complex 
condition is often only diagnosed at presentation with life-threatening arterial 
rupture in early adulthood.  
Collagen I is a potential substrate for TG2 and transglutaminase cross-linked 
collagen shows resistance to proteolysis and degradation in vitro.(Wang and Griffin, 
2012) Various applications for TG2-collagen matrices have been proposed in 
bioengineering as cells seeded on these scaffolds show increased adhesion and 
proliferation when compared to seeding in non-cross linked collagen 
templates.(Chau et al., 2005) Conversely, excess TG2-mediated collagen 
crosslinking has been implicated in fibrosis (Johnson et al., 2003b) and the 
pathogenesis of abnormal wound scarring,(Verderio et al., 2004) diabetic 
nephropathy (Zsoldos et al., 2006) and atherosclerosis (Van Herck et al., 2010) 
where a loss of regulation by NO has been proposed as the mechanistic basis of 
TG2 over activity.(Telci et al., 2009) Clearly the potential links between aneurysm 
formation (with initial collagen synthesis and eventual insufficiency), collagen cross-
linking (which increases resistance to breakdown) and TG2 warrant further 
investigation, as does the role of TG2 in the maintenance of normal arterial 
structure and function. 
1.1.5 Smooth muscle cells  
Vascular smooth muscle cells have been identified as a “key player” in aneurysm 
formation and VSMC apoptosis is a histological feature of human aneurysmal 
tissue, hence they will be discussed in brief below. 
Originating from a number of embryonic sources (including the cranial neural crest 
and mesoderm in the case of the aorta)(Wagenseil and Mecham, 2009) arterial 
SMCs are the predominant stromal cells of the vascular wall and are found within 
the tunica media. Arranged in helical layers between elastic fibres, these cells are 
the source of ECM constituents during vascular development and following vessel 
injury when repair/regeneration is required. The primary function of VSMCs is 
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contraction, to enable regulation of blood vessel tone and thus systemic blood 
pressure and the adult (differentiated) phenotype of these cells have decreased 
proliferation rates and relatively little synthetic ability (Owens et al., 2004) but show 
high sensitivity to mechanical stress.  
In contrast to most differentiated cells however, VSMCs retain phenotypic plasticity 
and are able to switch to a predominantly synthetic phenotype with high proliferative 
capacity. It is likely that these two “extreme” phenotypes actually represent 
opposing ends of a continuum of phenotypic profiles which can be assumed 
depending on local stimuli which may be acute (triggering ligand-receptor 
interactions) or more chronic (leading to epigenetic modifications).(Lacolley et al., 
2012) 
VSMCs are critical for the response to changes in pressure or strain experienced at 
the vessel wall. With raised blood pressure, for example, VSMCs sense “stretch” 
which triggers an increase in contractility (and tone) initially and then the 
coordinated process of hypertrophic inward remodelling to ultimately increase 
media:lumen ratio and restore normal stress levels. 
Age-related changes in VSMC phenotype and function have been linked to arterial 
stiffness with VSMC hypertrophy and increased collagen production evident in the 
aortic wall. Important changes are also seen in VSMCs in aneurysmal tissue as 
VSMC density is reduced in the media of tissue samples from human aneurysms 
(Lopez-Candales et al., 1997) with evidence of p53 production and cell apoptosis.  
Aside from their matrix producing capabilities, VSMCs can also recruit inflammatory 
cells via cytokine and chemokine release, synthesise proteases and are the primary 
source of inhibitors of tissue proteases (including the TIMP (tissue inhibitor of 
metalloproteinases) family and plasminogen-activator inhibitor-1 (PAI-1) amongst 
others). Numerous studies have shown that VSMCs constitutively express MMP-2 
and can be induced to express MMPs 3, 7, 9 and 12 under conditions of stress (e.g. 
inflammation and vascular injury).(Curci, 2009) VSMCs could, therefore, potentially 
contribute to aneurysm pathogenesis by increased matrix degradation or by 
decreased inhibition of this proteolysis and/or reduced ECM synthesis.  
Although the evidence in this area is conflicting, some authors hypothesise that 
aneurysmal VSMCs represent a unique sub-population of cells with a distinctive 
gene expression profile and enhanced elastolytic activity.(Airhart et al., 2014) It 
would be attractive to assume that such cells are different due to their mesodermal 
embryonic origin, and hence the infra-renal aorta shows a “regional predominance 
of cells with a differentiation bias towards matrix degradation”.(Curci, 2009) VSMCs 
certainly represent an important area for future study; key to this will be a clearer 
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understanding of the factors that influence and control VSCM phenotype “switching” 
or dedifferentiation. A number of signalling pathways have been implicated in 
dedifferentiation, including the PDGF/Akt1 and the β-catenin pathways, both have 
which have been linked to neointimal formation and re-stenosis following injury. A 
recent study by Nurminskaya et al in Baltimore (Nurminskaya et al., 2014) suggests 
that these pathways may be dependent on extracellular TG2, acting as a receptor 
agonist and/or a bridging molecule between signalling receptors, however further 
work is required to validate this proposed mechanism.  
1.2 Matrix metalloproteinases  
1.2.1 MMPs in general  
The matrix metalloproteinases or MMPs are a family of structurally related 
endopeptidases which (among other functions) are able to catalyse the proteolytic 
breakdown of the extracellular matrix. Twenty-three distinct enzymes are 
recognised in humans,(Page-McCaw et al., 2007) which, although structurally and 
evolutionarily related, show diverse substrate specificity, enzymatic efficiency and 
tissue location. The structure of MMPs in general will be discussed briefly and then 
the key MMPs implicated in aneurysm pathogenesis will be introduced and their 
roles in cardiovascular disease outlined. An overview of the role of MMPs in AAA 
formation and development is given in section 1.3.4 
The first member of the MMP family (MMP-1 or interstitial collagenase) was 
described in 1962 by Gross et al (Gross and Lapiere, 1962) in relation to the loss of 
the tadpole tail during normal metamorphosis. Subsequently, further enzymes were 
discovered which showed a similar three-domain structure with a conserved 
methionine residue and histidine bound zinc ion at the enzyme active site. These 
“metzincin” proteases have a characteristic structure which comprise a pro-peptide 
domain, a catalytic domain and a hemopexin-like C-terminal domain (Nagase et al., 
2006) (Figure 5) and are synthesised (+/- secreted) in an inactive or pro-MMP form. 
The pro-peptide contains a conserved cysteine residue which interacts with the 
active site zinc ion, thus preventing the binding of an essential water molecule and 
inhibiting catalysis;(Nagase et al., 2006) MMP activation requires removal of this 
pro-peptide, usually as the first stage of a multi-step activation process (see (Visse 
and Nagase, 2003) for more detail). MMPs can also be activated without pro-
domain cleavage by disruption of the zinc-cysteine bond, for example by reactive 
oxygen species (ROS) binding.(Van Wart and Birkedal-Hansen, 1990) The third, 
hemopexin-like, domain is joined to the catalytic domain by a flexible “hinge” region 
and has a “four-bladed-β-propeller” structure which determines substrate specificity 
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and is the site of binding of the endogenous inhibitors of MMPs, the TIMPs.(Page-
McCaw et al., 2007) 
The MMPs were initially named based on their observed function, location and 
substrate specificity however recently discovered MMPs do not fit neatly into this 
classification system and there is increasing evidence that some MMPs may 
straddle more than one group. These groups are summarised in Table 1 and are 
the collagenases, the gelatinases, the stromelysins, the matrilysins, the membrane-
type MMPs (which are transmembrane or membrane-anchored proteins) and then 
those that fall outside these groups which include MMP-12 or macrophage 
metalloelastase.(Visse and Nagase, 2003) MMP activity is tightly regulated by an 
endogenous group of four inhibitors (TIMPs 1-4) which are wedge shaped 
molecules (Visse and Nagase, 2003) that form tight 1:1 complexes with the catalytic 
domain of the active enzyme. The TIMPs are able to inhibit the MMP family with 
varying efficiency depending on which enzyme-inhibitor relationship is studied and 
they are also able to interact with other proteases (including the ADAM and 
ADAMTS proteases) as well as components of cell signalling pathways (such as 
growth factor receptors and integrins).(Newby, 2012) As well as TIMP inhibition, 
MMPs are subject to regulation at a transcriptional level via cytokine signalling, by 
post-translational modification and by the action of other MMPs and serine 
proteases (such as thrombin and plasmin).(Yabluchanskiy et al., 2013) Hence, in 
health, MMP activity is tightly controlled and held in balance with its natural 
inhibitors. Upset of this balance, by whatever means, is implicated in numerous 
disease processes including cancer, arthritis, atherosclerosis, fibrosis and, of 
course, aneurysm formation.(Visse and Nagase, 2003) 
MMPs do not just promote ECM breakdown and instead participate in a plethora of 
cellular processes. Some of these functions occur as a direct result of MMP action 
on ECM components which may, for example, produce biologically active cleavage 
fragments or release sequestered stores of growth factors, whereas other functions 
result from MMP interaction with non-ECM substrates which include cytokines, 
tyrosine kinase receptors, growth factors and other MMPs.(Page-McCaw et al., 
2007) Given the vital processes in which MMPs participate it seems likely that 
knockout of  these genes in transgenic mouse models would have devastating 
consequences. However, no reported MMP gene knock out has been shown to be 
embryonically lethal and most show remarkably mild phenotypes. This suggests 
that MMPs are either not required during embryonic development (which seems 
unlikely) or instead that there is a high degree of “enzymatic redundancy [and] 
compensation”(Page-McCaw et al., 2007) during development that allows for loss 
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of one member of the enzyme family without complete loss of function. This 
redundancy, along with the complex networks of interactions within which MMPs 
and TIMPs act, contribute to the difficulties in developing therapeutic modulators of 
MMP activity. These potential therapies are discussed by Newby in reference to the 
treatment of atherosclerosis and MI and would need to “target a specific adverse 
effect of MMPs whilst leaving intact essential physiological functions”.(Newby, 
2015) 
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Subgroup MMP Name ECM Substrate(s) (if known) 
Collagenases MMP-1 
 
MMP-8 
 
MMP-13 
Collagenase-1 
 
Collagenase-2 / 
Neutrophil 
Collagenase 
Collagenase-3 
Col I, Col II, Col III, Col VII, Col VIII, Col X, Gelatin 
Col II, Col III, Col VII, Col VIII, Col X, Aggrecan, 
Gelatin 
Col I, Col II, Col III, Col IV, Col IX, Col X, Col XIV, 
Gelatin 
Gelatinases MMP-2 
MMP-9 
Gelatinase A 
Gelatinase B 
Gelatin, Col II, Col III, Col IV, Col VII, Col X 
Gelatin, Col IV, Col V 
Stromelysins MMP-3 
MMP-10 
MMP-11 
Stromelysin-1 
Stromelysin-2 
Stromelysin-3 
Col II, Col IV, Col IX, Col X, Col XI, Gelatin 
Col IV, Laminin, Fibronectin, Elastin 
Col IV, Fibronectin, Laminin, Aggrecan 
Matrilysins MMP-7 
MMP-26 
Matrilysin-1 
Matrilysin-2 
Fibronectin, Laminin, Col IV, Gelatin 
Fibrinogen, Fibronectin, Gelatin 
Membrane Type 
MMPs 
MMP-14 
MMP-15 
MMP-16 
MMP-17 
MMP-24 
MMP-25 
MT1-MMP 
MT2-MMP 
MT3-MMP 
MT4-MMP 
MT5-MMP 
MT6-MMP 
Gelatin, Fibronectin, Laminin 
Gelatin, Fibronectin, Laminin 
Gelatin, Fibronectin, Laminin 
Fibrinogen, Fibrin 
Gelatin, Fibronectin, Laminin 
Gelatin 
Others MMP-12 
 
MMP-19 
MMP-20 
MMP-21 
MMP-23 
MMP-27 
MMP-28 
Macrophage 
Metalloelastase 
- 
Enamelysin 
XMMP 
CA-MMP 
CMMP 
Epilysin 
Elastin, Fibronectin, Col IV 
 
Aggrecan, Elastin, Fibrillin. Col IV, Gelatin 
Aggrecan 
Aggrecan 
Gelatin, Casein, Fibronectin 
- 
- 
Table 1. Members of the matrix metalloproteinase family 
Table showing a summary of the current knowledge about human matrix 
metalloproteinases, including the traditional classification system, MMP number, 
alternative names (if any) and information about known ECM substrates.  
Col = collagen 
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1.2.2 Matrix metalloproteinase 2 (MMP-2) 
Matrix metalloproteinase 2 is a 72kDa protein, also known as type IV collagenase 
or gelatinase A (reflecting its membership of the gelatinase sub-group of MMPs 
(see Table 1)), that is encoded by the MMP2 gene at human chromosome locus 
16q12.2. MMP-2 is able to degrade denatured collagen (gelatin) through binding at 
its fibronectin-repeat region which lies adjacent to the catalytic domain (see Figure 
5) as well as degrading collagens IV, V and IX and laminin and, with less efficiency, 
collagens I and II.  
MMP-2 is secreted constitutively from VSMCs and endothelial cells,(Galis and 
Khatri, 2002) however is inactive in non-diseased vessels, becoming upregulated 
and activated under conditions of stress, after injury, or with changes in stretch and 
haemodynamic flow.(Galis and Khatri, 2002, Newby, 2006) Although the 
mechanisms by which upregulation occurs are yet to be fully elucidated they are 
likely to be multifactorial and effected through various cell types and signalling 
pathways. For example; ROS produced by foam cells within atherosclerotic lesions 
can upregulate MMP2 gene expression as well as activate latent pro-MMP2 
complexed within the vessel wall,(Rajagopalan et al., 1996) an effect mitigated by 
overexpression of endothelial nitric oxide synthase (eNOS) to reduce ROS.(Gurjar 
et al., 1999) ROS also promote VSMC migration and proliferation (Papaharalambus 
and Griendling, 2007) (which is facilitated by MMP-mediated ECM breakdown), 
thus increasing the numbers of a cell type which produces MMP-2. This is just one 
example of the typical amplificatory cascades seen in MMP regulation and 
emphasises how important the fine balance between proteolysis and inhibition is in 
preventing pathology.    
Although predominantly extracellular, there is increasing evidence that MMP-2 has 
important intracellular roles which are mediated through non-matrix substrates. In 
the cardiovascular system such substrates include α-actin, myosin light chain and 
troponin I found within myocytes (DeCoux et al., 2014) and the intracellular action 
of MMP-2 mediates the reperfusion syndrome seen after myocardial 
ischaemia.(Wang et al., 2002) Although the means by which MMP-2 is targeted to 
the cytosol are not yet fully understood, there are splice variants of MMP2 which, 
when translated, would lack the ER signal sequence seen in the conventional form 
of the gene,(Ali et al., 2012) thus representing a presumed mechanism for specific 
targeting of the intracellular protease.  
MMP-2 is activated by a unique mechanism whereby the latent form (pro-MMP-2) is 
secreted extracellularly and is recruited to the cell surface by a complex of 
membrane-type MMP-1 (MT1-MMP) and TIMP-2. An additional MT1-MMP 
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molecule (in close proximity within the cell membrane) is then required to cleave the 
pro-peptide of pro-MMP2 to generate the active form.(Lafleur et al., 2003) This 
process requires sufficient TIMP-2 (to generate the initial MT1-MMP.TIMP-2 
complex) but an excess of TIMP-2 will bind and inhibit all available MT1-MMP and 
prevent pro-MMP2 activation, thus highlighting, again, the importance of balance 
between these proteases and their inhibitors. Crucially the activation complex 
described here is different from that formed during inhibition of active MMP-2 by 
TIMP-2 (Morgunova et al., 2002) hence the potential for specific modulation of 
MMP-2 activity.   
Despite its multiple extra- and intra-cellular substrates, MMP-2 does not appear to 
be essential for any key developmental processes and MMP-2-/- mice are fertile and 
phenotypically normal although show smaller birth weights and slower growth rates 
when compared to WT mice.(Itoh et al., 1997) Mutations in human MMP-2 lead to a 
rare autosomal recessive form of multicentric osteolysis (Martignetti et al., 2001) 
characterised by bone resorption particularly in the hands and feet, suggesting that 
MMP-2 has a key role in bone formation and/or turnover. 
Aside from its evidenced roles in AAA pathogenesis (see section 1.3.4) and 
ischaemia/reperfusion syndrome, MMP-2 has been implicated in other 
cardiovascular diseases such as atherosclerosis (MMP-2-/- mice show reduced 
atherosclerotic plaque formation in an apolipoproteinE (ApoE) deficiency 
model)(Kuzuya et al., 2006) and hypertension.(Azevedo et al., 2014) It also has a 
key role in angiogenesis or neovascularisation (van Hinsbergh and Koolwijk, 2008) 
both in normal development, and under pathological conditions of injury and 
tumorigenesis and MMP-2 is thought to be required for the “angiogenic switch” 
seen in many tumour types (see Bergers et al (Bergers and Benjamin, 2003) for a 
review). Interestingly TG2 has been shown to be a potential target of MMP-2 (and 
MT1-MMP)(Belkin et al., 2004) and there is a single report of TG2 regulating MMP-
2 transcription (via CREB phosphorylation) in ovarian cancer cell lines,(Satpathy et 
al., 2009) perhaps suggesting a reciprocal relationship between the 
transglutaminases and the metalloproteinases which warrants further investigation. 
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Figure 5. Structure of matrix metalloproteinase-2 
Schematic showing three-dimensional structure of MMP-2 illustrating three 
key domains (pro-peptide, catalytic and hemopexin domains) common to all 
metalloproteinases as well as the fibronectin-repeat region which confers the 
ability of MMP-2 to bind gelatin. Image based on modification of (Sigma-
Aldrich, 2016). 
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1.2.3 Matrix metalloproteinase 9 (MMP-9) 
MMP-9 is a gelatinase of molecular weight 92kDa in the zymogenic form and 
88kDa in the active form in humans. Also known as type IV collagenase, MMP-9 
has a triple repeat fibronectin-like domain which, as in MMP-2, gives rise to its 
ability to bind gelatin for proteolysis. MMP-9 is secreted by a number of cell types 
including neutrophils, macrophages (particularly foam cells) and fibroblasts and is 
inhibited and bound to TIMPs -1 and -3 via its hemopexin domain prior to 
secretion.(Yabluchanskiy et al., 2013, Siwik et al., 2001) As previously discussed, 
there is increasing evidence that matrix metalloproteinases may be activated and 
function intracellularly although the evidence for this is limited with regards MMP-
9.(Pereira et al., 2005) 
Transgenic MMP-9-/- mice have been generated by Vu et al (Vu et al., 1998) by 
replacement of part of exon 2 and all of intron 2 of MMP9 with a neomycin 
resistance cassette. These mice are fertile although pups show defects in bone 
development and impairment of vascularisation and ossification of cartilage, 
corresponding to the rare human condition of Metaphyseal Anadysplasia Type 2 
(MANDP2) seen with homozygous loss-of-function mutation of MMP9.    
A number of insights have been gained through the study of the MMP-9 KO mouse, 
particularly with regards the role of MMP-9 in cardiovascular pathology; MMP-9 is 
required for SMC migration and neointimal formation (Johnson and Galis, 2004) 
and contributes to the angiogenesis seen after femoral artery ligation in a murine 
critical limb ischaemia model.(Johnson et al., 2004) Mice deficient in MMP-9 show 
decreased atherosclerosis (Luttun et al., 2004) and MMP-9-/- animals show 
decreased rates of left ventricular rupture and ventricular dilatation following 
experimentally induced myocardial infarction (MI).(Ducharme et al., 2000) This 
change in cardiac re-modelling is thought to be due to decreased macrophage 
recruitment however increases in MMP-9 activity are also seen in cardiac 
fibroblasts subjected to oxidative stress (Siwik et al., 2001) and have been 
implicated in cardiac fibroblast migration and differentiation to a myofibroblast 
phenotype. Roles in embryo implantation, embryogenesis, immune cell functioning 
and nerve myelination amongst others have also been ascribed to MMP-
9.(Yabluchanskiy et al., 2013) 
As with all the MMPs, regulation of MMP-9 is complex and multifaceted, and 
includes transcriptional regulation, activation by other MMPs and by other 
proteases, regulation via cytokine (e.g. TNF-α and IL1β) stimulated signalling 
pathways and post-transcriptional modifications to confer mRNA stability.(Yan and 
Boyd, 2007) Many of the stimulators of MMP transcription signal via nuclear factor 
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kappa B (NFκB) and binding sites for this factor are seen in MMP1, 3, 9, 14 and 19 
(Fanjul-Fernandez et al., 2010) although not yet reported within the MMP2 gene. 
This differential expression of transcription-binding domains in functionally related 
proteases is discussed in (Yan and Boyd, 2007) and a detailed description of the 
genetic regulation of MMPs is given by Clark et al.(Clark et al., 2008) Given the 
complex nature of MMP-9 regulation and the fact that TG2 has been implicated in 
the induction of NFκB,(Lee et al., 2004) it is perhaps not surprising that there are 
reports of TG2 activity influencing MMP-9 expression via this (Lin et al., 2011) and 
other intermediates (Ahn et al., 2008) in cancer cell lines; whether this relationship 
is borne out in vivo remains to be seen. 
1.2.4 Matrix metalloproteinase 12 (MMP-12) 
MMP-12, also known as macrophage metalloelastase, is a 54kDa protein encoded 
on chromosome 11 in humans. MMP-12 is induced in response to injurious stimuli 
(such as cigarette smoke) and is found only at low levels in health, being primarily 
expressed by inflammatory macrophages (although also osteoclasts and 
chondrocytes). Despite its pseudonym, MMP-12 has multiple ECM substrates in 
addition to elastin, including fibronectin, collagen IV and laminin, and its protease 
activity is crucially important for normal macrophage migration and emigration 
through the basement membrane.(Shipley et al., 1996)   
The catalytic form of MMP-12 is produced by cleavage of the pro-domain and a 
mature (22kDa) form is also seen following subsequent cleavage of the hemopexin 
domain.(Nar et al., 2001) Like the other MMPs, MMP-12 expression and activation 
is tightly regulated and can be initiated by numerous pathways including the 
plasmin/thrombin-PAR-1 (protein activated receptor 1) cascade, TNF-α signalling 
and via interferon-γ (IFN-γ) released from circulating lymphocytes.(Houghton, 2015) 
Complete deficiency of MMP-12 (Shipley et al., 1996) results in offspring that are 
phenotypically normal and show conventional development, however, litter sizes in 
this line are reduced by as much as 60%. In human pregnancy, placental 
macrophages express MMP-12 during the first trimester (Harris et al., 2010) when it 
is thought to have a role in vascular remodelling and maintenance of blood flow to 
the developing foetus; MMP-12 deficiency presumably therefore results in placental 
abnormalities which are unable to sustain normal litter sizes.  
Much of the evidence about MMP-12 function and regulation has been generated 
from the study of cigarette-smoke-induced lung injury in murine models of 
emphysema since; 1) inherited deficiencies of alpha-1-antitrypsin (an inhibitor of 
neutrophil elastase) lead to early-onset emphysema, and 2) MMP-12-/- mice fail to 
develop lung destruction in this model.(Hautamaki et al., 1997) Emphysema is one 
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of the disease entities seen under the umbrella of chronic obstructive pulmonary 
disease (COPD) which results in over 25,000 deaths each year in Great Britain 
(Executive, 2015) and (in emphysema) results in enlarged bronchiolar and alveolar 
air spaces due to destruction of the elastin walls of these structures, ultimately 
causing impaired ventilation and oxygenation. The role of MMP-12 in emphysema 
is complex but involves direct elastolysis of pulmonary constituents, production of a 
chemotactic gradient (MMP-12 recruits inflammatory macrophages and neutrophils 
to sites of injury), and production of EDPs which are themselves chemotactic to 
macrophages.(Houghton, 2015) MMP-12 can also degrade alpha-1-antitrypsin 
(α1AT) (Nar et al., 2001) - removing its potent inhibition of neutrophil elastase - and 
facilitate TNF-α release, thus potentiating an inflammatory cascade which ultimately 
results in disease.  
Aside from its role in emphysema, MMP-12 also has a physiological function in host 
defence both through a direct bactericidal action of the C-terminal domain on 
bacterial cell walls (Houghton et al., 2009) and via its regulation of IFN-γ in 
response to viral infection.(Dandachi and Shapiro, 2014) In the cardiovascular 
system, MMP-12 is involved in the control of angiogenesis by generating 
angiostatin (from plasminogen) (Dong et al., 1997) which is a specific and highly 
effective inhibitor of angiogenesis (and hence tumour growth and metastasis) in 
vivo (Sang, 1998) and MMP-12 has also been implicated in the VSMC mediated 
arterial stiffening seen with age or vascular injury,(Liu et al., 2015) and 
atherosclerosis.(Liang et al., 2006) Its role in aneurysm formation is discussed in 
section 1.3.4. Clearly MMP-12 represents a potential therapeutic target for the 
treatment of chronic lung diseases but its multiple actions in this, and other, organ 
systems will need to be better understood before its potential can be realised. 
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Figure 6. Role of MMP-12 in emphysema 
Schematic showing some of the multiple mechanisms by which MMP-12 
(predominantly released from inflammatory macrophages) facilitates the bronchiolar 
and alveolar elastin wall damage seen in emphysema. MMP-12 is both directly 
chemoattractive to inflammatory cells and also generates elastin degradation 
products (EDPs) or elastin fragments (EFs) which recruit monocytes and 
macrophages to the site of injury. MMP-12 can also cleave α-1-antitrypsin, thus 
removing the inhibition of neutrophil elastase which can cause damage directly or 
via inhibition of TIMPs. Endothelial damage promotes MMP-2 production via the 
action of plasmin/thrombin acting via protein activated receptor-1 (PAR-1).  
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1.2.5 Tissue inhibitors of metalloproteinases (TIMPs) 
MMP activity is regulated (amongst other mechanisms) by TIMPs 1-4. These 
proteins are highly evolutionarily conserved and inhibit MMP catalytic activity by 
chelation of the active site zinc molecule via a conserved cysteine residue in the N-
terminal domain of the TIMP.(Visse and Nagase, 2003) The TIMPs, which are 21-
29kDa in size, show different affinities for the various MMPs, with TIMP-3 – a 
membrane bound TIMP – having the broadest action and TIMP-1 the most 
restrictive.(Brew and Nagase, 2010) As well as MMP-inhibition, the TIMPs (and 
particularly TIMP-3) are also capable of inhibiting the activity of the ADAM and 
ADAMTS proteases,(Newby, 2012) can affect pro-MMP activation, and they have a 
number of identified MMP-independent functions. These include promotion of cell 
growth, suppression of cell growth and anti-angiogenesis and anti-apoptotic 
activity.(Brew and Nagase, 2010)   
As shown by the complex nature of MMP activity, it is unlikely that TIMPs act in a 
uniquely MMP-dependent or  MMP-independent fashion, instead displaying multiple 
actions simultaneously. For example; in angiogenesis, by inhibiting MMP-mediated 
breakdown of the ECM, TIMPs can influence the migration of endothelial cells and 
subsequent sprouting and tube formation preceding new vessel development.(van 
Hinsbergh and Koolwijk, 2008) Concurrently, TIMP-2 acting via the MAPK signalling 
pathway (Feldman et al., 2004) can inhibit endothelial cell proliferation and 
migration whilst direct binding of TIMP-3 to vascular endothelial growth factor 
(VEGF) can prevent the interaction of this growth factor with endothelial cells,(Qi et 
al., 2003) thus limiting its angiogenesis promoting effects. Similar coordinated 
networks of action can be seen in the nervous system (Jourquin et al., 2005) which 
requires neuronal turnover and differentiation to facilitate learning and memory, and 
in the inflammatory system.  
Mouse models of TIMP deficiency have contributed to evidence of the above, as 
well as additional important roles of TIMPs in development. However, single-TIMP 
deficient mice are viable and fertile (Page-McCaw et al., 2007) and show no 
obvious compensatory upregulation of other TIMPs. TIMP-3-/- mice primarily show 
features of “unbalanced matrix degradation”(Brew and Nagase, 2010) with 
development of spontaneous emphysematous change in the lungs, dilated 
cardiomyopathy and age-related arthritis, thus confirming its broad inhibition of 
ECM proteolysis. Specific roles within the cardiovascular system have been 
identified for TIMP-1 in relation to cardiac remodelling and atherosclerosis (TIMP-1-
/- mice show reduced atherosclerosis (Silence et al., 2002) with more stable, more 
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calcified plaques (Orbe et al., 2003)) and several studies have investigated the role 
of TIMPs in abdominal aortic aneurysm formation and progression.  
The relationship between MMPs (and other proteases) and TIMPs (and other 
protease inhibitors) is finely balanced and targeted modulation of this balance may 
allow the development of novel therapies for a number of pathological conditions 
(see (Newby, 2012) for a review in vascular diseases); it is important, however, that 
the effects of these proteins outwith their traditional ECM roles are fully elucidated 
and understood in order that the potential side effects of such therapies are 
mitigated without causing harm. 
1.3 Abdominal aortic aneurysms 
1.3.1 General pathology, epidemiology and clinical course 
An abdominal aortic aneurysm or AAA is the term given to a localised increase in 
diameter of the abdominal aorta; the blood vessel supplying the abdominal viscera 
which commences at the level of the diaphragm and terminates at its bifurcation 
into the iliac vessels at the L4 vertebral level.(Feller and Woodburne, 1961) The 
normal aorta measures approximately 2.0cm in diameter and aneurysmal dilatation 
is classified as an increase in size by 50% of normal. Such dilatation is often 
diagnosed incidentally on imaging or examination for another presenting complaint 
and is increasingly discovered in England through the NHS AAA Screening 
Programme (NAAASP) which was established nationally in 2014 and offers “one-
off” ultrasound imaging of the abdomen to all men over the age of 65.  
 
Table 2. Annual rupture risk by AAA diameter 
From the European Society for Vascular Surgery (ESVS) AAA Guidelines 
2011 (Moll et al., 2011)  
 
The prevalence of detected AAA in the screening programme has been much lower 
than predicted (just 1.4%)(NAAASP, 2014) – due predominantly to a reduction in 
the “lifestyle” related risk-factors of AAA such as smoking and an increased 
population use of cardiovascular (CV) preventative medications such as anti-
hypertensives and statins. Despite this, the NAAASP is cost effective (Glover et al., 
2014) because of the potential fatal consequences of AAA which, if left unchecked, 
AAA Diameter (mm) 12-month Rupture Risk (%) 
30 – 39 0 
40 – 49 1 
50 – 59 1 – 11 
60 – 69 10 – 22 
>70 30 – 33 
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will continue to increase in size and eventually rupture. As discussed earlier, 
mortality rates from aneurysm rupture are high whether rupture occurs with 
(41%)(Bown et al., 2002) or without (90% out-of-hospital mortality)(Earnshaw et al., 
2004) intervention and hence patients with AAA are closely monitored with serial 
imaging and offered repair when the risk of intervention is balanced by the risk of 
rupture (Table 2). 
AAA disease is estimated to cost in excess of $3 billion per year in the United 
States,(Go et al., 2013) and much of this cost is associated with either aneurysm 
repair itself (either surgical graft repair or endovascular with stent-device insertion) 
or with the complications of intervention. Complications from open surgical repair 
can be considerable and range from minor wound problems through to bowel 
ischaemia, organ failure and death (mortality rate 3-10% depending on population) 
whilst endovascular repair has a not insignificant risk of kidney injury, graft failure 
and need for re-intervention. Given that the risk factors for AAA are also those that 
increase risk of all cardiovascular disease it is easy to see why this population 
represents a co-morbid group which is at high risk of complications, and specifically 
post-intervention cardiovascular events such as stroke and MI. Clearly, therapeutics 
that could either stop aneurysm development or, more likely, slow progression after 
early detection, would be incredibly valuable and would have huge potential benefit 
in reducing morbidity and mortality in this population.  
Although aneurysms do form at other sites in the vascular tree, the abdominal aorta 
is unique in terms of the frequency of aneurysm development and the fact that 90% 
of aortic aneurysms are located infra-renally (i.e. below the origin of the renal 
arteries). The aorta is a non-uniform structure with distinct regions (Tsamis et al., 
2013) which have differing embryological origins and which are subject to vastly 
different haemodynamic forces. The abdominal aorta, for example, has a 
mesodermal origin (with the ascending aorta and arch formed from neural crest 
cells), has an elastin:collagen ratio which is lower than the thoracic aorta (Ailawadi 
et al., 2003) and is exposed to pulse wave reflections from the aortic bifurcation 
which increase relative pressure at this site.(Dua and Dalman, 2010) These and 
other anatomical and structural observations, such as the lack of vasa vasorum and 
the reduced elastic lamellar density have all been proposed as factors predisposing 
to aneurysm development in the abdominal portion of the aorta. There are also 
striking differences between AAA and the thoracic counterpart (TAA) which tend to 
occur in younger patients with a strong family history (as much as 20%) and no 
clear male predominance. Clearly these differences require investigation but the 
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extent to which these factors can be modified is obviously minimal and hence their 
relative importance in the pathogenesis of aneurysmal disease is, as yet, unclear.  
As mentioned, there are a number of clear risk factors for AAA which include 
smoking, hypertension, hypercholesterolaemia, increasing age and male gender. Of 
these, smoking has been shown to be the most important risk factor with a greater 
influence than is seen in either stroke or coronary heart disease.(Lederle et al., 
2003) As well as increasing incidence of AAA, cigarette smoke also promotes 
aneurysmal growth (Brady et al., 2004) and rupture in a dose-dependent manner, 
with both amount and duration of exposure being important parameters of risk. The 
mechanism(s) underlying this association are not clear but may include epigenetic 
modification of genes such as 5-LO involved in inflammation,(Krishna et al., 2010) 
effects on the inflammatory cell infiltrate seen in the aneurysmal wall, as well as 
direct effects of cigarette smoke on VSMC proliferation and survival.  
In contrast to the effects of smoking, there is an inverse relationship between the 
presence of Diabetes Mellitus (DM) and aneurysm development, expansion and 
rupture; with patients with DM having an odds ratio (OR) of AAA diagnosis of 0.75 
in a study of over 3 million individuals.(Kent et al., 2010) Again, the mechanisms 
behind this relationship are unclear but may include the ability of AGEs to induce 
protective collagen cross-linking with the aortic media.(Lederle, 2012) By studying 
populations with significantly increased or decreased AAA risk we may be able to 
elicit some of the mechanisms involved in pathogenesis but the fact that AAA 
disease is seen both in patients who have never smoked and in patients with 
severe diabetes is evidence of the multifactorial nature of this condition. Indeed, 
despite extensive research, the pathophysiology of aneurysmal disease remains 
poorly understood and it is becomingly increasingly evident that the factors that 
initiate aneurysm development may be very different from those that lead to 
disease progression and eventual rupture.(Thompson et al., 2002)  
1.3.2 ECM breakdown and atherosclerosis 
Whereas initial theories pointed to atherosclerosis as the causative lesion in 
aneurysmal disease (because of the almost universal finding of atherosclerosis in 
the walls of AAA),(Dobrin, 1989) this has not been borne out by recent studies and 
one current theory regards AAAs as a localised presentation of a systemic disease 
of the vasculature.(Nordon et al., 2009)  
Atherogenesis and aneurysmal disease, although similar, have key differences in 
terms of risk factors, response to therapy and genetic predisposition.(Newby, 2012) 
The discrepancy between smoking status and risk of AAA vs athero-occlusive 
disease has been discussed and clearly the identification of DM as a negative risk 
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factor for AAA points to a different pathogenic mechanism than that seen in 
atherosclerosis and strongly suggests that these two conditions are distinct disease 
entities. Likewise, animal models have demonstrated that therapies effective 
against atherosclerosis have little or no effect in terms of aneurysm development 
(Golledge et al., 2010) and that the atherosclerosis seen in aneurysms develops as 
a consequence of altered flow, rather than occurring prior to dilatation. If 
atherosclerosis did precede vessel expansion it would be expected that severity of 
atherosclerosis would correlate with AAA development; this relationship is not seen 
in large cohort studies and the reverse is also not true, as anatomical sites that are 
prone to the atherosclerosis (such as the superficial femoral artery (SFA)) are not 
common sites for aneurysm development.(Norman and Powell, 2010) 
Rather than a localised disease, some have suggested that AAA represents a 
single manifestation of a more generalised pathology (Nordon et al., 2011) with 
increased MMP-2 levels at remote vascular sites (Goodall et al., 2001) and venous 
abnormalities including reduced elastin content.(Goodall et al., 2002) Whilst the 
causes of such systemic pathology are unknown, the histological manifestations of 
aneurysms are clear. AAAs are characterised by alterations in the arterial media 
and adventitia that include medial thinning, disruption and loss of elastin,(Campa et 
al., 1987) a decreased elastin to collagen ratio,(Mesh et al., 1992) disordered ECM 
remodelling and loss of VSMCs.(Alexander, 2004)  
This elastin breakdown or elastolysis may be triggered by a number of factors but is 
then potentiated by chronic inflammation (predominantly T-cells) resulting in an 
imbalance between proteolysis and normal proteolytic inhibition.(Knox et al., 1997)  
Although the initiation of AAA formation is therefore loss of elastin, the arterial 
dilatation, progression (and subsequent rupture), is thought to occur when collagen 
deposition (which reinforces the arterial wall)(Berillis, 2013) is outweighed by 
collagen degradation. Newby has described a “multi-stage initiation and 
destabilisation paradigm for aneurysm growth and rupture”(Newby, 2012) which we 
attempt to summarise in Figure 7. Clearly, a greater understanding of this paradigm 
is required, as is the ability to identify patients at risk of entering, or at the early 
stages of this process and, crucially, an ability to manipulate this ECM destruction 
to prevent the vicious cycle of AAA expansion, increased wall stress (Dobrin, 2000) 
and eventual rupture.  
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Figure 7. Pathogenesis of AAA 
Schematic of AAA pathogenesis emphasising the importance of elastin loss in 
initiating and potentiating aneurysm development. The cartoon illustrates the crucial 
role of invading inflammatory cells and matrix metalloproteinases (MMPs) in the 
breakdown of the extracellular matrix (ECM). Novel tropelastin formation and 
collagen deposition both occur as a compensatory response to elastin loss and 
dilatation occurs when collagen degradation exceeds deposition. The role of the 
intraluminal thrombus (ILT) in aneurysm progression is controversial. 
U-pa = urokinase type plasminogen activator 
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1.3.3 Inflammation and aneurysm pathogenesis  
The histology of aneurysmal disease is well characterised and is typified by an 
intense inflammatory cell infiltrate composed predominantly of macrophages and 
lymphocytes.(Freestone et al., 1995) Inflammation is therefore reported to be key to 
aneurysm pathogenesis, although this view is challenged by single reports of rapid 
aneurysm expansion in immunosuppressed individuals.(Lindeman et al., 2011) 
Certainly it appears that inflammation is triggered by elastin breakdown (Hance et 
al., 2002) and that recruited inflammatory cells produce both inflammatory cytokines 
and ROS (Miller et al., 2002) (thus potentiating an inflammatory cascade) as well as 
being the source of the MMPs which facilitate further ECM degradation. 
In 2010 Wang et al showed that monocytes are likely to be a key regulator in the 
inflammatory process seen in aneurysms. They generated mice with clodronate-
depleted monocytes and saw a dramatically reduced incidence, severity and 
rupture rate of AAA generated using the Angiotensin II (AngII) experimental 
model.(Wang et al., 2010) Likewise deficiency of certain chemokine receptors 
(CCR2)(Daugherty et al., 2010, Moran et al., 2013) usually involved in macrophage 
recruitment, and factors involved in macrophage lineage differentiation (e.g. 
MyD88)(Owens et al., 2011) have also been shown to reduce aneurysm formation 
in various murine models.  
Xiong et al reported that CD4+ T-cells, the most predominant lymphocyte present in 
aneurysms, are required for AAA development in the calcium chloride (CaCl2) 
murine model (Xiong et al., 2004) and T-helper subtypes Th1, Th2 and Th17  have 
all been shown to be increased in human and AngII induced aneurysms (see Dale 
et al (Dale et al., 2015) for a review). Interestingly the role of B-cell lymphocytes has 
been less well investigated although some authors have hypothesised that AAA 
development represents an autoimmune process and various auto-antigens 
(including AAAP-40 and CA1) have been proposed as triggers for lymphocyte 
activation, stimulation of the complement system and further inflammation.(Zhang 
and Wang, 2015) 
Given that early aneurysms show a relative paucity of inflammatory cells (Freestone 
et al., 1995) it is likely that those that are present (possibly neutrophils (Tilson, 
2005)) are crucially important in aneurysm pathogenesis. Targeting cell recruitment 
and signalling at this early stage could be a realistic strategy in preventing AAA 
initiation as, at a later stage, when these cells are present in any significant number, 
the “tipping point” of AAA development could already have been reached.  
In view of the important role of inflammation in aneurysm progression it is 
unsurprising that several inflammatory chemokines have been reported to be critical 
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in aneurysm development in both animal experiments and in human studies looking 
at cytokine levels in aneurysm samples. As previously noted, however, these 
samples reflect end-stage disease and the extent to which results can be 
extrapolated to the early phases of AAA development are unclear. Several of the 
interleukin family members (including IL-1β, and IL-6) have been shown to be 
increased in aneurysm tissue relative to control (Abdul-Hussien et al., 2010, 
Harrison et al., 2013) and patients with AAA have increased circulating plasma IL-
1β levels.(Juvonen et al., 1997) In a murine elastase model of AAA induction, 
Johnston et al showed that IL-1β depletion (or inhibition of its receptor) prevented 
aneurysm development.(Johnston et al., 2013)  
TNF-α, a key inflammatory chemokine released by T-cell lymphocytes initially and 
then by macrophages, has also been shown to be upregulated in the plasma of 
AAA patients (Juvonen et al., 1997) and Xiong et al showed that TNF-α-/- mice 
failed to develop aneurysms in a CaCl2 model and infliximab (a TNF-α antagonist) 
also blocked formation.(Xiong et al., 2009) Unfortunately infliximab treatment failed 
to prevent aneurysm development if given after the injury model had been 
undertaken and failed to prevent aneurysm growth once established. These results 
have also not been replicated in the AngII aneurysm model and hence their 
relevance to clinical practice is uncertain. 
One cytokine that has attracted a lot of interest in the aneurysm field is TGF-β and 
many leading researchers have attested to the importance of this signalling protein. 
Wang et al (Wang et al., 2013b) summarise the literature with regards TGF-β and 
AAA but essentially TGF-β is thought to decrease inflammatory cell infiltration (and 
thus MMP activity and ECM breakdown), decrease VSMC apoptosis and even 
enhance the production of ECM components by VSMCs and fibroblasts.(Newby, 
2012) In animal models TGF-β inhibition has been shown to augment AngII induced 
AAA (with increased VSMC death and elastin fragmentation),(Wang et al., 2010) 
whilst overexpression of TGF-β can stabilise pre-existing experimental AAA (Dai et 
al., 2005) and protect against AAA rupture. Various single nucleotide 
polymorphisms (SNPs) in genes encoding TGF-β forms and their receptors have 
been reported in genetic studies of AAA populations, although many of these 
appear to be important only in concert with other SNPs or in the presence of 
additional risk factors.(Wang et al., 2013b) TGF-β signalling is downregulated in 
human AAA (Biros et al., 2012) and hence represents an important potential target 
for study; both in terms of the downstream effects discussed here but also because 
of the ability of TGF-β signalling to upregulate TG2 transcription (Ritter and Davies, 
1998) (see section 1.4.1) in response to cellular stress.  
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1.3.4 MMPs and aneurysm pathogenesis 
Matrix metalloproteinases, and specifically MMP-2, -9 and -12, have been 
implicated in the breakdown of the ECM in AAA and are released and activated (via 
uPA and plasmin) by invading macrophages. As the damaged vessel wall dilates, 
intraluminal thrombus is laid down which may drive further expansion (although this 
remains controversial) by aggregating platelets, “trapping” cells and thereby acting 
as a source of secreted proteases.(Fontaine et al., 2002) Whilst much research has 
focussed on the inflammatory nature of aneurysmal disease (Duftner et al., 2006) 
the ability to strengthen elastin and protect it from degradation could prevent the 
initiating event in the pathway detailed in Figure 7 and thus provide a therapeutic 
target for aneurysmal disease.  
A pathway for the time course of MMP production and activity in aneurysms can be 
constructed from the literature; with tissue obtained from early aneurysms showing 
a relative paucity of inflammatory cells and elastin destruction associated with 
MMP-2 produced from VSMCs.(Freestone et al., 1995) In line with the known 
mechanism of activation of MMP-2, TIMP-2 and MT1-MMP are also present but 
MMP-9 is notably absent from AAA samples at this stage of disease. MMP-2 KO 
mice do not develop CaCl2-induced AAA (Longo et al., 2002) and likewise 
deficiency of TIMP2 leads to a decrease in AAA formation, probably via a decrease 
in MMP-2 activation.(Xiong et al., 2006) Transplant of WT macrophages into these 
mice does not return aneurysm formation to control rates, emphasising that the 
likely source of MMP-2 is VSMCs rather than inflammatory 
monocyte/macrophages.(Keeling et al., 2005) 
Additional MMPs are then thought to be recruited by a combination of inflammation 
+/- angiogenesis (Tedesco et al., 2009) and activated MMP-3 and -9 are present in 
aneurysmal aortas in contrast to non-dilated samples. Silence et al reported that 
MMP-3-/-. ApoE-/- double knockout mice show decreased AAA formation but 
persistent atherogenesis, adding weight to the argument that atherosclerosis and 
AAA are divergent processes, but also suggesting that MMP-3 may cause medial 
degeneration, either directly or via activation of MMP-9.(Silence et al., 2001) 
MMP-9 expression is increased 12-fold in patients with aneurysms vs. control 
subjects (Tung et al., 2001) probably due to both increased production by VSMCs 
and release from infiltrating macrophages, and its use as a potential biomarker has 
been proposed. Plasma levels of MMP-9 do appear to be elevated in patients with 
AAA (McMillan and Pearce, 1999) and various authors have shown MMP-9 levels 
in tissue that correlate with increasing size (McMillan et al., 1997) and/or rupture 
risk.(Petersen et al., 2002) There is, however, data that conflicts these findings and 
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certainly no clear indication of how MMP-9 levels could be used clinically either as a 
marker of risk, progression or to indicate complications post repair. Pyo et al 
showed that MMP-9 deficient mice have attenuated development of both elastase- 
and CaCl2 induced aneurysms (Pyo et al., 2000a) and that infusion of WT 
macrophages was sufficient to remove this attenuation, suggesting that 
macrophage derived MMP-9 is required for dilatation in these models.  
MMP-12 has been localised to the aortic media of aneurysmal samples where it is 
produced by inflammatory macrophages (Thompson et al., 1995) and binds with 
high affinity to elastic fibres.(Curci et al., 1998) Transgenic mice deficient in MMP-
12 show reduced (but not absent) aortic dilatation with CaCl2 application (26% vs 
63% dilatation in WT mice) (Longo et al., 2005) perhaps suggesting that MMP-12 
produces dilatation in combination with other MMPs and is involved in the later 
stages of aneurysm progression. 
In a study by Eskandari et al (Eskandari et al., 2005) TIMP-KO mice developed 
larger aneurysms than their WT countertypes suggesting that an imbalance of MMP 
activity versus inhibition is fundamental to AAA development. In line with this, the 
pharmacological inhibition of MMP activity has been widely investigated in relation 
to aneurysm formation, however, with somewhat inconsistent results. Doxycycline, 
a broad spectrum MMP inhibitor, has been shown to decrease aneurysm formation 
in both rat (Petrinec et al., 1996, Sho et al., 2004) and mouse (Bartoli et al., 2006) 
elastase models and in various cellular, murine and human studies has been shown 
to reduce MMP expression as well as activity (see (Newby, 2012) for further 
details). It is unclear whether doxycycline reduces inflammation per se, or “just” 
ECM proteolysis, and if so what the pathogenic significance of each of these 
scenarios might be. Certainly the clinical trials of doxycycline have as yet been 
inconclusive and underpowered to assess action on aneurysm size or growth rate 
(Dodd and Spence, 2011) and a large scale, randomised, clinical trial (Non-Invasive 
Treatment of AAA Clinical Trial – NCT01756833) is currently underway in the 
United States to validate the potential use of doxycycline as a therapeutic agent in 
AAA. 
There is now a wealth of evidence implicating MMPs in the pathogenesis of 
aneurysm disease; further understanding is needed as to how these proteases 
interact with each other, and with their inhibitors, to effect the ECM breakdown seen 
in aneurysmal disease and crucially whether their actions can be modified to 
prevent disease without deleterious side effects.  
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1.3.5 Genetic basis for AAA 
Family history is a strong risk factor for the development of AAA, second only to 
smoking, and is independent of both atherosclerosis and smoking.(Nordon et al., 
2011) A history of a first degree relative with a diagnosed AAA doubles the risk of 
AAA prevalence (Larsson et al., 2009) and if a family history is present then 
subjects are also more likely to develop AAA at a younger age. It has been argued 
that this represents a high-risk population who should be offered screening at an 
early age.(Moll et al., 2011)  
There is also a very high male preponderance of AAA compared to female patients 
(ratio 6:1) which is higher than the discordance seen in coronary artery disease 
(ratio 2:1) and is not explained by gender bias in any one known risk factor; again 
suggesting that aneurysmal disease is distinct from atherosclerotic disease.  
The heritability of AAA has been assessed in a number of twin studies with a 
reported OR of 36 in monozygotic and 5 in dizygotic twins.(Wahlgren et al., 2010) 
This Swedish study concluded that the heritability of AAA was very high (70%), 
suggesting that key genetic causative factors are waiting to be discovered. Despite 
this promise, candidate gene association studies and genome wide linkage studies 
have thus far produced variable results and have generally been under-powered to 
draw meaningful conclusions. Many of the problems with these studies stem from 
the late age of onset of AAA disease, the low post-mortem rates in many countries  
and the lack of available biological samples from patients with AAA.(Golledge and 
Kuivaniemi, 2013) Coupled with these issues are the difficulties in classifying study 
controls which may variably come from the unscreened population (i.e. those not 
known to have a AAA diagnosis), the screened population (with an ultrasound-
proven normal aortic diameter) or those who have undergone aortic surgery for 
another reason (e.g. aorto-occlusive disease).  
The key findings from gene-association studies are summarised in Table 3 
however, whilst genome wide association studies (GWAS) may represent the best 
opportunity for identifying target genes, they require extremely large patient (and 
control) numbers and rely on collaborations between extensive networks of 
researchers and clinicians. Others have focussed their efforts on specific genes 
based on the known likely mechanisms of AAA development and Morris et al report 
on a meta-analysis of all published data related to SNPs within MMP and TIMP 
genes and their association with AAA.(Morris et al., 2014) Once again, the authors 
comment on the problems of under-powered studies which incompletely report on 
other risk parameters, but they do find that the 5A risk allele in the MMP3 gene is 
associated with AAA with an OR of 1.48 in a dominant inheritance model. This 
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deletion polymorphism is associated with an increase in MMP-3 mRNA expression 
and protein content in aneurysm samples and clearly represents a biologically 
plausible gene candidate. 
Whilst human studies are plagued by a lack of early disease samples, there are a 
multitude of animal studies, and predominantly genetic mouse models, which have 
aimed to identify or confirm genes of interest in AAA disease. These range from the 
“blotchy” mouse (Brophy et al., 1988) – which has defective ECM cross-linking due 
to impaired copper metabolism and develop thoracic aortic aneurysms – to the 
ApoE and (low density lipoprotein receptor (LDLR) (Tangirala et al., 1995) knockout 
mice which develop spontaneous AAA if subjected to a high fat diet. Other 
transgenic mice models of relevance to this thesis are discussed where appropriate 
and clearly much can be learnt from these animals, however any findings obtained 
from murine studies must be confirmed in human patients. It is this ability, to 
translate preclinical findings to the care of patients, that has, as yet, been absent in 
the field of AAA research.  
  
- 39 - 
Type of 
Study 
Patient 
Numbers 
Key Finding Proposed 
Mechanism 
Reference 
Candidate 
gene study  
2836 cases, 
16 732 
controls 
(unscreened) 
AAA associated with 
locus on 
chromosome 9p21.3 
in non-coding RNA 
gene CDKN2BAS 
(OR 1.31) 
CDKN2BAS thought 
to regulate cyclin 
dependent kinase 
inhibitors CDKN2A 
and CDKN2B. 
Cdkn2b
-/-
 mice show 
increased elastase-
induced AAA 
(?mediated via p53 
apoptosis pathways) 
(Helgadottir 
et al., 2008) 
GWAS 123 cases, 
112 controls 
(screened) 
AAA associated with 
SNP in contactin-3 
gene 
(OR 1.33) 
Not fully understood. 
Contactin-3 gene 
encodes a cell 
adhesion molecule 
found in aortic wall 
(Elmore et 
al., 2009) 
GWAS 1292 cases, 
30503 
controls 
(unscreened) 
AAA associated with 
SNP in DAB21P 
gene 
(OR 1.21) 
DAB21P encodes a 
protein known to be 
involved in the 
downregulation of 
cell survival and 
proliferation 
(Gretarsdottir 
et al., 2010) 
GWAS ~2000 cases, 
~ 5000 
controls 
AAA associated with 
SNP in LRP-1 gene 
(OR 1.15) 
LRP-1 gene encodes 
low density 
lipoprotein receptor 
protein-1 which is 
thought to signal via 
Smad pathway and 
may be involved in 
maintaining normal 
blood vessel stability 
(Bown et al., 
2011) 
Table 3. Key findings from genetic studies in AAA 
The table summarises some of the key genetic associations reported for AAA with 
the highest level(s) of supporting evidence. None of the GWAS (or candidate gene 
studies) have reported odds ratios that would be consistent with the high degree of 
heritability seen in population based epidemiology studies and from screening 
programmes and registry data.   
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1.3.6 Newer therapies  
The potential of MMP inhibitors as treatments for AAA have been discussed, but 
there are clearly complex mechanistic networks involved in the pathogenesis of 
aneurysm disease and any therapeutic agent would have to specifically target some 
or all of the involved pathways without causing unwanted side effects. Davis et al 
(Davis et al., 2014) outline a number of novel therapies which include anti-
hypertensives (ACEi and ARBs which have been linked in animal studies to 
inhibition of AAA development) and immunosuppressive agents, and emphasise the 
importance of evidence for therapies which target aneurysm progression rather 
than initiation. From a clinical perspective, patients are only diagnosed and 
identified as having an aneurysm once significant ECM degradation has already 
occurred. Potential therapies must be able to prevent progression and slow growth 
through ECM protection and/or regeneration.  
One signalling pathway which appears amenable to modification is the c-Jun N-
terminal kinase (JNK) pathway which is stimulated by numerous “stress molecules” 
including Ang-II, TNF-α and IFN-γ, which have all been implicated in aneurysm 
disease. Yoshimura et al (Yoshimura et al., 2005) found that this pathway is 
upregulated in AAA samples in humans and using two different murine models of 
AAA showed that inhibition of JNK could both prevent initiation of experimental 
dilatation and, more importantly, cause regression of established aneurysms.  
Micro-RNAs (miRNA or miRs) may represent another mechanism whereby several 
different cellular processes can be targeted simultaneously in a tissue-specific 
manner.(Maegdefessel et al., 2013) These small, non-coding RNA molecules can 
act to silence mRNA and regulate gene expression and have been implicated in 
numerous disease processes (see Bartel for a review (Bartel, 2004)). In AAA, miR-
21,(Maegdefessel et al., 2012a) miR-29b (Maegdefessel et al., 2012b) and miR-712 
(Kim et al., 2014) have all been shown to have a role in aneurysm development and 
manipulation of these molecules can reduce aneurysm formation in the Ang-II 
infusion aneurysm model. Although miRNA-targeting molecules are currently in pre-
clinical development for the treatment of cancer, heart disease and insulin 
resistance there are numerous challenges with these therapies, including off-target 
effects and the ability to deliver the drug to the target cells in a therapeutic dose.(Li 
and Rana, 2014)  
Novel therapies for the treatment of AAA are clearly needed to help what is a very 
high-risk population; currently available interventions are associated with 
considerable risk and a better understanding of aneurysm pathogenesis is 
fundamental to the development of effective medical therapies. As yet it is unclear 
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whether expansion of AAA occurs through the same mechanism as formation, and 
delineating these two processes will be key to furthering our collective 
understanding of this potentially fatal disease. 
1.3.7 Experimental models of aneurysms 
AAA is a major cause of death in the western world yet its pathophysiology remains 
poorly understood, in part because of the progressive, silent nature of aneurysm 
development. Surgical AAA repair gives access to only “end-stage” tissue for 
histological analysis and even this is decreasing in availability due to the increased 
rate of endovascular repair. There is a lack of age-matched “normal” aortic tissue 
with which to compare disease samples (with most “control” tissue originating from 
young deceased patients or elderly vascular patients undergoing surgery for aorto-
occlusive disease) and even if available this would not allow for study of disease 
progression (Tsui, 2010) and/or potential therapeutic interventions.  
In vivo models are therefore required and a number of large animal models have 
been proposed in the literature. Whilst each species has its advantages – sheep 
have a similar coagulation system to that of humans whilst the swine arterial system 
is comparable in terms of size and anatomy – and large animal models will 
undoubtedly be required to study future surgical and technological advancements, 
mouse models of disease predominate in pathogenesis hypothesis testing because 
of “their small size…cheapness…ability to compare well documented genetic 
backgrounds and the ability to delete or overexpress specific genes”.(Daugherty 
and Cassis, 2004) 
Although spontaneously occurring genetic mutations have been shown to lead to 
aneurysm development (as in the “blotchy” mouse) these animals are limited in 
their usefulness because of systemic pathology and thus, three key mouse models 
of aneurysm development have evolved and are discussed below. 
1.3.7.1 Angiotensin II model 
First described by Daugherty et al,(Daugherty et al., 2000)  the AngII model of 
aneurysm formation was discovered as a “by-product” of experiments to identify the 
role of AngII in atherosclerosis in ApoE deficient (hyperlipidaemic) mice. These 
mice had AngII infused (at a dose of 500-1000ng/kg/min) for 28 days via a 
subcutaneous osmotic mini-pump and showed an increased number of new 
atherosclerotic lesions and (unexpectedly) AAA development in the suprarenal 
aorta. This dilatation was not related to local atherosclerosis but histologically did 
show medial breaks and dissections (a feature not commonly seen in human 
aneurysms), gross inflammation and thrombus formation.  
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In this model aneurysm formation appears to be independent of changes in blood 
pressure, cholesterol and triglyceride levels and has a male predisposition as in 
human disease. However this model has a number of limitations in that WT mice 
are relatively resistant to AngII aneurysm formation, with much lower incidence than 
hypercholesterolaemic mice (Daugherty et al., 2011) (meaning that an ApoE 
deficient or LDLR deficient background is necessary, and adds to the complexity of 
transgenic experiments), and Ang II induced aneurysms are prone to rupture (Cao 
et al., 2010) with quoted rates of 10-47% (Chamberlain et al., 2010, Saraff et al., 
2003) leading to high rates of mouse mortality. In addition, several studies have 
shown that ApoE-/- mice have altered immune responses with impaired immunity 
after bacterial challenge (Roselaar and Daugherty, 1998) and decreased delayed-
type hypersensitivity.(Laskowitz et al., 2000) Ang II appears to act through 
angiotensin 1a (AT1a) receptors to induce aneurysm formation; as shown by the 
inhibition of aneurysm development by AT1-receptor blockers or by the transgenic 
knockout of the AT1a receptor completely (causing inhibition of aneurysm 
development) or in endothelial cells (causing attenuated aneurysm 
development)(Rateri et al., 2011) however the relevance of this mechanism to 
human aneurysm formation is yet to be fully elucidated. 
1.3.7.2 Elastase model 
The elastase model of AAA development was first introduced because of the 
disrupted nature of elastin observed in human aneurysmal tissue. Initially 
established in rats (Anidjar et al., 1990) and subsequently adapted by Pyo et al 
(Pyo et al., 2000b) for use in mice, this model involves infusion of type-1 porcine 
pancreatic elastase (PPE-1) into the infra-renal aorta, after isolation from the rest of 
the circulation by proximal (distal to the renal arteries) and distal (at the level of the 
iliac bifurcation) ligatures. The procedure is technically very difficult and results in 
immediate mechanical dilatation of the vessel that persists for up to a week. This is 
followed by an inflammatory response with adventitial macrophage infiltration, 
destruction of the medial elastic lamellae and rapid vessel dilatation. Although this 
model has been used to study a number of gene targets (Thompson et al., 2006) it 
should be noted that some authors claim that aneurysm development varies 
depending on the source of the elastase used,(Carsten et al., 2001, Curci and 
Thompson, 1999) possibly suggesting a role for “contaminators” found in some 
commercial preparations. A recent publication by Bhamidipati et al (Bhamidipati et 
al., 2012) has attempted to simplify this model by reporting the development of AAA 
with periadventitial application of elastase. Regardless of route of administration 
however, the administration of elastase as an experimental model shortcuts the 
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“trigger factors” for AAA development, focusses solely on the downstream effects of 
elastolysis and hence is not first choice for our work investigating the potential 
protective role of TG2.  
1.3.7.3 Calcium chloride (CaCl2) model  
Intimal calcification is a common feature of vessels displaying atherosclerosis and 
up to 80% of human AAAs show significant arterial wall calcification.(Maier et al., 
2010) First published by Gertz et al (Gertz et al., 1988) the CaCl2 aneurysm model 
was initially described as application of 0.5M CaCl2 on to the carotid arteries of 
rabbits. A 60% increase in diameter was seen after just 3 weeks and crucially, 
histological examination revealed some of the key features of human aneurysmal 
tissue; specifically elastin calcification, thinning of elastin and loss of fibre waviness 
as well as MMP induction, inflammatory cell infiltration and loss of VSMCs. 
In 1997 Freestone et al (Freestone et al., 1997) adapted the model to induce 
aneurysms in rabbit aortas (using a combination of CaCl2 and thioglycylate 
application) but it was not until 2001 that Chiou et al (Chiou et al., 2001) reported 
the use of CaCl2 as a reproducible model of AAA formation in mice. Since then 
many authors have used the technique of applying CaCl2 directly to the ventral 
surface of the aorta and “knock-out” and transgenic technologies have been utilised 
to investigate different aspects of aneurysm formation. 
The specifics of the model (CaCl2 concentration, duration of application and time 
from induction to harvest) differ significantly between research groups and some 
authors advocate the use of CaCl2 application plus either elastase or collagenase, 
the combination of which seems to generate larger diameter aneurysms than CaCl2 
alone. The ability to accelerate or retard aneurysm development by altering CaCl2 
concentration has potential benefits in a novel project such as this where the 
response to injury is unpredictable, however no matter which protocol is used, the 
CaCl2 model displays may of the features of human AAAs, as summarised by 
Wang et al.(Wang et al., 2013a) It is also relatively simple to perform, results in 
minimal bleeding (pilot data) and CaCl2 application can be localised to the infra-
renal aorta, the site of 95% of AAA development in humans, thus minimizing the 
confounding variable of altered blood flow in the renal arteries 
Unlike the AngII model, the CaCl2 model does not have a male preponderance and 
does not require a hyperlipidaemic, pro-atherosclerotic background. As such it can 
be undertaken in WT mice meaning that subsequent transgenic studies do not 
require complex, time-consuming breeding strategies. Furthermore the CaCl2 
model allows direct comparison between pre- and post-induction vessel diameter 
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and between adjacent or opposing (ventral vs. dorsal) sections of treated and 
untreated aorta so that each mouse can act as its own control.  
Freestone et al (Freestone et al., 1997) and others have reported that CaCl2 
application appears to cause aortic wall thickening rather than true dilatation (as 
observed by an increase in outer vessel diameter (OD) but not inner diameter (ID)) 
however all studies utilising this model have employed similar techniques of aortic 
measurement (either analysis of photographs of the exposed vessel or in-vivo 
analysis by digital callipers, a micrometer, video microscopy or calibrated grids) 
(Wang et al., 2013a) and it is generally accepted that this model represents the 
early stages of vascular injury (and aneurysm development) rather than an end-
point of gross dilatation.   
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1.4 Transglutaminases  
Transglutaminases (TGs) were first described in 1959 (Clarke et al., 1959) and 
comprise a family of 8 catalytically active enzymes (and 1 inactive homologue) 
which have the primary function of introducing intra-chain and inter-chain isopeptide 
linkages between polypeptide chains. These calcium dependent enzymes catalyse 
the formation of a covalent bond between a free amine group (for example that 
found on a protein-bound lysine residue) and the gamma-carboximide group of a 
protein or peptide bound glutamine residue (see Figure 8). This ε(γ-glutamyl) lysyl 
bond shows high resistance to proteolytic breakdown and hence transglutaminases 
have been described as “biological glues”(Griffin et al., 2002) and the process of 
bond formation likened to “spot-welding”. This section gives an overview of the 
structure and function of TG2 and FXIII-A, the transglutaminases of interest in this 
study, and briefly outlines the roles of the other family members, both in terms of 
their known physiological functions and their contributions to various disease 
processes. The evidence from  mouse models of TG2 and FXIII-A deficiency is 
summarised in chapter 2, however, where relevant, knock-out models of the other 
transglutaminases are discussed here. 
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Figure 8. Transamidating role of TG2 
Schematic showing the various transamidation reactions catalysed by TG2. In A) two proteins are cross-linked through the formation of a covalent 
bond between the γ-carboxyamide group of a peptide bound glutamine and the ε-amino group of a peptide bound lysine residue. In B) a protein 
modification occurs by reaction with a primary amine. Finally in C), if there is no suitable amine available then a water molecule acts as an acyl 
acceptor to deaminate a glutamine residue to glutamate. This situation may require the presence of an acidic environment however selective 
deamidation of certain residues with concurrent transamidation of others has been reported (see text).
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1.4.1 Transglutaminase 2 (TG2)  
Transglutaminase 2, also known as tissue transglutaminase (tTG), cytosolic- or 
liver-type transglutaminase, is the most ubiquitous of the transglutaminase family, is 
found in numerous mammalian tissues (including lung, liver, heart, bone and 
spleen) and is expressed by almost all cell types including osteoblasts, 
mesenchymal stem cells, endothelial cells and SMCs; although the level of 
expression varies considerably with cell type. 
Encoded by a gene mapping to human chromosome locus 20q11-12, TG2 is a 
protein comprising 687 amino acids with a molecular mass of 77.3kDa and four 
distinct structural domains; an N-terminal β-sandwich domain, a catalytic core and 
two C-terminal β-barrel domains. As with the other TGs, the most recognised 
function of TG2 is its ability to transamidate proteins, leading to protein cross-
linking, protein modification (by addition of a primary amine) and/or deamidation. 
These reactions are summarised in Figure 8 and this function is located within the 
catalytic core of TG2 which contains the “catalytic triad” of cysteine (at position 
277), histidine (335) and aspartate (358) residues seen within numerous cysteine 
proteases.(Gundemir et al., 2012) The transamidating activity of TG2 is calcium 
dependent and cooperative binding of calcium at (at least) 6 binding sites is thought 
to give rise to the “open” or active conformation of TG2 (see Figure 9). There is 
increasing evidence, however, that a rise in calcium concentration alone is not 
sufficient for activation and that TG2 is probably latent in terms of its transamidation 
activity in most circumstances and that its non-enzymatic functions are of greater 
importance than previously recognised. 
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Figure 9. Regulation of TG2 activity 
Cartoon depicting the regulation of TG2 transamidating activity. TG2 with bound 
GDP/GTP is held in a stable compact “closed” structure which is inactive in terms of 
transamidating function. Binding of calcium promotes an “open” or “active” 
confirmation whilst oxidation of this protein results in the formation of disulphide 
bridges within the active site, and catalytic inactivity. Figure re-drawn and modified 
from Eckert et al. (Eckert et al., 2014) 
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Uniquely amongst the TGs, TG2 can bind guanine nucleotides and hydrolyses GTP 
to couple adrenoreceptors, thromboxane and oxytocin receptors (amongst others) 
to phospholipase C in cell-signalling pathways.(Lorand and Graham, 2003) TG2 
has also been hypothesised to bind ATP and function as a protein kinase (Mishra 
and Murphy, 2004) (although this function has not been demonstrated in vivo) and it 
has been shown to have actions as a protein disulphide isomerase and a protein 
scaffold.(Wang and Griffin, 2012) This multitude of actions has led to TG2 being 
described as a “molecular Swiss army knife”,(Gundemir et al., 2012) a term which 
highlights the importance of the structural conformation of TG2 in its various 
functions (see Figure 9). For example; binding of GDP/GTP, which occurs between 
the catalytic core and the first β-barrel domain,(Jang et al., 2014) stabilises a 
compact “closed” structural form of TG2 which inhibits its transamidating function. 
Likewise, calcium binding inhibits GTP binding, thus providing reciprocal regulation 
of function.(Nakaoka et al., 1994)  
Further regulatory mechanisms have been identified which mean it is likely that the 
enzymatic activity of TG2 is transient in most situations. For example, key cysteine 
residues can be nitrosylated by reaction with NO (Lai et al., 2001) leading to 
inactivation of its transamidating function and predominance of other roles. This is 
hypothesised to be the mechanism which links TG2 to arterial stiffening, whereby 
decreased NO bioavailability leads to decreased S-nitrosylation and a relative 
increase in TG2 cross-linking of vascular wall proteins.(Santhanam et al., 2010) 
Likewise, reduction of TG2 (possibly by thioredoxin)(Jin et al., 2011) reverses the 
vicinal disulphide bond formation which occurs between cysteine residues (Cys 370 
and 371) and which normally render extracellular TG2 catalytically inactive. Finally, 
the ability of TG2 to act at the cell surface to bind fibronectin, integrins (and other 
partners) with high affinity, means that it becomes unable to participate in cross-
linking reactions. Although much of this data needs confirmation in the in vivo 
setting, it is clear that TG2 regulation is complex and multifactorial and that its 
primary function at a given time point is influenced by a number of factors.  
As well as the structure of TG2, it is also apparent from the literature that the 
location of TG2 is critically important in determining activity. TG2 has intracellular 
roles as well as those within the ECM and at the cell surface and its various 
functions take precedence depending on its location; for example the protein 
disulphide isomerase activity of TG2 (Hasegawa et al., 2003) appears to be key in 
the cytosolic compartment where TG2 can modify mitochondrial proteins to affect 
ATP homeostasis, whereas the scaffolding function (i.e. its ability to form 
complexes with fibronectin and integrins) is crucial at the cell surface where it 
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mediates cell-adhesion and migration. Clearly this location-specific activity adds a 
layer of complexity when trying to investigate the actions of TG2 and means that in 
vitro data must be appreciated with caution.  
Given the importance of TG2’s physical location is seems surprising that more is 
not yet known about how it reaches the extracellular space. The TG2 protein lacks 
a conventional hydrophobic leader sequence so must be secreted by an alternative 
mechanism to the conventional Golgi/ER pathway.(Cordell et al., 2010) It had 
previously been assumed that TG2 was only found extracellularly when cells 
became damaged or membrane integrity was compromised but Verderioet al 
showed that increased TG2 expression in cultured fibroblasts results in increased 
extracellular TG2 without the need for conditions of cellular stress.(Verderio et al., 
1998) No clear secretion mechanism has as yet been discovered but some authors 
suggest that TG2 is released via microparticle formation (van den Akker et al., 
2012) whilst others report that either an intact structure (Gaudry et al., 1999) or the 
ability of TG2 to alter its structural confirmation may be a key determinant in its 
extracellularisation.(Balklava et al., 2002)   
The control of TG2 expression is primarily mediated at the transcriptional level and 
various activators of transcription (and their respective downstream binding sites on 
the TGM2 gene) have been identified and include retinoic acid, IL-6, NFκB, hypoxia 
inducible factor (HIF), TNF-α and TGF-β. Because of these activators, and its 
upregulation under conditions of tissue injury, TG2 is increasingly recognised as a 
stress-related protein (Wang and Griffin, 2012) which acts to limit cell damage. Just 
as cell stress increases TG2 expression, it may also increase nuclear translocation 
of TG2, thus enabling TG2 to act as a regulator of transcription in its own right. 
Some of these actions are mediated through transamidation – for example the 
cross-linking of transcription factor SP1 by TG2 in response to ethanol, 
downregulates SP1 mediated gene transcription (Tatsukawa et al., 2009a) – whilst 
the observed TG2 mediated increase in NFκB transcriptional activity occurs by 
mechanisms which are as yet incompletely understood. 
Another means by which protein function may be altered is through the generation 
of splice variants which may be preferentially expressed in disease states. At least 
4 splice variants of TG2 (TG2H, TG2H2, TG2v1 and TG2v2) have been reported, all 
of which show alternative C-terminal domains (Phatak et al., 2013) with loss, or 
impaired, GTP-binding. TG2H is a truncated isoform which shows increased 
transamidating activity (presumably due to removal of GTP-mediated inhibition) and 
upregulated levels of TG2H have been reported in the brains of patients with 
Alzheimer’s disease. TG2H2 is also a shortened form of the TG2 protein at only 349 
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amino acids in length and has been shown to be induced in rat neuronal astrocytes 
after exposure to inflammatory cytokines; this splice variant has a lower 
transamidating activity than constitutive TG2, but activation requires lower 
concentrations of calcium. TG2v1 and TG2v2 are both generated by alternative 
splicing events (Lai et al., 2007) and have decreased catalytic activity but the 
biological significance of these (and other) isoforms is yet to be fully investigated. 
One of the most examined roles of TG2 is its association with apoptosis and it has 
variably been described as having either a primarily pro- or anti-apoptotic 
phenotype. Certainly, overexpression of TG2 has been linked to increased 
apoptosis and in response to “stressful” conditions such as UV radiation, TG2 
accumulates and is activated by Ca2+ release brought about by the same stimuli 
(Odii and Coussons, 2014) (which may include the production of ROS, or retinoic 
acid, for example). TG2 can then initiate apoptosis via cross-linking of intracellular 
proteins and subsequently mediates the clearance of dying cells by a) formation of 
chemoattractant molecules (which promote macrophage migration), b) the 
activation of macrophage released TGF-β and c) the release of phosphatidyl serine 
which increases the recognition of apoptotic cells by macrophages.  
When located in the nucleus however, TG2 has anti-apoptotic effects which are 
independent of its transamidation and cross-linking activity and relate instead to its 
interaction with nuclear transcription factors. One example of this is the interaction 
of TG2 with retinoblastoma protein (pRb) which results in the polymerisation of 
transcription factors (e.g. NFκB), prolongation of activity and the up-regulation of 
anti-apoptotic genes. Such interactions have been shown in several cancer cell 
lines (Verma and Mehta, 2007, Kim et al., 2006) and also in breast tumours where 
levels of TG2 expression correlate with NFκB activity and are related to resistance 
to doxyrubicin chemotherapy.(Park et al., 2009) In the ECM, TG2 can stabilise 
ECM-cell binding in cooperation with fibronectin and/or integrins and thus can 
protect against anoikis (Verderio et al., 2003) (a form of apoptosis occurring when 
normally anchored cells detach from the ECM) and activate cell survival pathways 
mediated via FAK and PI3K/Akt (Verma and Mehta, 2007) or Rho/ROCK 
signalling.(Wang and Griffin, 2012)  
TG2 has many other functions which may impact on the cardiovascular system 
including roles in inflammation and platelet function, however its contribution to 
apoptosis may prove critical to its role in aneurysm development. TG2 expression 
shows a close correlation with the occurrence of developmental (Fesus, 1999) and 
induced (Fesus et al., 1987) apoptosis yet TG2-/- mice show normal development 
and induced thymocyte apoptosis.(De Laurenzi and Melino, 2001) Some authors 
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have postulated a direct role of TG2 in programmed cell death (Melino et al., 1994) 
whilst others emphasise the relationship with the apoptosis regulator BAX (Rodolfo 
et al., 2004) (leading to mitochondrial pore formation and permeabilisation), and 
others report that TG2 can induce release of apoptosis inducing factor (AIF) in a 
caspase-independent apoptosis pathway.(Fok and Mehta, 2007) Certainly the 
cross-linking function of TG2 may help stabilise dying cells (Fesus and Szondy, 
2005) and help to minimise the leakage of intracellular components and the Melino 
TG2-/- mouse has been reported to  have macrophages with impaired ability to 
engulf and clear apoptotic cells, possibly due to the formation of fewer, less efficient 
phagocytic portals.(Toth et al., 2009) TG2-null macrophages may also show an 
altered, pro-inflammatory, cytokine response to apoptotic cells (Falasca et al., 
2005) thus potentiating the risk of subsequent inflammation. Whether the pro-
apoptotic roles reported are truly due to increased death in vivo, or actually, to 
impaired macrophage clearance of apoptotic cells warrants further study.  
In contrast to its pro-apoptotic function, many authors report a protective effect of 
TG2 against apoptosis, primarily due to its role in adhesion dependent survival 
signalling (Fesus and Szondy, 2005, Kotsakis and Griffin, 2007) thus it is possible 
that TG2 may promote survival of “damaged” cells, and hence inflammation and 
tissue damage, in aneurysm development rather than affording protection. 
Gundemir et al (Gundemir et al., 2012) hypothesise that “overall TG2 is upregulated 
in response to stress…however if the insult is excessive…TG2 may also facilitate 
cell death”.  
Aside from its role in cancer through its anti-apoptotic function, TG2 has been 
postulated to have roles in numerous other disease processes, the best studied of 
which is gluten mediated enteropathy or Coeliac Disease (CD). This autoimmune 
condition affects up to 2% of the general population, is characterised by intestinal 
villous atrophy and inflammation, manifesting as chronic diarrhoea and 
malabsorption and is triggered by dietary exposure to gluten. TG2 has a dual role in 
CD in that it deamidates glutamine residues within protease-resistant gluten 
peptides  prior to their uptake by antigen presenting cells (thus stimulating the T-cell 
mediated adaptive immune response), and it forms complexes with gluten proteins 
+/- collagen which act as triggers for B-cell production of TG2-specific antibodies 
(thus stimulating the humoral immune response).(Iismaa et al., 2009) Anti-TG2 
autoantibodies can be detected on serological testing or patients and NICE 
guidelines recommend IgA tissue transglutaminase testing as first-line investigation 
in anyone suspected of having CD.(NICE, 2015) 
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TG2 has also been implicated in the pathogenesis of cataracts (through cross-
linking of lens proteins), Huntington’s disease (by promoting the formation of 
neurotoxic insoluble aggregates of the huntingtin protein within the striatum and 
cerebral cortex) and Alzheimer’s Disease (via TG2 mediated formation of 
angiotensin-II (AT2) receptor oligomers). Within the cardiovascular system TG2 has 
been reported to be involved in cardiac hypertrophy,(Small et al., 1999) arterial 
remodelling,(Bakker et al., 2005) atherosclerosis,(Haroon et al., 2001) coronary 
artery disease (Sumi et al., 2002) and arterial calcification (Faverman et al., 2008) 
although reports are conflicting with (for example) work from our group showing no 
difference in buried plaque formation in ApoE.-/-TG2-/- mice when compared with 
ApoE-/- mice.(Williams et al., 2010) Much of the controversy regarding TG2 arises 
from the theoretical ability of FXIII-A to compensate for TG2 deficiency, highlighting 
the potential value of the TG2-/-.FXIII-A-/- double knockout (DKO) mice in teasing out 
the roles of TG2 in health and disease. 
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Figure 10. Cellular source of plasma FXIII-A 
Diagram summarising the work from our group undertaken through a BHF Programme Grant (PG/03/080/15731). Using two different thrombocytopenic 
mouse lines and cre-lox fingerprinting we have generated evidence to disprove the historical theory that platelets are the source of plasma FXIII-A. We instead 
hypothesise that the cellular source of plasma FXIII-A is a population of resident tissue cells, most likely macrophages, which are located in the heart and 
aorta. These cells are generated from primitive (flt-3-independent) yolk-sac haematopoiesis and migrate early to the dorsal aorta. We believe that the cells are 
primed to produce FXIII-A in foetal and adult life, and may act as a source of FXIII-A to facilitate tissue repair after injury. These cells can replace themselves 
autonomously or can be displaced by bone-marrow derived macrophages generated via definitive (flt-3-dependent) haematopoiesis. Full publication in 
preparation; Characterisation of the cellular source of plasma FXIII-A using a novel FXIII-A floxed mouse – Griffin, Simpson & Beckers et al.(Griffin et al., 
2015)  
HSC = haematopoietic stem cell, CMP = common myeloid progenitor, GMP = granulocyte/macrophage progenitor, MEP = megakaryocyte/erythrocyte 
progenitor, MP = megakaryocyte precursor, Meg = megakaryocyte, AGM = aorto-gonadal mesonephros, Pf4 = Platelet factor-4, Mpl = thrombopoietin 
receptor, flt-3 = Fms-like tyrosine kinase-3.  
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1.4.2 Factor XIII-A (FXIII-A) 
Factor XIII is a pro-transglutaminase found in plasma – complexed as a 
heterotetrameric structure (A2B2 or pFXIII-A) consisting of two globular active “A” 
subunits and two strand-like inactive, carrier “B” subunits – and in cellular form (as 
A2 or cFXIII-A) in megakaryocytes, chondrocytes, osteoblasts and certain 
macrophage populations. FXIII-A is the only transglutaminase which is known to 
exist in dimeric form and consists of two polypeptides of mass 83kDa which each 
contains an N-terminal β-sandwich domain, a central core domain for catalysis 
(containing the Cys/His/Asp triad) and two β-barrel domains as are seen in other 
TGs. FXIII-A also possesses a 34-residue N-terminal activation peptide which is 
cleaved during FXIII-A activation enabling access to the active site cysteine 
residue. 
FXIII-B is a monomeric protein of ~80kDa mass which is encoded by the F13B 
gene on human chromosome 1 and which consists of 10 short “sushi” repeat 
domains. FXIII-B, which is synthesised in, and secreted from hepatocytes, does not 
contain the catalytic triad, has no transglutaminase activity and is thought to act 
primarily to carry FXIII-A and protect it in the circulation. In agreement with this role, 
homozygous deficiency of F13B leads to markedly reduced pFXIII-A protein and 
activity levels,(Souri et al., 2008a) however, FXIII-B is also thought to have a 
regulatory role in the thrombin activation of pFXIII-A (see Figure 11) and mediates 
the binding of the A2B2 structure to fibrinogen. FXIII-B is present in excess in the 
circulation with up to 50% found in a non-complexed state,(Komaromi et al., 2011) 
meaning that newly secreted FXIII-A can be rapidly and efficiently bound. 
Similarly to TG2, FXIII-A lacks an identifiable hydrophobic leader sequence and 
secretion could not be observed under conditions where interleukin-1β (a non-
classically secreted protein) could be demonstrated.(Cordell et al., 2010) The 
cellular source of the plasma pool of FXIII-A is also, as yet unknown, although 
historically bone marrow transplant experiments have been interpreted as showing 
that the likely source is platelets or platelet precursors of the megakaryocytic 
lineage.(Poon et al., 1989) Experiments conducted by our group however, have 
previously demonstrated that pFXIIIA levels are normal in two thrombocytopenic 
mouse lines; the Bcl-xplt20 mouse, which shows rapid platelet turnover and 
clearance and the Mpl-/- mouse, which has a targeted mutation of the 
thrombopoietin receptor.(Cordell et al., 2010)  
A programme of work has subsequently shown that in fact, the likely source of 
pFXIII-A is a subset of resident aortic macrophages which are generated early in 
embryonic development and are variably replaced and repopulated by circulating 
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monocyte/macrophages. This work has relied on the use of lineage specific deletion 
of FXIII-A using the FXIII-A floxed mouse (described in section 2.1) and mice 
expressing cre-recombinase driven by the following promoters; Pf4, Cd11b, LysM 
and Flt-3 which would be expected to cause gene deletion in megakaryocytic cells, 
macrophages – CD11b and LysM cre are both (differentially) expressed in 
macrophage populations – and bone marrow derived cells respectively. We have 
compared the effects of –cre deletion on both pFXIII-A and cellular FXIII-A mRNA 
and by this “fingerprinting” approach have shown that the profile of depletion of 
pFXIII-A closely resembles that of FXIII-A mRNA in the aorta, suggesting that aortic 
resident macrophages and/or cells closely related to them, maintain pFXIII-A. The 
dorsal aorta is a site to which primitive haematopoietic cells migrate early in 
development, raising the possibility that location within this aortic niche “primes” 
macrophages to secrete pFXIII-A into the circulation. Heidt et al (Heidt et al., 2014) 
have shown that occupation of certain tissue niches is associated with 
conformational and cytoskeletal changes (as in the heart where resident 
macrophages become elongated and spindle shaped) and it may be that similar 
structural changes are ultimately required for pFXIII-A secretion. A summary of this 
work can be seen in Figure 10 and further details obtained in (Griffin et al., 2015).  
The primary function of pFXIII-A is haemostasis and its roles in fibrin-matrix 
stabilisation and platelet activation are well established.(Muszbek et al., 1999) 
Although FXIII-A does not impact clotting-time, it cross-links monomers within the 
fibrin mesh of the developing thrombus and thus increases the stiffness of the fibrin 
clot 5-fold. FXIII-A cross-linking also incorporates α2-plasmin inhibitor (α2-PI) into 
the clot and reduces plasminogen-fibrin binding thus increasing the resistance of 
the clot to lysis. The activation of FXIII-A in the circulation is shown in Figure 11 and 
is maximally efficient in the presence of both thrombin and calcium (although 
activation can proceed in a non-thrombin dependent pathway) and is enhanced in 
the presence of fibrin.(Komaromi et al., 2011) Intracellular activation of FXIII-A also 
requires calcium binding to elicit a conformational change, exposing the catalytic 
site, but this requires only a small increase in calcium concentration in comparison 
to that seen in the coagulation cascade. In contrast to its activation, FXIII 
inactivation is less well studied but appears to occur through oxidation (Robinson et 
al., 2000) and to a lesser extent via proteolytic inactivation by non-specific 
proteases such as MMP-9 and elastase.(Muszbek et al., 2011b) 
Unsurprisingly, patients with FXIII-A deficiency show prolonged bleeding time with 
weaker clots that are easier to lyse. The bleeding phenotype seen in these patients 
can vary markedly but spontaneous haemorrhage, haemarthroses and recurrent 
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miscarriage are all features of deficiency.(Muszbek et al., 2011a) It should be noted 
however that only ~5% plasma activity of FXIII-A is required to control bleeding in 
humans and heterozygous FXIII-A deficiency in humans (with resulting 50% plasma 
activity) is usually asymptomatic.  
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Figure 11. Activation of clotting Factor XIII 
Schematic showing activation of clotting factor XIII and its role in the production of a 
cross-linked fibrin clot. Plasma FXIII is activated in a thrombin-mediated pathway by 
cleavage of a 34-residue activation peptide. Following calcium binding, the carrier 
B-subunits are released to generate activated clotting FXIII-A. This enzyme, via its 
transglutaminase activity, is able to cross-link fibrin fibres in the developing 
thrombus as well as incorporating protease inhibitors (such as α-2-plasmin inhibitor) 
and thus contributes to the generation of a stable clot that is resistant to lysis. For 
further details see text. 
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Multiple polymorphisms of the F13A gene have been reported with 5 (Val34Leu, 
Tyr204Phe, Pro564Leu, Val650Ile, Glu651Gln) being the most common. Of these 
polymorphisms, the change from valine to leucine at position 34 (Mikkola et al., 
1994) is the most well studied and frequent, occurring in up to 25% of Caucasians 
and with less frequency amongst African populations. The Val34Leu site is close to 
the cleavage site for thrombin and the Leu polymorphism accelerates the release of 
the activation peptide from pFXIII-A by 2.5-fold. The Tyr204Phe and Pro564Leu 
polymorphisms have been shown to decrease FXIII-A activity, consistent with their 
location within the catalytic core of the enzyme, and although FXIII-A 
polymorphisms have variably been reported to be related to risk of myocardial 
infarction (MI), deep vein thrombosis (DVT) and arterial thrombosis (amongst other 
pathologies) these claims have not been supported by evidence from GWAS 
studies.   
As yet, FXIII has not been shown to have the pleiotropic actions of TG2 however 
there is significant evidence of protein disulphide isomerase activity (Lahav et al., 
2009) and certainly the transglutaminase actions of FXIII-A are not limited to fibrin 
cross-linking. Additional substrates of FXIII-A catalysis include other fibrinolytic 
proteins (e.g. plasminogen and thrombin activatable fibrinolysis inhibitor (TAFI)), 
ECM proteins (including fibronectin, osteopontin and vitronectin), cytoskeletal 
proteins (including actin and myosin) and others such as the AT1 receptor and α-2-
macroglobulin.(Muszbek et al., 2011b)  
Although many of the non-clotting functions of FXIIIA remain controversial, there is 
a significant body of evidence supporting its role in wound healing, inflammation 
and angiogenesis. Patients with FXIII deficiency may show impaired wound healing 
– an observation first made in 1961 (Beck et al., 1961) – however not all patients 
show impairment with rates reported at 14-36% (Muszbek et al., 2011b) depending 
on study population and inclusion criteria. Certainly, FXIII-A deficient mice show 
decreased wound healing, delayed re-epithelialisation and abnormal scar formation 
(Lauer et al., 2002, Inbal et al., 2005) and there is evidence of the involvement of 
FXIII-A in chronic venous leg ulceration.(Zamboni and Gemmati, 2007) The 
potential mechanisms by which pFXIII-A exerts its action on wound healing are 
multiple and include a role in fibroblast and monocyte proliferation, migration and 
survival (Soendergaard et al., 2013) as well as pro-angiogenic effects via 
endothelial cells, downregulation of thrombospondin-1 (TSP-1, an inhibitor of 
angiogenesis) and vascular endothelial growth factor (VEGF) receptor-2 mediated 
signalling.(Dardik et al., 2006) Cellular FXIII-A may also be in involved in wound 
healing; its expression is increased in activated macrophages (Torocsik et al., 
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2005) and it has been shown by one group to cross-link AT1 receptors in 
monocytes leading to enhanced G-protein signalling and increased phagocytosis of 
apoptotic cells and cellular debris (although this has not been replicated by other 
investigators). The actions of pFXIII-A and cFXIII-A in response to tissue injury are 
summarised succinctly in (Muszbek et al., 2011b) and are clearly worthy of further 
study to determine their importance in clinical practice. 
FXIII-A has numerous other postulated roles in addition to its clotting function which 
include the cross-linking of platelet proteins (facilitating platelet spreading and clot 
retraction) and the induction of hypertrophic differentiation in chondrocytes and 
osteoblasts.(Nurminskaya and Kaartinen, 2006) This function is not well 
characterised although some authors have hypothesised a cooperative role of TG2 
and FXIII-A in this potentially pathological process (hypertrophy is characteristic of 
osteoarthritis) which can be induced by IL1-β and TGF-β.(Johnson et al., 2001, 
Johnson et al., 2008b) Given that DKO mice do not show any skeletal pathology it 
seems unlikely that either enzyme has an essential role in bone development and 
calcification (Cordell et al., 2015) although further studies may yet uncover a role in 
healing and repair. 
In the cardiovascular system FXIII-A has been shown to be expressed at the site of 
myocardial infarction, has been implicated in hypertension induced endothelial 
dysfunction and arterial remodelling (Taherzadeh et al., 2010) and may have a role 
in the maintenance of normal vascular permeability (Wozniak et al., 2001, Noll et 
al., 1999a) through cross-linking of ECM proteins such as fibronectin in the 
intracellular clefts between endothelial cells.(Muszbek et al., 2011b) In 2006 
Nahrendorf et al  undertook experiments examining the role of FXIII-A in cardiac 
remodelling, utilising a murine coronary ligation model of MI and comparing FXIII-A 
deficient mice with WT animals and with deficient animals given exogenous FXIII-A 
supplementation. They showed that both heterozygous (FXIII-A+/-) and homozygous 
(FXIII-A-/-) mice suffer from infarct expansion, left ventricular rupture and death 
within 5 days of surgery, whereas the WT, sham operated and reconstituted 
animals had much lower mortality rates (~40% at 10 days). The authors conclude 
that the findings can be explained by an impaired inflammatory response – with 
decreased neutrophil and macrophage recruitment – and an imbalance in matrix 
turnover (with decreased collagen and increased MMP-9 seen in FXIII-A deficient 
animals). Although mortality rates were returned  to normal by FXIII-A 
supplementation there were still physiological and histological differences seen in 
these animals in comparison with controls, supporting an additional role for cFXIII-A 
in cardiac remodelling post-infarct.  
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Interestingly, Souri et al (Souri et al., 2008b) have reported that older male mice 
with FXIII-A deficiency show spontaneous cardiac fibrosis with widespread 
haemosiderin deposition seen on histology. This gender-specific pathology resulted 
in high mortality rates (50% at 10 months) due at least in part to intrathoracic 
haemorrhage. Although the authors hypothesis that the “fighting behaviours” of 
male mice may explain the gender bias in these findings, this has not been proven 
and clearly warrants further study to determine whether cardiac fibrosis is 
secondary to impaired vascular barrier function or to impaired repair post-injury, or 
both. 
Taken as a whole, the above evidence suggests that FXIII-A may have a role in 
cardiovascular stability and repair, which may overlap with that of TG2. A greater 
understanding of this is critical, both in our study of aneurysm development but also 
to investigate the suitability of FXIII-A inhibitors which have been proposed as 
therapeutic strategies for thrombosis (Lorand, 2000b) and arterial 
calcification.(Matlung et al., 2009) 
1.4.3 TG1, 3 and 5: The “keratinocyte-type” transglutaminases  
TG1, 3 and 5 are collectively known as the keratinocyte transglutaminases and are 
primarily found within the spinous and granular layers of the skin epidermis. Each 
enzyme is secreted as an inactive zymogen and all three have transglutaminase 
cross-linking actions which are involved in the formation of the cornified cell 
envelope (CE) in both hair follicle and epidermal development. 
Transglutaminase 1 is encoded by the TGM1 gene at human chromosome locus 
14q11.2 and is predominant in the epidermis where its expression is progressively 
increased in keratinocytes as they migrate towards the surface of the epidermis and 
terminally differentiate into corneocytes. TG1 is also expressed in epithelial cells in 
a variety of organs and has been reported in the endothelium of the cardiac 
microvasculature (Baumgartner et al., 2004) however, experimental TG1 deficiency 
reveals that the primary function of TG1 is in the formation of the lipid and protein 
cell envelope of the skin.  
TG1+/- mice are phenotypically normal, however knockout of TG1 leads to 
impairment of normal skin development, rapid dehydration and death within a few 
hours of birth. In humans, lamellar ichthyosis occurs as a result of defects in TG1 
activity and X-linked ichthyosis is due to excess cholesterol sulphate inhibiting the 
cross-linking ability of TG1. As with all ichthyoses, these conditions manifest as 
thickened, scaly skin which is excessively keratinised and which is thought to be a 
secondary response to try to prevent water loss through an inadequate/absent cell 
envelope.     
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TG5 is also found in the spinous and granular layers of the skin epidermis and is 
thought to stabilise the junction between the stratum granulosum and the stratum 
corneum (the “outermost” layer of the skin that is continuously shed and 
regenerated). A loss-of-function mutation (G113C) within the catalytic core of TG5 
has been shown to be responsible for the autosomal recessive clinical condition 
Acral Peeling Skin Syndrome (APSS) (Cassidy et al., 2005) which presents with 
spontaneous, painless, peeling of the superficial skin of the palms and soles of the 
feet, however no mouse model of TG5 deficiency has as yet been reported.  
TG3 is secreted as an inactive 77kDa zymogen and following activation (by 
cathepsin) is able to cross-link proteins such as loricrin and involucrin during CE 
formation in the upper granular skin layer and within the inner root of hair follicles. 
Although no human disease resulting from TG3 defect or deficiency has been 
discovered, there are conference reports of TG3-/- mice showing curled fur and 
whiskers,(Iismaa et al., 2009) possibly due to a deficiency of crosslinking of the hair 
structural protein trichohyalin. TG3, like TG2, possesses a GTP binding domain and 
has been shown to be expressed at high levels in the amygdala region of human 
brain samples (Kim et al., 1999) but further work is needed to determine the roles of 
TG3 in normal physiology as well as its potential function in disease states. 
1.4.4 Transglutaminases 4, 6, 7 and band 4.2 
The remaining transglutaminase (TG4, 6, 7 and band 4.2) are considerably less 
well understood, in part due to the absence of murine models of deficiency of these 
proteins and/or the lack of a clear role in human disease.  
TG4 or prostatic transglutaminase is a 73kDa protein present in the prostate gland, 
prostatic fluid and seminal plasma of male rodents and humans.(Eckert et al., 2014) 
Rat studies have shown that this enzyme is regulated by androgen levels,(Dubbink 
et al., 1998) and deficiencies in TG4 cross-linking function lead to defective 
copulatory plug formation and decreased fertility in rats and mice. Although initial 
studies about the role of TG4 in prostate cancer were conflicting, it now seems 
likely that TG4 expression correlates with the “aggressiveness” of prostate tumour 
cells and an increased ability to migrate and invade.(Jiang and Ablin, 2011) Davies 
et al have shown that TG4 is expressed in a prostate cancer cell line and knocking 
down transglutaminase function reduced invasive potential in these cells.(Davies et 
al., 2007) Differential expression of several splice variants of TG4 in prostate 
cancer versus benign prostatic hypertrophy has also been cited as potential marker 
of disease (Cho et al., 2010) but this has not been borne out thus far; clearly a 
better understanding of the role of TG4 in this common, often chronic, malignant 
process may lead to earlier diagnosis and more targeted therapies in the future.   
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TG6 is poorly characterised in terms of structure and function. Recent molecular 
modelling studies suggest that TG6 requires proteolytic cleavage to generate the 
catalytically active form of the protein, and, like TG2, likely has GTP-binding 
(intracellular) functions as well as (extracellular) cross-linking roles.(Thomas et al., 
2013) Expression of TG6 is highest in the brain, although transcripts are also seen 
in the testes and lung, and TG6 has been implicated in a number of neurological 
conditions including gluten ataxia (Hadjivassiliou et al., 2008a) and spinocerebellar 
ataxia type-35.(Guo et al., 2014)  Gluten ataxia is a cerebellar disorder presenting 
with loss of coordination, gait abnormality and disorders of eye movement and is 
the result of the production of TG6 autoantibodies to the cerebellum of affected 
gluten-sensitive (coeliac disease) patients.(Hadjivassiliou et al., 2008b) TG6 
autoantibodies can be present in patients with or without neurological symptoms 
and recently have also been implicated in a sub-type of Amyotrophic Lateral 
Sclerosis (ALS) or motor neurone disease.(Gadoth et al., 2015) Although TG6 
function in health and development is poorly understood, mutations in the TGM6 
gene result in the autosomal dominant spinocerebellar ataxia type-35 (SCA35), a 
progressive neurological disorder seen within families in China.(Guo et al., 2014) 
No mouse model of TG6 is currently available however the development of such a 
knockout could provide vitally important insights into these devastating conditions.  
TG7 is the least well studied of the transglutaminases and no genetic KO models of 
this enzyme exist. TG7 appears to be ubiquitously expressed although high levels 
have been reported in testicular and lung tissue specifically.(Eckert et al., 2014) 
Despite this, the function of TG7 is as yet unknown and no specific role in human 
disease pathogenesis has been reported although there is a single observational 
study from Jiang et al (Jiang et al., 2003) suggesting that TG7 expression is 
increased in breast tumour samples as compared to normal breast tissue. Whether 
this represents compensatory upregulation following loss of another 
transglutaminase or a similar role of TG7 to that of TG2 in tumour metastasis 
remains to be seen. 
Band 4.2, a 72kDa protein found on the cell membrane of red blood cells, is the 
only catalytically inactive member of the transglutaminase family,(Iismaa et al., 
2009) due to the active site substitution of alanine for cysteine,(Korsgren et al., 
1990) but it is able to bind ATP and has role in maintaining erythrocyte shape and 
membrane stability.(Eckert et al., 2014) Band 4.2 appears to act by regulating the 
association of band 3 (also known as anion exchanger 1 (AIE-1)) with Ankyrin 
(band 2.1), a protein that facilitates attachment of membrane proteins to the 
structural cytoskeleton. Mutations encoding band 4.2 are rare but account for an 
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atypical form of hereditary spherocytosis in humans (primarily seen in Japanese 
patients) giving rise to haemolytic anaemia, jaundice and splenomegaly. In mice, 
deficiency of band 4.2 (Peters et al., 1999) gives rise to dehydrated red blood cells 
(RBCs) that are smaller and spheroid in shape. These mice are phenotypically 
normal with only mild anaemia and show no changes in the rhesus protein complex, 
which is altered in human deficiency, thus highlighting the importance of 
recognising differences in phenotype (and severity) between human disease and 
transgenic mouse models and the potentials dangers of extrapolating from one to 
the other. 
1.4.5 TG2 and FXIII-A inhibitors 
Transglutaminase 2 inhibitors have been proposed as potential therapeutic targets 
for a number of pathological conditions including pulmonary (Olsen et al., 2011b) 
and liver fibrosis,(Daneshpour et al., 2011) as well as neurological diseases such 
as Alzheimer’s (Johnson et al., 1997) and Huntington’s Disease.(Prime, 2011) It 
has been hypothesised that selective inhibition of FXIII-A may be a viable 
therapeutic approach to thrombosis,(Lorand, 2000a, Leidy et al., 1990) 
atherosclerosis (Lorand, 2000a) and in limiting the complications of indwelling 
central venous catheters.(Daneshpour et al., 2013) These theoretical therapeutic 
agents would function to inhibit the enzymatic activity of the TGs, i.e. their cross-
linking ability, and relies on the assumption that the role of TGs in these disease 
processes is based on their TG function, rather than on the other described roles of 
TG2 and (to a lesser extent) FXIII-A. As further knowledge is acquired about the 
multitude of functions undertaken by TG2/FXIII-A and their roles in important 
cellular signalling, it may be that inhibition is deemed more or less favourable but 
certainly, TG inhibitors in general suffer from a lack of specificity; both in terms of 
specificity of inhibition of enzymatic activity and with regards specificity of inhibition 
of one TG over another.  
Reported TG inhibitors can be classified as either irreversible (the majority of which 
target the active site cysteine residue) or reversible, of which there are competitive 
and non-competitive sub-types. Irreversible inhibitors, also known as suicide 
inhibitors, prevent substrate binding by covalently modifying the enzyme and 
include halomethyly carbonyls (such as iodoacetamide), the Michael acceptors and 
sulfonium inhibitors which are negatively charged at physiological pH and hence 
have been proposed as a viable target to the extracellular pool of TG2.(Keillor et al., 
2015)  These irreversible inhibitors all contain an electrophilic “warhead” which can 
react with the catalytic cysteine residue (Siegel and Khosla, 2007) and a number of 
these agents have been used in in vivo studies, for example in a murine model of 
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diabetic nephropathy (Huang et al., 2009) where irreversible TG2 inhibition with 
NTU281 (a sulfonium)  was shown to reduce collagen accumulation and improve 
the disease parameters of serum creatinine and albuminuria.  
Competitive inhibitors of TGs are those which act as an enzyme substrate 
themselves and hence compete with the natural amine substrates in the cross-
linking reaction. These drugs include the widely used monodansylcadaverine 
(MDC) and in general are widely available (and hence widely used), stable and 
non-toxic.(Siegel and Khosla, 2007) Cystamine also acts as a competitive inhibitor 
of TG2 and has been used in a number of models (both cellular and animal) of 
neurodegenerative disease, (Junn et al., 2003, de Cristofaro et al., 1999, Karpuj et 
al., 2002) however this molecule also inactivates TG2 over time, possibly via the 
oxidation of the disulphide bond within the active site. The competitive TG inhibitors 
are non-specific and will inhibit all TGs and although useful in vitro they pose a 
theoretical risk of generating aminated proteins in vivo which could promote an 
autoimmune response similar to that seen in CD.   
The non-competitive reversible inhibitors are a group of compounds which prevent 
TG activity but do not covalently modify the enzyme, and include GDP/GTP 
analogues (which, on binding, promote the “closed” conformation of the enzyme 
and thus prevent access to the active site), zinc ions (which compete with the 
calcium binding site(s) to prevent activity) and others. It should be noted however 
that TG3 and TG5 also bind GTP, and all the TGs are calcium dependent and 
hence these agents will still have potential problems with specificity.(Badarau et al., 
2013) 
Recent advances in the design and development of TG inhibitors has included the 
use of high throughput screening to identify small molecules which have the 
potential to inhibit enzyme activity. One such study by Yakubov et al (Yakubov et 
al., 2014) targeted the binding of fibronectin to TG2 (because of the known role of 
this interaction in facilitating β-integrin mediated cell adhesion), and found that 
inhibition of this binding site could block cell migration, invasion and proliferation 
without affecting TG2 enzyme activity. Given that TG2 is increasingly implicated in 
numerous signalling pathways it may be that target of its binding partners may 
prove to be a mechanism by which inhibition can be localised to (for example) 
areas of high cell activity in cancer. Work from our group has utilised molecular 
modelling to modify the known binding of the natural compound cerulenin 
(produced by a rice fungus) to FXIII-A to try to generate novel FXIII-A 
inhibitors.(Avery et al., 2015) Although the resulting compound was selective when 
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compared to cathepsin S, it was still not able to differentiate between FXIII-A and 
TG2, again highlighting the challenges of drug design in this field. 
Clearly the ability to inhibit TG function has potential therapeutic benefits in a 
number of conditions and the speed of discovery in this area has increased 
dramatically in recent years however it is important that we continue to investigate 
the role of TGs and their mechanisms of action, particularly in terms of arterial 
protection and response to injury. This understanding may help to mitigate the 
cardiovascular side effects of treatment with TG2 inhibitors or, if TG2 activity is 
found to have a detrimental effect in arterial injury, may identify a new condition in 
which TG2 inhibition is desirable. 
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Chapter 2: TG2 and FXIII-A Deficiency 
Animal studies allow the “integrated actions of proteins to be evaluated in the 
setting of diverse cellular contexts and inputs”,(Iismaa et al., 2009) and murine 
models are increasingly used in basic scientific research because of their 
advantages in terms of small size, relative inexpensiveness and the ability to 
manipulate specific genes either by modification, addition or deletion. This chapter 
introduces the three mouse lines utilised in this work; the TG2-deficient mouse 
(TG2-/-), the FXIII-A deficient mouse (FXIII-A-/-) and the double deficient mouse 
(TG2-/-.FXIII-A-/- or DKO). 
 2.1 TG2 and FXIII-A deficient mouse lines 
Given the multiple ascribed roles of TG2, it would seem likely that knockout of the 
TGM2 gene would prove lethal or at least generate severe phenotypic 
abnormalities. This has not been observed in either of the two widely used TG2-/- 
mouse lines, leading to suggestions that upregulation of, and compensation by, 
other transglutaminases occurs. Numerous authors have hypothesised that 
compensation may occur between TG2 and FXIII-A, however evidence for this is 
lacking and Ismaa et al (Iismaa et al., 2009) have called for use of a double-
knockout mouse model to dissect the “overlapping or opposing roles” of these two 
enzymes. The published literature relating to these mice is summarised (where 
available) and background data from our previously established collaboration with 
the Bristol Heart Institute is provided as context to the results from this thesis. 
2.1.1 The Graham TG2-deficient mouse 
Mice derived by Prof Graham at the Victor Chang Institute in Sydney (Nanda et al., 
2001) (and utilised by us in this work) are produced by cre-lox 
recombination,(Sauer and Henderson, 1988) whereby lox-P sites are inserted into 
introns 5 and 8 of the TGM2 gene (flanking the catalytic core domain). These 
“floxed” mice are crossed with transgenic mice expressing cre-recombinase in the 
germline (under the control of the ubiquitous CMV-promoter) to generate TG2-/- 
mice (Figure 12). These TG2-/- mice show no gross phenotypic abnormality and are 
born at normal size and weight and with expected Mendelian frequency. 
Specifically, Nanda et al report that developmental apoptosis is not 
impaired,(Nanda et al., 2001) although dexamethasone induced apoptosis of 
thymocytes revealed an increased susceptibility to death and increased clearance 
of dead cells. Mearns et al have shown that these TG2-/- mice do show some 
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deficiencies in dermal healing (Mearns et al., 2002) with a reported role of TG2 in 
promoting cell proliferation and stabilising collagen fibrils.  
Professor Graham and his collaborators have gone to considerable lengths to show 
that TG2 is not involved in glucose homeostasis and have challenged the views of 
others who suggest that TG2 is a candidate gene for maturity-onset diabetes of the 
young (MODY). They report that TG2 deficiency on both a C57Bl/6 and a 
129T2/SvlmsJ background is not associated with any difference in fasting blood 
glucose or serum insulin level (compared to WT mice from the same congenic 
background) or in the response to either oral or intra-peritoneal (IP) glucose 
challenge.(Iismaa et al., 2013) Furthermore, they show that constitutive activation of 
the transamidase activity of TG2 (via generation of the TG2R579A mouse) does not 
result in any change in glucose homeostasis. They (and others)(Leiter, 2002) 
advocate the use of >2 strains of unrelated mice when confirming metabolic 
phenotype, as it is clear that susceptibility to DM is influenced by components of 
parental genetic background in ways that are as yet undefined.  
Similar strain differences have been described in the response of TG2-/- mice to 
hepatic injury with both protective and pathological roles of TG2 reported,(Nardacci 
et al., 2003, Sarang et al., 2005, Tatsukawa et al., 2009b, Strnad et al., 2007) 
highlighting the importance of accurate reporting of strain background data and 
emphasizing the need for sequential back-crossing to achieve a known genetic 
background.(Wong, 2002, Lambert, 2007)  
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A
 
B 
Figure 12. Generation of the Graham TG2-/- transgenic mouse 
Panel A depicts a schematic of the cre-lox strategy used by Nanda et al (Nanda et 
al., 2001) whereby loxP sites are inserted within introns 5 and 8 of the TGM2 gene, 
flanking the catalytic core domain. Panel B shows that “floxed” (flanked by loxP) 
mice are then crossed with mice expressing cre-recombinase in the germline 
(under the control of the ubiquitous CMV-promoter). Recombination occurs 
between the loxP sites in all cells and the TGM2 gene is no longer expressed, 
generating TG2-/- offspring. 
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2.1.2 The Melino TG2-deficient mouse  
Mice generated by homologous recombination by Melino et al (De Laurenzi and 
Melino, 2001) have replacement of 1.2kbp of the TGM2 gene with a neomycin 
resistance gene. These mice show loss of the TG2 protein however demonstrate 
some residual TGase activity despite the replacement of exon 6 which contains the 
enzymatic active site of TG2; this residual activity is hypothesised to be due to TG1 
function. These knockout mice (on a mixed background) show no phenotypic, 
developmental or reproductive abnormality and show normal induction of apoptosis 
in both thymocytes and mouse embryonal fibroblasts (MEFs). Szondy et al 
demonstrated, however, that these mice show marked suppression of macrophage 
uptake of apoptotic cells as well as features of autoimmunity.(Szondy et al., 2003)  
This transgenic line has been utilised in numerous studies and has highlighted 
potential roles of TG2 in sepsis,(Bijli et al., 2014) in the development of post-injury 
intimal hyperplasia (Min et al., 2014) and, as discussed above, in glucose 
homeostasis. Bernassola et al reported in 2002 that these TG2-deficient mice were 
glucose intolerant and hyperglycaemic due to impaired insulin secretion, a situation 
analogous to that seen in MODY.(Bernassola et al., 2002) In contrast to these 
results, a hypoglycaemic response was observed following exogenous insulin 
challenge, which, the authors hypothesise, is due to a compensatory increased 
insulin sensitivity in peripheral tissues. This situation is not recapitulated in the 
MODY population, and has not been observed in the Graham mouse and hence its 
relevance to human disease is unclear. Given the more severe phenotype of the 
Melino TG2-/- mouse, and the fact that there is no universally accepted TG2-
deficient mouse model, we elected to use the Graham TG2-deficient mouse in our 
work. This mouse was kindly provided by Professor Bob Graham and was imported 
on a known C57Bl/6 background, eliminating the highlighted issues of mixed strain 
backgrounds and their variable phenotypes. 
2.1.3 The Dickneite FXIII-A-deficient mouse  
Dickneite and colleagues produced a FXIII-A-deficient mouse line (on a mixed 
129Ola/CBACa background) by homologous recombination, with replacement of 
exon 8 (coding exon 7) by a neomycin phosphotransferase selectable 
cassette.(Lauer et al., 2002) Heterozygote offspring (FXIII-A+/-) have plasma activity 
that is 50% reduced when compared with WT and show no obvious phenotype, 
whilst the KO mice have absent plasma FXIII-A activity and show increased tail-tip 
bleeding with decreased clot stability and rapid clot degradation. Subsequent 
studies have shown that these FXIII-A deficient mice show no differences in the 
number of pregnancies achieved, however parturition rates are decreased, with a 
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higher occurrence of miscarriage, maternal bleeding events (including 
subcutaneous bleeding, haemothorax and haemoperitoneum),(Koseki-Kuno et al., 
2003) and maternal death.  As mentioned earlier, male FXIII-A deficient mice 
produced by this technique show a gender-specific decreased survival rate thought 
to be related to cardiac haemosiderin deposition and subsequent fibrosis. These 
pathological changes were found in male mice that had died spontaneously as well 
as those sacrificed at 10 months of age despite apparently normal cardiac function 
in vivo.(Souri et al., 2008b)  
Recent work from Myeni et al has implicated FXIII-A in pre-adipocyte proliferation 
and differentiation (Myneni et al., 2014) and has suggested that the 
transglutaminase activity of FXIII-A leads to crosslinking of fibronectin and matrix 
assembly. This in turn provides a framework on which pre-adipocytes can 
proliferate more readily (in response to insulin) and thus these cells differentiate at 
a lower rate, resulting in less lipid accumulation. This work, combined with findings 
of increased circulating FXIII-A levels in patients with type 2 diabetes (Mansfield et 
al., 2000) and associations of F13A gene SNPs with obesity in GWAS studies 
(Naukkarinen et al., 2010) have prompted suggestions that FXIII-A may play a key 
inhibitory role in the development of obesity. Crucially, there have been no reports 
of obesity in the Dickneite FXIII-A-deficient mouse, and obesity and/or metabolic 
dysfunction are not recognised phenotypes of patients with FXIII-A deficiency. 
Further evidence to support or refute this purported role of FXIII-A has been called 
for (Mosher, 2014) and would obviously be extremely important given the current, 
and increasing, global obesity epidemic. 
Personal communication from the facilities manager at Harlan laboratories (and 
confirmed by our collaborators in Bristol) revealed that the Dickneite  transgenic line 
underwent a phenotypic shift with continued breeding. In contrast to the reports of 
Koseki-Kuno,(Koseki-Kuno et al., 2003) pregnancy and delivery was achieved in 
homozygous KO females (on a mixed background) without any increase in bleeding 
or mortality. This shift occurred with no concurrent change in the impaired clotting 
phenotype and unstable thrombi that were more liable to embolisation were 
observed on intravital microscopy. This observation lends weight to the hypothesis 
that FXIII-A plays a role in (placental) vessel integrity and that this role is distinct 
from its crosslinking function in coagulation.  
To enable us to produce cell-type-specific FXIII-A KO animals for a programme of 
work investigating the cellular source of pFXIII-A (see section 1.4.2), and in light of 
concerns about the stability of the vascular phenotype, we chose not to utilise the 
Dickneite mouse, instead commissioning the generation of a novel floxed FXIII-A 
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mouse from GenOway (Lyon, France). Details of the cre-lox strategy utilised in the 
generation of this mouse are shown in Figure 13 and results from the 
characterisation of this mouse are discussed in Chapter 5. 
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Figure 13. Generation of the FXIII-A-/- transgenic mouse 
Schematic of the cre-lox strategy used by GenOway in the generation of our novel 
floxed FXIII-A mouse. The endogenous gene locus is shown (A) as is the locus with 
the addition of LoxP sites which were inserted adjacent to exon 8 of the FXIIIa1 
gene (B). A neomycin cassette flanked by FRT sites is utilised for selection of 
embryonic stem cells. This neomycin cassette was later excised by flp-
recombination to generate FXIII-A floxed mice (C) that can be used for breeding of 
conditional KO lines. We crossed this (mixed background) mice with mice 
expressing cre-recombinase under the control of the ubiquitous CMV promoter to 
generate a constitutive FXIII-A KO line. Back-crossing to >95% C57Bl/6 
background was undertaken to eliminate issues with mixed-strain backgrounds. 
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2.2 TG2 and FXIII-A double knockout mouse line (DKO) 
2.2.1 Rationale for generation of DKO 
It has been widely suggested that some of the pleiotropic functions of FXIII-A and 
TG2 may overlap as they often co-localise intracellularly and both perform intra- 
and extra-cellular cross-linking.(Iismaa et al., 2009) There is also significant 
substrate overlap between the two enzymes (e.g. fibrin, vimentin, osteopontin, type 
III collagen, α-2-antiplasmin and PAI-2 are all crosslinked by both TG2 and FXIII-A) 
and both transglutaminases are expressed and activated in response to tissue 
injury.  
Specifically, overlapping roles for TG2 and FXIII-A have been proposed in the 
cardiovascular system and in the skeletal system during epiphyseal growth plate 
maturation. Expression of TG2 has previously been shown  to correlate with 
chondrocyte differentiation and matrix mineralisation (Aeschlimann et al., 1993, 
Nurminskaya et al., 1998) and in 2009, Tarantino et al reported that expression of 
FXIII-A was increased 5-fold in the distal femoral epiphysis of newborn TG2-/- mice 
which they cite as evidence of functional compensation between the two 
enzymes.(Tarantino et al., 2009) Certainly cultured osteoblasts show a lack of 
mineralisation in the presence of the relatively non-specific TGase inhibitor 
cystamine (Nakano et al., 2007) but this may not reflect the situation in vivo and 
transglutaminase-independent pathways of mineralisation have also been 
reported.(Johnson et al., 2003a) 
Arterial calcification is thought to occur through a process analogous to that in the 
skeletal system and staining for both TG2 and FXIII-A is seen in calcified 
atherosclerotic plaques.(Matlung et al., 2009) Van Herck et al reported that TG2-
deficient mice have a more vulnerable plaque structure but show no difference in 
the number of buried plaques (a surrogate for plaque rupture).(Van Herck et al., 
2010) They hypothesise that this is due to compensation by FXIII-A which is 
expressed within the atherosclerotic plaque and possibly released by infiltrating 
macrophages. Similar overlapping roles have also been proposed in the formation 
of coated platelets (Jobe et al., 2005) since platelet lysates from FXIII-A deficient 
mice show an increased transamidase activity, suggesting that TG2 may 
compensate for a lack of cross-linking activity in this process. 
The most convincing evidence for compensation is from Bakker et al (Bakker et al., 
2006) who showed that TG2-/- mice demonstrate delayed flow-dependent inward 
remodelling. This was associated with an increase in arterial expression of FXIII-A 
and significant transglutaminase activity at the site of injury. Administration of 
liposome-encapulsated clodronate to remove monocyte/macrophages reduced this 
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FXIII-A expression and abolished the delayed remodelling, suggesting that 
macrophage-associated FXIII-A is compensating for a lack of TG2. 
Given the above evidence, it is a clear that a mouse deficient in both TG2 and 
FXIII-A (if viable and lacking any severe phenotype) would eliminate the 
confounding effects of compensation observed in single KO mice and would enable 
the investigation of the functions of these enzymes in the cardiovascular and 
skeletal systems as well as revealing other, potentially unexpected, roles.  
2.2.3 ApoE/TG2/FXIII-A triple knockout (TKO) mouse  
Work performed previously by us and in collaboration with the University of Bristol 
has utilised a triple knockout mouse line with “knockout” of both TG2 and FXIII-A on 
an Apo-E-/- background These mice were found to be viable, fertile, and grossly 
normal in appearance with no apparent deficiencies in growth or skeletal 
development (Cordell et al., 2015)  and normal survival up to the age of 6 months. 
Specifically this work showed no evidence of compensatory upregulation of other 
transglutaminases to WT levels and there was no observed difference in terms of 
atherosclerotic plaque area or stability, as per previous work from our group 
(Williams et al., 2010) although a difference in plaque composition was seen.  
Crucially, Newell et al have observed spontaneous cardiac fibrosis within the hearts 
of ApoE-/-.FXIII-A-/- male mice, which correlates with haemosiderin deposition, 
possibly due to the extravasation of blood from “leaky” cardiac vessels (Newell et 
al, in preparation). This effect is exacerbated by the additional absence of TG2 
however  no cardiac fibrosis was observed in the ApoE-/-.TG2-/- cohort, suggesting 
that TG2 compensates for FXIII-A deficiency, but that dual deficiency leads to 
impaired vessel integrity. Although cause of death data was not collated in this 
study there was a significantly increased observed mortality in the ApoE-/-.FXIII-A-/- 
and TKO groups when the mice were subject to a 12-week period of high-fat 
feeding (mortality rate: ApoE-/- 2.0%, ApoE-/-.FXIII-A-/- 13.2% (p<0.05), ApoE-/-.TG2-/- 
2.2%, TKO 20.5% (p<0.01)). The confounding ApoE-/- background utilised in this 
work (designed primarily to investigate atherosclerosis) may obviously explain 
some of these findings and ApoE may have anti-oxidant and anti-proliferative 
effects (Zadelaar et al., 2007) (which could contribute to its protective role in 
atherosclerosis), as well as immunomodulatory effects.(Laskowitz et al., 2000, 
Tenger and Zhou, 2003).  
Some authors have suggested that ApoE-/- deficiency can lead to increased 
permeability in the blood-brain-barrier (BBB) of KO mice (Methia et al., 2001, 
Hafezi-Moghadam et al., 2007) with implications for the pathobiology of Alzheimer’s 
disease and other neurodegenerative conditions. Although Methia et al did not 
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observe increased permeability in the systemic vasculature, others have reported 
increased Evans Blue leakage in atherogenesis-prone areas (in the aorta and 
carotid) in ApoE-/- mice.(Lundeberg et al., 2015, Phinikaridou et al., 2012) The 
ability to investigate the overlapping roles of TG2 and FXIII-A without the ApoE-/- 
background is obviously critical in my project and in future work pertaining to 
cardiac fibrosis. 
As part of the work undertaken by Newell et al, a carotid artery ligation model was 
utilised to stimulate local vascular remodelling, with thrombosis and neointimal 
formation typically seen in wild-type mice. The results of this work are currently in 
preparation for publication and are summarised in Figure 14. Unexpectedly the 
TKO mice displayed vessel damage with frequent elastic lamellar breaks and 
ultimate vessel rupture. Such a finding could be explained by decreased vessel 
stability (due to TG2 deficiency) combined with an increased bleeding tendency 
(due to FXIII-A deficiency) or alternatively could be due to a dual effect of both TGs 
on arterial structure. The carotid ligation model does not allow for differentiation 
between these two hypotheses, in contrast to the tunable CaCl2 injury model. It 
should be noted however, that similar breaks were also seen in operated TG2-
deficient mice and even in sham-operated triple knockouts (although without 
rupture) indicating that TG2 confers vessel wall stability, but that both 
transglutaminases can contribute to maintaining arterial integrity under basal 
conditions.   
Elastic lamellar flattening - a feature preceding aneurysm development - was also 
seen in the triple knockout mice and dilatation of the carotid artery was observed in 
the ApoE/TG2 double knockout mice, thus adding weight to the hypothesis that 
FXIII-A and TG2 have overlapping structural roles and one (likely TG2) or both may 
be implicated in aneurysm formation. The use of a targeted, modifiable injury model 
to tease out the roles of TG2 and FXIII-A (without a ApoE-deficient background) in 
vessel stability, repair and aneurysm formation is an obvious “next step” to the work 
presented here and I am grateful to Drs Newell and Jackson for their advice and 
guidance in the early stages of this project. 
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 ApoE-/-.FXIII-A-/- ApoE-/-.TG2-/- ApoE-/-.TG2-/-.FXIII-A-/- 
Vessel Dilatation 0 ↑↑ (Died) 
Vessel Wall Breaks 0 ↑↑↑ (Died) 
Vessel Rupture 0 0 ↑↑↑  
                       0/26     6/12 
                                  p<0.01 
Figure 14. Carotid artery ligation model – summary 
Schematic showing carotid artery model. Panels A-D show representative histology 
at each of points A-D from the ligated carotid artery in the triple knockout mouse. 
Panel C demonstrates the characteristic flattening of the elastic lamellae and 
vessel dilatation whilst D shows elastin breaks and vessel rupture. The table 
summarises the results from this work with TG2-deficient mice showing vessel wall 
breaks and increased medial area (vessel dilatation) as in early aneurysm 
formation. The triple knockout mice showed a severe phenotype with vessel rupture 
and a significantly increased mortality rate when compared to either of the single-
transglutaminase deficient mouse lines. Scale bars represent 100µm. All images 
and data received from L. Newell with thanks. 
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Chapter 3: Hypothesis and Aims 
3.1 Hypothesis 
Under basal conditions both TG2 and FXIII-A contribute to the maintenance of 
arterial integrity. TG2 appears to be more important for stability under conditions of 
stress or injury and hence would determine the response to aneurysm induction. 
TG2 can compensate for FXIII-A deficiency and therefore FXIII-A does not play an 
essential role under conditions where TG2 is expressed and can be considered as 
an anti-thrombotic target.   
 3.2 Aims 
1. Generate and characterise mice deficient in TG2, FXIII-A and both TG2 and 
FXIII-A on a C57Bl/6 background 
2. Elucidate the roles of TG2 and FXIII-A in basal vessel structure and 
function, and investigate the evidence for upregulation of other 
transglutaminases to compensate for single/dual deficiency. 
3. Establish the murine calcium chloride model of abdominal aortic aneurysms 
in our Institute  
4. Investigate the roles of TG2 and FXIII-A in aneurysm induction and 
progression using the above model. 
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Chapter 4: Materials and Methods 
4.1 Mouse breeding & husbandry 
All animals were conventionally housed at the University of Leeds. Animal housing, 
husbandry, care and procedures were conducted in accordance with guidelines and 
regulations of the CBS unit of the University of Leeds and of the United Kingdom 
Home Office (Project license holder: Dr Stephen Wheatcroft – Nos. 40/3523 and 
70/8115, Personal license holder: Miss Kathryn Griffin – No. 40/10367). All mice 
had ad libitum access to food (standard chow diet) and water throughout the 
duration of all studies unless specifically outlined. 
4.1.1 Breeding strategy 
TG2 heterozygote founder mice on a C57Bl/6 background were obtained from 
Professor Graham in Australia, housed in the CBS unit of the University of Leeds 
and crossed to generate TG2-/- progeny. Breeding was closely controlled to obtain 
true littermates and to regulate the availability of mice for experimental work.  
To obtain FXIII-A-/- mice, mice floxed in the F13A gene (Figure 13) were crossed 
(by GenOway) with transgenic mice expressing cre-recombinase under the control 
of the ubiquitous CMV-promoter. These commercially obtained heterozygous mice 
were genotyped as detailed below and then bred to homozygosity with back-
crossing (to >95% C57Bl/6) to eliminate strain differences. Double knockout mice 
were obtained following the strategy detailed in Figure 15. In brief, TG2-/- mice were 
crossed with FXIII-A-/- mice to generate double heterozygote (TG2+/-FXIII-A+/-) 
offspring. Further breeding with TG2-/- mice increased Bl6 background percentage 
at each generation whilst ultimately generating TG2-/-FXIII-A+/- mice for eventual sib-
cross breeding.  
Although we undertook a trial breeding programme utilising FXIII-A-/- females 
(results outlined in chapter 5), KO pups were routinely obtained from heterozygous 
female breeding i.e. FXIII-A-/- male x FXIII-A+/- female.  
4.1.2 Breeding and frequency calculation 
To assess the impact of TG2 and FXIII-A deficiency on mouse fertility and breeding 
we analysed litter size and offspring genotype from the following breeding pairs 
(and trios where appropriate). 
1. TG2+/- male x TG2+/- female 
2. FXIII-AWT/flox male x FXIII-AWT/flox female 
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3. FXIII-A-/- male x FXIII-A+/- female 
4. TG2-/-.FXIII-A-/- male x TG2-/-.FXIII-A+/- female 
The average litter size was compared across these breeding pairs/trios and 
analysed by Kruksall Wallis testing. Observed genotype frequencies were 
compared to those expected by Mendelian inheritance and the chi-squared statistic 
used to assess statistical significance of any differences found.  
4.1.3 Weighing 
Groups of mice were weighed weekly to characterise any phenotypic differences 
between the transgenic lines and all mice subject to surgical procedures were 
weighed at regular intervals post-operatively to establish animal well-being 
(standard protocol; day 1, 2, 5, 7 and weekly thereafter). Animals were also 
routinely weighed prior to any study being undertaken to confirm “fitness” to 
undergo the procedure. Any animal showing >15-20% weight loss following any 
procedure was culled as per Home Office guidelines using an approved Schedule 1 
method. 
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Figure 15. Breeding strategy to generate DKO offspring 
Schematic outlining the breeding strategy implemented to generate pups deficient 
in both TG2 and FXIII-A for further experimental work. TG2-/- mice obtained from 
heterozygous founders were crossed with FXIII-A-/- mice to generate double 
heterozygote (TG2+/-FXIII-A+/-) offspring. Further breeding with TG2-/- mice 
increased Bl/6 background percentage at each generation whilst ultimately 
generating TG2-/-FXIII-A+/- mice for eventual sib-cross breeding 
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4.2 Genotyping  
4.2.1 DNA extraction   
Mouse ear notch samples were obtained from newly weaned pups by CBS unit 
staff. These notches are used as both an identification system (see Appendix A: 
Murine ear code identification system) and as samples for DNA genotyping. DNA 
was extracted by placing the ear clippings in a PCR tube and adding 100µl of 
25mM NaOH / 0.2mM EDTA. The sample was then heated in a Thermo cycler 
(Harlow Scientific, UK) to 95ºC for 20 minutes. 100µl of 40mM Tris-HCl was then 
added and the sample vortexed for a few seconds. After nano-drop (NanoDropTM 
1000 Spectrophotometer, ThermoScientific, UK) analysis to assess the DNA 
concentration and purity, samples were frozen at -20ºC prior to PCR. 
4.2.2 Standard PCR and primer details 
Standard PCR was used to determine the genotype of each sample (Figure 16). 
The PCR methods for each of the two genes of interest are described below with 
full details of the primer sequences (all from Sigma, UK) and amplicon sizes shown 
in Table 4. The TG2 primers were already in use in the lab and had previously been 
designed by Dr Richard Pease (University of Leeds) whereas de novo FXIII-A 
primers were designed specifically for this project. 
4.2.2.1 TG2 PCR 
Each reaction mixture was prepared using 0.5μL Taq polymerase 
(ThermoScientific, UK), 0.2 μL primer 1 (RPmouP1L) (amplifies knockout allele-
specific sequence), 0.4μL primer2 (RPmouP2L) (amplifies wild-type allele-specific 
sequence), 0.4 μL primer 3 (RPmouP3L) (amplifies sequence common to both wild-
type and knockout alleles), 0.5 μL dNTPs (Thermoscientific, UK), 2.5 μL of PCR 
buffer solution (ThermoScientific, UK),  17.3μL nuclease-free water and 2 μL 1:10 
diluted DNA. Reaction mixtures were overlaid with 15 μL mineral oil (Sigma, UK) 
prior to PCR to prevent evaporation. PCR cycle details are as follows:  
1. 94ºC for 2 minutes 
2. 94ºC for 15s 
3. 64ºC for 20s 
4. 72ºC for 45s 
5. Repeat steps 2-4 another 29 times 
6. 72ºC for 5 minutes 
7. Cool at 4ºC 
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Products were resolved on an agarose gel consisting of 2% w/v agarose (Bioline, 
UK), 150ml 1X TAE, and 15µl ethidium bromide. A molecular ladder 
(ThermoScientific, UK) was used to estimate amplicon size and the bands were 
visualised under UV light (G:Box scanner, Syngene, UK) after electrophoresis at 
100V for 60 minutes. 
4.2.2.2 FXIII-A PCR 
Each reaction mixture was prepared using 0.5μL Taq polymerase 
(Thermoscientific, UK), 0.4 μL primer 1 (13 intron8FL) (amplifies knockout allele-
specific sequence), 0.4μL primer 2 (13i8R2) (amplifies wild-type allele-specific 
sequence), 0.4 μL primer 3 (13i9R2) (amplifies sequence common to both wild-type 
and knockout alleles), 0.5 μL dNTPs (Thermoscientific, UK), 2.5 μL of PCR buffer 
solution (ThermoScientific, UK),  17.1μL nuclease-free water and 2 μL 1:10 diluted 
DNA. Reaction mixtures were overlaid with 15 μL mineral oil (Sigma, UK) prior to 
PCR to prevent evaporation. PCR cycle details are as follows:  
1. 94ºC for 2 minutes 
2. 94ºC for 15s 
3. 62ºC for 20s 
4. 72ºC for 45s 
5. Repeat steps 2-4 another 29 times 
6. 72ºC for 5 minutes 
7. Cool at 4ºC 
Products were resolved on an agarose gel consisting of 2% w/v agarose (Bioline, 
UK), 150ml 1X TAE, and 15µl ethidium bromide. A molecular ladder 
(ThermoScientific, UK) was used to estimate amplicon size and the bands were 
visualised under UV light (G:Box scanner, Syngene, UK) after electrophoresis at 
100V for 90 minutes. 
 
Figure 16. Genotyping of TG2 and FXIII-A deficient mouse lines 
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Images showing representative gels from the PCR genotyping of ear notches 
obtained from newly weaned pups. Panel A shows genotyping of nine samples from 
FXIII-A breeding with WT (+/+) pups showing a single band of 126bp size, KO (-/-) 
pups showing a single band of 199bp size and heterozygous offspring (+/-) 
displaying both bands. Panel B shows genotyping of 7 samples from TG2 breeding 
with WT (+/+) pups showing a single band of 100bp size, KO (-/-) pups showing a 
single band of 280bp size and heterozygous offspring (+/-) displaying both bands. 
 
Gene Target Allele Sequence 
TG2 KNOCK-OUT 
(280bp) 
GGAGCACACAGGCCTTATGAGCTGAAG 
TG2 WILD TYPE 
(100bp)  
GCACAGATAGGGATACAAGAAGCATTGAAG 
TG2 COMMON GTCCTCGGATGACAAGGTGACAGAGCA 
FXIII-A KNOCK-OUT 
(199bp) 
TCTGGGCCAAACCAAGTACCTGG 
FXIII-A WILD TYPE 
(126bp) 
CAAGACCAGACTGTGCAAAGGG 
FXIII-A COMMON GGGGCATTGCTCCCATGTAAA 
Table 4. PCR primer details; amplicon length and target sequence 
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4.3 Metabolic testing 
4.3.1 Glucose tolerance testing 
Mice of 10 or 40 weeks of age were subject to an overnight fast (~16 hours) prior to 
weighing and measurement of baseline fasting glucose level. An intra-peritoneal 
(IP) injection of 200mg/ml glucose solution was then administered at a dosage of 
1mg/g body weight and blood glucose measurements (in mmol/l) recorded at 30, 
60, 90 and 120 minutes. All samples were obtained from a single tail bleed where 
possible and analysed using the Accu-chek® Aviva glucometer and test strips 
(Roche, UK). Mice were monitored for signs of distress throughout the study and 
food supply was restored immediately after the test had been completed. ANOVA 
testing was used to analyse group average values at each time point as well as 
summary area-under-the-curve data for the tolerance test as a whole.  
4.3.2 Insulin tolerance testing 
Mice of 10 or 40 weeks of age were subject to a 4 hour fast prior to weighing and 
measurement of baseline fasting glucose level. An IP injection of diluted Actrapid 
insulin (Novo Nordisk, UK) solution (0.2 iU/ml) was then administered at a dosage 
of 0.75 iU/kg body weight and blood glucose measurements (in mmol/l) recorded at 
30, 60, 90 and 120 minutes, All samples were obtained from a single tail bleed 
where possible and analysed using the Accu-chek® Aviva glucometer and test 
strips (Roche, UK). Mice were monitored closely for signs of hypoglycaemia 
(irritability, lethargy and coma) and if present were given a “rescue” injection of 
glucose. ANOVA testing was used to analyse group average values at each time 
point as well as summary area-under-the-curve data for the tolerance test as a 
whole.  
4.4 Tissue harvesting 
4.4.1 IVC blood sampling 
To obtain blood samples for FXIII-A activity, 8-10 week old mice were 
anaesthetised with isoflurane and blood was collected under direct vision from the 
inferior vena cava into syringes containing the anticoagulant CTAD (BD 
Biosciences, UK) using a 23 Ga needle. Blood to CTAD ratios (by weight) were 
recorded for later calculation and samples were placed on ice. Plasma was 
separated by centrifugation at 10000g for 10 minutes and then samples were stored 
at -20ºC prior to assay.  
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4.4.2 Organ harvesting 
Tissue samples for analysis were obtained by standard operative techniques 
following perfusion exsanguination (with 5ml PBS) via the left ventricle under 
isoflurane general anaesthesia. Aortas were dissected free of surrounding tissue 
and samples from descending aorta (beyond aortic arch) to iliac bifurcation were 
extracted and snap frozen in liquid nitrogen prior to storage at -80ºC. Where 
required, carotids, hearts, livers, and spleens were also harvested, snap frozen and 
stored.  
4.5 FXIII-A activity assay 
FXIII-A activity was determined with a microtiter assay using fibrinogen and 5-
(biotinamido)pentylamine as substrates, based on a method described by Song et 
al.(Song et al., 1994) Nunc Immuno Maxisorp 96-well microtiter plates (Nunc A/S, 
UK) were coated with 100μL per well of fibrinogen (Calbiochem, UK) at 40μg/mL in 
Tris buffered saline (TBS) (pH 8.3) and incubated at room temperature for 40 
minutes, or overnight at 4ºC. 
The microtiter plate was emptied and washed 3 times with 300µl per well of TBS 
(pH 8.3).  To each well, 300μL of 1% BSA in TBS (pH 8.3) was added and the plate 
was incubated at 37°C for a minimum of 90 minutes before washing with 4 x 300µl 
per well of TBS (pH 8.3). 
10μl of citrated mouse plasma samples, diluted 1 in 100, 1 in 200 or 1 in 400 (to 
give the equivalent of 0.1, 0.05 or 0.025µl neat plasma respectively) in TBS, was 
added in 3 duplicates to the wells, and the cross-linking reaction was started by 
addition of 150μL of the reaction mixture (see Appendix B). 
After incubation at room temperature, the reaction was stopped at 7.5 minutes by 
addition of 200μL of 200mM EDTA. Wells were washed 4 times with 300 μL 
TBS1/0.1% Tween20 and incubated with 100μL of 10μg/mL streptavidin–alkaline 
phosphatase (Sigma, UK) in 1% BSA/TBS1 /0.1% Tween20 for 1 hour at 37°C.  
After 4 washes with 300μL of TBS1/0.1% Tween20, colour was developed by 
incubation with 100μL of 1 mg/mL p-nitrophenyl phosphate (Sigma, UK) in 1 mol/L 
diethanolamine/0.5mmol/L MgCl2 (pH 9.8), for 1 hour at 30ºC. Absorbance was 
measured at 405nm on a Labtek plate reader (ThermoScientific, UK) with readings 
taken every minute for the hour long incubation period.  
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4.6 Rotational thomboelastometry 
Coagulation analysis of murine whole blood was undertaken by rotational 
thromboelastometry using the ROTEM® system (Tem Ltd, UK) which is an 
established viscoelastic method for haemostasis testing. Briefly, IVC blood samples 
were obtained as above and kept on ice prior to rapid transfer to the ROTEM® 
analyser. Each sample was analysed under three conditions designed to replicate 
either activation of clotting by 1) the extrinsic coagulation pathway or 2) the intrinsic 
coagulation pathway or 3) the fibrinolysis of the formed clot. In each case, a 
disposable pin is suspended in the whole blood sample (150µl) and rotated slowly 
back and forth to mimic venous blood flow. Changes in elasticity in the developing 
and resolving blood clot are then transmitted using an optical detector system, and 
are displayed graphically. Measures of clotting time (CT, time until the sample starts 
to clot), clot formation time (CFT, time taken to reach a clot firmness of 20mm), 
alpha angle (a surrogate of CFT), maximum clot firmness (MCF, reflecting the 
absolute clot strength) and lysis index (LI30, the % of the remaining clot stability in 
relation to maximum clot firmness at 30 minutes) were recorded and analysed by 
ANOVA with Bonferroni correction for multiple testing.  
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A. 
 
B. 
 
Figure 17. ROTEM® – experimental set up and representative trace 
Panel A illustrates the experimental set up for the ROTEM® system whereby a 
suspended pin is rotated within the whole blood sample. As a clot is formed the 
movement of the pin is impeded and this resistance is transmitted by the optical 
detection system resulting in a graphical output. Panel B demonstrates a typical 
trace from the ROTEM® system and highlights the key measured parameters of 
clotting time (CT), clot formation time (CFT), alpha angle, maximum clot firmness 
(MCF) and lysis index (LI30). Both images are freely available downloads from the 
ROTEM® page of the TEM group (Basel, Switzerland) product website accessed 
June 2016 (https://www.rotem.de/en/products/rotem-delta/) 
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4.7 Quantitative RT-PCR  
4.7.1 RNA extraction   
RNA was extracted from snap-frozen tissues using the TRIzol method, whereby 
1ml of TRIzol reagent (Life Technologies, UK) was added per 100mg of lysed 
tissue. Phase separation was undertaken by addition of 100µl of 
bromochloropropane (per ml of TRIzol), incubation, and centrifugation at 12000g for 
15 minutes at 4ºC. The aqueous phase was then retained and precipitated with 
10µl of glycogen and 0.5ml of ice-cold isopropanol. After centrifugation, the 
supernatant was removed and the pellet repeatedly washed with 75% ethanol and 
centrifuged (at 7500g for 5 minutes at 4ºC). The pellet was then re-suspended in 
RNAse-free water and either stored at -80ºC or DNA contamination was removed 
immediately using the TurboTM DNAse kit (Ambion, Life Technologies, UK). RNA 
concentration and purity was analysed using the NanoDropTM 1000 
Spectrophotometer (ThermoScientific, UK) and if required, ethanol precipitation was 
performed to concentrate and de-salt preparations. 
4.7.2 Reverse transcription  
Reverse transcription was performed using the Applied Biosystems High capacity 
cDNA reverse transcription kit (Life Technologies, UK). Samples were placed in a 
thermal cycler under optimised conditions (25ºC for 10 minutes, 37ºC for 2 hours, 
85ºC for 5 minutes, 4ºC to cool) and the resultant cDNA diluted 1 in 10 to give a 
10ng/µl solution for real-time PCR. 
4.7.3 Reference gene determination 
Personal experience from our lab and pilot data from this thesis revealed that 
standard reference or “housekeeping genes” such as GAPDH may show 
considerable variation in expression in different mouse tissues; several authors 
have suggested that reference genes should be selected for each experimental 
model used and/or that multiple reference genes used in combination may provide 
a better reference than any one gene in isolation.(Barber et al., 2005, Szabo et al., 
2004, Hruz et al., 2011) 
A combination of literature searching, personal communication (from the Baxter 
group, Nebraska, USA) and use of the “Refgenes” online tool (Hruz et al., 2011) 
(available from http://www.refgenes.org/rg/) revealed that both β-actin (a 
cytoskeletal actin involved in cell motility, structure and integrity) and Rpl-32 (a 
ribosomal protein component of the 60S subunit) have been suggested as suitable 
reference genes for use in studies of arterial gene expression. Testing with qPCR of 
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aortic samples (addition of presumptively similar amounts of DNA) across the 
different experimental genotypes revealed some minor variation in the expression 
of β-actin with relative stability of expression of Rpl-32. This data is shown below 
(Figure 18). For all further qPCR we used both β-actin and Rpl-32 as reference 
genes, standardising to the arithmetic mean of the Ct values obtained from each 
assay. 
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Figure 18. Reference gene determination 
qPCR of aortic samples was undertaken to assess variability of gene expression of 
two potential reference genes; β-actin and Rpl-32. Average Ct (“crossing 
threshold”) values are shown with 95% confidence intervals. ANOVA testing 
revealed no statistically significant difference in Rpl-32 expression (p=0.686), but 
some variation in β-actin expression (p=0.027) across experimental genotypes.  
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4.7.4 Quantitative RT-PCR (qPCR) 
All quantification of gene transcript expression was performed using quantitative 
real-time PCR using the Roche LightCycler 480-II (Roche Diagnostics, UK). 
Reactions were performed in duplicate with 20ng of cDNA added to 15µl of a 
master mix containing DNA primer pairs, water, Taq DNA polymerase and SYBR 
green I dye (Roche). Primer sequences are listed in Appendix E: Quantitative real 
time PCR primer sequences 
Optimised thermal cycling settings were used (95ºC for 10 minutes, 45 cycles of 
(95ºC for 15 seconds then 60ºC for 60 seconds)) and raw threshold cycle (Ct) data 
extracted. The averaged Ct of the reference genes (β-actin and Rpl-32) was then 
subtracted to determine relative gene expression (ΔCt ) and duplicate sample ΔCt 
values were averaged. Mean ΔCts were calculated per mouse genotype group for 
each experimental condition and inserted into the standard formula (2-ΔCt) to 
calculate the relative change in amount of gene product (compared to the 
reference). The value for each gene product was then compared to that seen in the 
wild type e.g. for elastin in the TG2-/- mouse: 
Change in elastin expression = (2-ΔCt of ElastinTG2
-/-) / ((2-ΔCt of ElastinWT) 
and this was compared across mouse genotypes to give a relative fold-change for 
each gene of interest. All statistical analysis was performed on raw ∆Ct values 
rather than transformed data.  
4.8 Basal vessel biochemistry 
Prior to biochemical analysis, snap frozen aorta samples were dehydrated under 
vacuum for 1 hour (which in testing resulted in no further weight change) and then 
weighed. Samples were lysed for a minimum of 48 hours at 4ºC in 750µl of lysis 
buffer (50mM NaH2PO4, 50mM NaCl, 1% Triton, 0.1% SDS) and then centrifuged at 
14000rpm for 10 minutes at 4ºC. The lysate was used for determination of LDH, 
DNA and solubilised protein and the pellet for analysis of either elastin or collagen. 
4.8.1 LDH quantification 
Following the lysis step described above, LDH content was determined using a 
modification of the CytoTox 96 LDH assay (Promega, UK). Samples (50µl) and a 
positive control (supplied) were transferred in triplicate to a 96-well plate 
(ThermoScientific, UK) and incubated with an equal volume of substrate mix 
(supplied) for 30 minutes at room temperature. The enzymatic reaction generated is 
the reduction of NAD+ to NADH, which is catalysed by cellular LDH. A red formazan 
product is then generated by NADH reduction of a tetrazolium salt and hence 
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formazan production is proportional to LDH concentration. Reactions were stopped 
at 30 minutes by addition of a “stop solution” (supplied) and the absorbance was 
read using the Labtek plate reader (ThermoScientific, UK) at a wavelength of 
490nm. Adjusted absorbance was then calculated by subtracting the absorbance of 
the reagent blank (50µl substrate mix) and this was normalised to solubilised 
protein content.  
4.8.2 DNA quantification 
Following the lysis step described above, double stranded DNA content was 
quantified using a modification of the protocol described by Leggate et al in 
2006.(Leggate et al., 2006) In summary, 200µl of assay buffer (50mM NaH2PO4, 
2M NaCl, pH 7.4) containing SYBR green dye at a concentration of 1:20000 was 
added to 10µl of each sample in a 96-well plate and incubated in the dark, at room 
temperature, for 2 hours. Fluorescence was read using the Varioskan fluorometric 
plate reader (ThermoScientific, UK) with a 494/530nm excitation/emission filter set 
with a band width of 12nm. DNA content was then quantified using a standard 
reference curve (0-1000ng) and normalised to solubilised protein content. 
4.8.3 Solubilised protein quantification 
Following the lysis step described above, solubilised protein content was quantified 
using the Pierce BCA Protein Assay Kit (Thermofisher, UK). This colorimetric assay 
involves the reduction of Cu2+ ions to Cu1+ by proteins and the binding of Cu1+ ions 
to bicinchonic acid to generate a purple reaction product. Samples (25µl) and 
albumin standards (in the range 0-2000µg/ml) were transferred in triplicate to a 96-
well plate and 200µl of working reagent (supplied) added before thorough mixing 
and incubation for 30 minutes at 37ºC. Absorbance was read using the Labtek plate 
reader (ThermoScientific, UK) at a wavelength of 562nm and adjusted absorbance 
calculated. Solubilised protein content was determined using a reference standard 
curve. 
4.8.4 Elastin quantification 
Elastin content was determined per milligram of dry tissue using the FastinTM 
(Bicolor Ltd) elastin assay. Briefly, alpha-elastin was extracted by heating for three 
one-hour periods with 0.25M oxalic acid. After pooling of the extracts, Elastin 
Precipitating Reagent (supplied) was added and samples were vortexed and left to 
allow complete precipitation. An elastin-dye complex was formed by addition of the 
Dye Reagent (supplied) which was observed as a reddish-brown deposit after 
centrifugation and removal of unbound dye. Dye Dissociation Reagent (supplied) 
was then added and samples were transferred to a 96-well plate and absorbance 
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read using the Labtek plate reader (ThermoScientific, UK) at a wavelength of 
490nm. Adjusted absorbance was then calculated by subtracting the absorbance of 
the reagent blank (0.25M oxalic acid), elastin content was determined using a 
reference standard curve and this was then normalised to solubilised protein 
content.  
4.8.5 Collagen quantification 
Collagen content was determined per milligram of dry tissue using the SircolTM 
(Biocolor Ltd) soluble collagen assay. Briefly, Sircol Dye Reagent (supplied) was 
added and samples were mechanically mixed for 40 minutes to allow precipitation 
of a collagen-dye complex. Samples were then centrifuged and any unbound dye 
removed by washing with Acid-Salt Wash Reagent (supplied) and further 
centrifugation. The collagen bound dye was released by addition of Alkali Reagent 
(supplied), samples were transferred to a 96-well plate and absorbance was read 
using the Labtek plate reader at a wavelength of 555nm. Adjusted absorbance was 
then calculated by subtracting the absorbance of the reagent blank (100µl de-
ionised water), collagen content was determined using a reference standard curve 
and this was then normalised to solubilised protein content. 
4.9 MMP assay 
To generate conditioned media for zymography, non-operated and experimental 
aortas were harvested into 1ml of PBS on ice before transfer to a 96-well plate 
under sterile conditions. Vessels were submerged in 100µl of OptiMEM 
(Thermofisher, UK) culture media supplemented with penicillin and streptomycin. 
Samples were incubated for 48 hours at 37ºC, 5% CO2 and then 25µl aliquots snap 
frozen in liquid nitrogen and stored at -80ºC. Gelatin (for MMP-2 and -9) and casein 
(for MMP-12) zymography was undertaken using pre-cast gels from Invitrogen 
(Thermofisher, UK). A lane marker and positive control was included in each 
experimental run and 10µl of each sample was loaded per well in 1:1 ratio with 
loading buffer (0.2g SDS (2%), 0.01g bromophenol blue (0.1%) in 5ml stacking 
buffer (6.06g Tris-HCl (0.5M) and 0.05g Sodium Azide in 100ml water, pH 6.8) and 
5ml 40% glycerol). Gels were run in 1X SDS running buffer (10X solution - 30.2g 
Tris-HCl, 144g Glycine, 10g SDS in 1l water, pH 8.3) at 125V for 60-90 minutes. 
Gels were then washed (for 3 x 20 minutes) in 2.5% Triton X-100 before incubating 
at 37ºC for 3-7 days in developing buffer (7.5g Tris base (50mM), 11.7g NaCl 
(200mM), 0.7g ZnCl2, 0.74g CaCl2.2H2O (5mM), Triton X-100 (2%), Brij-35 (0.05%), 
0.2g NaN3 (0.02%) in 900ml water, pH 7.4). After staining for 1 hour (1g coomassie 
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blue in 500ml methanol, 200ml acetic acid and 300ml water), gels were de-stained 
(300ml methanol, 693ml water, 7ml formic acid) for a minimum of 2 hours before 
imaging under UV light (G:box scanner, Syngene, UK). 
4.10 Endothelial permeability 
Vascular permeability within the aorta was determined using a method similar to 
that described by Orr et al. (Orr et al., 2007) Briefly, 8-12 week old mice were 
anaesthetised using inhaled isoflurane, and were then warmed and restrained to 
allow injection of 0.1ml of 1% Evans Blue into the tail vein. Mice were recovered 
and then 30 minutes later were re-anaesthetised and euthanized by perfusion with 
10mls of 4% paraformaldehyde (PFA) (see Appendix) via cardiac puncture into the 
left ventricle. The whole aorta (from descending aorta to iliac bifurcation) was 
dissected and excised and samples were immediately dried in a vacuum oven for 1 
hour before weighing. After determination of weight, samples were incubated in 1ml 
of formamide for 24 hours at 60ºC. An Evans Blue concentration curve was 
constructed in the range 0-1000ng/ml and transferred to a 96-well plate along with 
the extracted samples. Absorbance was read using the Labtek plate reader 
(ThermoScientific, UK) at 620nm and adjusted absorbance calculated by 
subtracting absorbance of the reagent blank (formamide). Evans Blue content of 
each sample was calculated from the concentration curve and then normalised to 
sample weight. 
4.11 Wire Myography  
Wire myography studies were set up and optimised following a standardised 
experimental protocol and further assays were carried out in conjunction with Dr Lih 
Cheah. A summary protocol diagram is shown in Figure 19 but briefly; mice aged 8-
12 weeks old from each experimental genotype (n=4) were killed (as per Home 
Office Schedule 1 guidelines) and the abdominal aorta dissected in cold Hanks 
solution (see Appendix C: Wire myography solutions). 
Aortic rings (2 per sample) of 1mm length were then mounted in a myograph 
(610 M, Danish Myograph Technology), left to equilibrate for 30 minutes, and then 
placed under normalised tension in a bath of pre-warmed (to 37ºC), and gassed 
(with 5% CO2) Krebs solution.  
Contractile function of the vessel was assessed by the addition of 1) high 
concentration potassium (60mM K+ in Krebs solution), and then 2) phenylephrine 
(PE, 1µM), to the organ bath. A concentration response curve of % contraction vs. 
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PE dose was then constructed by the step-wise addition of 0.03, 0.1, 0.3, 1.0, 3.0 
and 10.0µM PE. Each concentration was applied and then contraction response 
recorded; when a steady state was reached, the next concentration was 
administered. 
Finally, the relaxation response to carbachol (CCh, 1µM) was observed following an 
induced vessel contraction with 1µM PE. A relaxation response to CCh - which 
occurs via NO release - confirms the presence of an intact endothelial layer and this 
step was performed as a control mechanism to ensure that the endothelium had not 
been damaged during dissection or mounting.  
EC50 values (the concentration of PE required to produce 50% maximal response) 
were calculated by non-linear regression analysis using Origin® software 
(OriginLab Corp., USA) and these, as well as area-under-the-curve data and force 
differences (maximum-minimum contraction), were compared across genotypes 
using ANOVA testing (with Bonferroni correction) or Kruksal-Wallis testing (with 
Dunn’s correction) as appropriate. 
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Figure 19. Myography experimental protocol 
Schematic showing myography experimental protocol. 60K=Krebs solution 
containing 60mM K+, PE=phenylephrine, CCh=carbachol, * denotes points at which 
the solution bathing the vessel was exchanged three times with fresh pre-warmed, 
gassed, Krebs solution.  
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4.12 Carotid ligation model 
The carotid ligation model was undertaken as previously carried out by Newell et al 
in Bristol; mice aged 8-12 weeks were weighed, anaesthetised with inhaled 
isoflurane and restrained on a warmed operating surface. A midline neck incision 
was performed and the right common carotid artery located and exposed using a 
combination of blunt and sharp dissection. The vessel was slung using a small strip 
of silicone and photographed using the OPMI-PICO video system (Carl Zeiss AG) 
to allow baseline vessel diameter measurements (below the carotid bifurcation) to 
be taken post-operatively. The common carotid artery was then ligated using a 3/0 
silk suture and the wound washed out with 0.9% sterile saline and closed using 
continuous 6/0 vicryl sutures. Operated mice were recovered in a warmed clean 
cage, returned to their cages and were given a soaked diet for 24-48 hours to 
facilitate adequate nutrition 
After 28 days mice were re-anaesthetised and arterial perfusion-exsanguination 
performed via the left ventricle using 5mls PBS (outflow via the transected IVC) 
followed by 10mls 4% PBS-buffered PFA. The right carotid artery was then 
dissected from surrounding tissue and removed for histological processing and 
analysis. 
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A. 
 
B. 
 
 
 
Figure 20. Carotid artery ligation model 
Panel A depicts a simplified diagram of the anatomy of the neck in the mouse when 
in a supine position. The right common carotid artery is identified and isolated 
(using a small piece of silicone) as shown in Panel B. The vessel is then 
photographed and can be measured (if required) at a later time, using the “invert 
contrast” function in Image Pro. After imaging, the vessel is ligated using a 3/0 silk 
suture to completely occlude blood flow and the wound is closed and the animal 
recovered. Scale bar = 1 millimetre 
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4.13 Calcium chloride (CaCl2) model  
The protocol for the CaCl2 model is summarised in Figure 21. Mice aged 8-12 
weeks were weighed, anaesthetised with inhaled isoflurane and restrained on a 
warmed operating surface. The abdomen was then shaved, epilated and cleaned 
with ethanol for laparotomy. In each case the abdominal aorta was exposed and 
isolated from the surrounding retroperitoneal structures using blunt dissection. 
Photographs of the abdominal aorta were captured using the OPMI-PICO video 
system (Carl Zeiss AG) and base-line vessel diameter measurements (midway 
between the left renal artery origin and the iliac bifurcation) were taken post-
operatively.  
After image capture, 0.25M or 0.5M CaCl2 was applied to the external surface of 
the aorta using a cotton gauze applicator. NaCl (0.9%) was substituted for CaCl2 in 
sham operated mice. After 7 minutes the applicator was replaced with a second 
solution-soaked applicator and after a further 7 minutes the aorta was rinsed with 
0.9% sterile saline and the incision was closed in layers using 8/0 and 6/0 vicryl. 
Buprenorphine in the form of Vetergesic® (Reckitt Benckiser) was administered as 
an intra-peritoneal injection (dose 0.5mg/kg) to minimise post-operative pain and 
then mice were recovered in a warmed clean cage and were returned to their cages 
when deemed fully recovered. Operated mice were given a soaked diet for 24-48 
hours to facilitate adequate nutrition. 
Either six weeks or six months later (depending on study group) the mice 
underwent re-laparotomy and dissection. Images were captured at the same 
location in the mid-infra-renal aorta. Aortas were then either harvested fresh (for 
myography), snap frozen in liquid nitrogen (for mRNA, biochemical and 
zymography studies) or perfusion-fixed with 4% PBS-buffered PFA and harvested 
for histological analysis.  
Vessel measurements pre-and post-injury were calculated from the calibrated 
captured images using Image-Pro software (MediaCybernetics). In all cases 
measurements were made in agreement by two investigators after processing the 
images using the “invert contrast” function to allow better visualisation of the vessel 
walls. An anatomical landmark (e.g. branch vessel point) was sought for pre-injury 
diameter measurement; for post-injury diameters, measurements were taken at the 
point of maximal dilatation. 
In a subset of mice, the CaCl2 model was applied to the common carotid artery 
rather than the abdominal aorta. In these mice the carotid was approached and 
exposed as per the carotid ligation model (see section 4.11), the vessel was then 
isolated from surrounding tissue using a small strip of silicone (Eddington’s Ltd., 
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UK) and photographed. Using a small cotton applicator, 0.5M CaCl2 was applied to 
the artery for 2 x 7 minutes as detailed above, the area was then washed with 
saline and the neck wound closed in a single layer with 6/0 vicryl sutures before 
recovery.  
Data were analysed by calculation of the % change in infra-renal aortic diameter 
and comparison across groups with Student’s t-test (for 2 groups) or one-way 
ANOVA testing with Bonferroni correction (for >2 groups). The proportion of mice 
that developed an aneurysm was generated by count of mice exhibiting a greater 
than 50% increase in aortic diameter; these data were analysed using Fisher’s 
exact test (of proportions). 
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Figure 21. CaCl2 aortic injury model 
Panel A details the overall experimental protocol for the CaCl2 aortic injury model. 
Panel B shows details of the operative procedure; i) laparotomy is performed with 
retraction of the skin edges (ii) and exposure of the aorta (iv). Blunt dissection is 
used to free the aorta from surrounding fascia (iv) and then CaCl2 is applied using 
cotton gauze (v and vi). Following 2 x 7 minute applications of CaCl2, the site is 
washed with normal saline (vii), dried (viii) and the wound closed in two layers (ix to 
xii).   
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4.14 Histology 
4.14.1 Processing 
Perfusion-fixed samples were stored in 4% PFA for a minimum of 48 hours and 
then dehydrated using the Leica TP1020 tissue processing carousel (Leica 
Microsystems) before paraffin embedding. All samples were subject to a 17 hour 
processing programme as detailed in Appendix D: Histology – additional 
methodological detail. Immediately after processing the tissue samples were placed 
into plastic moulds and embedded with liquid paraffin (Sigma-Aldrich, UK) which 
was then hardened by cooling. 
4.14.2 Sectioning 
All microscopy slides were pre-coated prior to use (see Appendix D). Either 
representative sectioning (at random intervals) or serial sectioning of vessel 
samples (from left renal artery to iliac bifurcation) was undertaken on the Leica 
RM2125 microtome (Leica Microsystems, UK) at a section thickness of 5μm. Slides 
were left to dry at 37ºC overnight and then stored.  
4.14.3 Haematoxylin and eosin 
Histological slides were de-waxed and rehydrated with xylene and stepwise ethanol 
before washing in distilled water. Slides were then stained in Harris’ haematoxylin 
solution (Sigma, UK) for approximately 10 minutes prior to washing and 
differentiating in 1% acid-alcohol (1% HCl in 70% EtOH). After washing, slides were 
allowed to “blue” in 0.2% ammonia water before washing with tap water and rinsing 
in 70% ethanol. Counterstaining with eosin Y stain (Sigma, UK) was undertaken for 
~30 seconds and then stains were dehydrated with ethanol and xylene. Coverslips 
were applied with DPX mountant (Sigma Aldrich, UK) 
4.14.4 Miller Van Gieson (for elastin) 
Histological slides were de-waxed and rehydrated with xylene and stepwise ethanol 
immersion and were then washed and dried. Slides were then sequentially placed 
in 0.5% potassium permanganate solution, 2% oxalic acid solution, distilled water 
and ethanol (to rinse) before staining with Miller stain (Cell Path, UK) for 1 hour. 
Excess stain was removed with ethanol, and then slides were stained with Van 
Gieson stain (100ml of saturated aqueous solution of picric acid added to 5ml of 1% 
aqueous solution of acid fuschin) for 15 minutes, prior to rinsing and incubation at 
70ºC for ~10 minutes until completely dry. Dehydration with xylene was then 
undertaken and coverslips were applied with DPX mountant. 
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4.14.5 Sirius Red (for collagen)  
After de-waxing and rehydration, slides were stained with Weigert’s haematoxylin 
(Atom Scientific, UK) for 10 minutes prior to thorough washing (for at least 5 
minutes) in tap water. Slides were then placed in 1% acid-alcohol to reduce 
background and then incubated in Picro-sirius red solution for 1 hour and washed 
twice in clean acidified water. Excess water was removed by vigorous shaking and 
then dehydration with 100% ethanol was undertaken prior to the application of 
coverslips wiih DPX mountant. 
4.14.6 Alizarin Red (for calcium) 
Histological slides were de-waxed and rehydrated with xylene and stepwise ethanol 
immersion. Slides were then stained with Alizarin Red Solution (see Appendix D) 
for ~2 minutes or until red-orange staining was observed microscopically. Excess 
stain was removed by blotting and then slides were dehydrated sequentially in 
100% acetone and then 1:1 acetone-xylene solution. Coverslips were then applied 
with DPX mountant. 
4.14.7 Perl’s Prussian Blue (for haemosiderin) 
Histological slides were de-waxed and rehydrated with xylene and stepwise ethanol 
immersion. Slides were then incubated with potassium ferrocyanide solution (see 
Appendix D) for 10 minutes before dehydration in histological grade alcohol and 
xylene. Coverslips were then applied with DPX mountant.  
4.14.8 Vessel morphometry analysis 
Maximum elastic lamellae number was quantified in un-operated (n=2 per 
genotype) and sham operated (n=2 per genotype) aortic samples. After perfusion-
fixation, processing and embedding, vessel samples were sectioned with  2 x 5µm 
sections cut at 200µm intervals throughout the area of injury. Maximum lamellae 
number was recorded for each section and then the mean maximum number 
calculated for each vessel and compared across genotypes using Kruksal-Wallis 
testing with Dunn’s correction.  
Elastin damage was quantified in the aneurysm model using an adaptation of the 
method reported by Watanabe et al.(Watanabe et al., 2012) Briefly, n=6 short-term 
aneurysms per group were fixed, processed, embedded and serial sectioned (if 
more than 6 samples were available for analysis then those closest to the average 
diameter change for the group were selected for study). The area of injury was 
identified (either at the time of harvest or on sectioning) and 20 x 5µm sections 
analysed from the central 100µm of injury. The vessel circumference was 
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measured on each section and elastin damage expressed as a proportion (%) of 
total circumference. Elastin fibres were classified by an investigator blind to 
genotype as either 1) healthy, 2) damaged but intact or 3) damaged and broken. A 
similar protocol was followed for examination of un-operated (n=2) and sham-
operated (n=2) aortas and of those injured with CaCl2 and harvested at 6 months 
(n=6). 
Collagen distribution and density was examined using multiphoton microscopy after 
the serial sectioning and sampling protocol as above and staining with Sirius Red 
stain. Slides were scanned at 10X magnification with the Zeiss 710 muliphoton 
microsope to detect the collagen second harmonic generation (SHG) signal at 
excitation wavelength 800-860nm. On each image three areas of interest were 
identified corresponding to healthy elastin, damaged (but intact) elastin and broken 
elastin fibres. Within each area a 10x10 (arbitrary units2) square was drawn and the 
integrated density of the collagen signal was measured using ImageJ software 
(nih.gov, USA). A similar protocol was followed for examination of aortas exposed 
to CaCl2 and harvested at 6 months (n=6). 
4.14.9 Cardiac fibrosis analysis 
Quantification of cardiac fibrosis was performed on 3-5 paraffin sections from n=10-
27 mice from each genotype at 8 weeks (baseline) and at 21 weeks. Briefly, 
analysis was performed using ImageJ software (nih.gov, USA) and involved 
calculation of the mean % area of fibrosis (collagen deposition, stained red with 
Sirius Red and manually defined) relative to the total myocardial area. 
Haemosiderin deposition was quantified in a similar way (relative to total area) after 
staining with Perl’s Prussian Blue stain. Data were analysed using Kruksall Wallis 
testing with Dunn’s test for multiple groups. 
4.14.10 Immunohistochemistry 
Histological slides were de-waxed with xylene (2 x 5 minutes) and then immersed in 
100% ethanol (2 x 5 minutes). Endogenous peroxidase activity was blocked using 
1:100 methanol:hydrogen peroxide and then slides were rehydrated in stepwise 
ethanol. Microwave antigen retrieval was performed with sodium citrate buffer 
(10mM trisodium citrate buffer, 0.05% Tween 20, pH6) before slides were cooled 
and washed in PBS. Cells were permeabilised with 0.1% Triton X100 and then 
slides washed prior to blocking with 4% BSA for 30 minutes at room temperature. 
Primary antibody incubation was carried out at room temperature for one hour at 
the following concentrations; anti-SMA (ab184675, mouse) – 10ug/ml,  anti-MMP-
12 (ab200410, rabbit) – 2.5ug/ml (all antibodies from Abcam Plc, UK. After 
- 109 - 
washing, slides were incubated with an equal volume of Polyview® anti-mouse 
horseradish peroxidase (HRP) and anti-rabbit alkaline phosphatase (AP) (ADI-950-
112, Enzo Life Sciences, UK) for 20 minutes. Slides were then washed, incubated 
with DAB and then HighDef red stain (for AP) (Enzo Life Sciences, UK) before 
mounting, drying and application of a coverslip with Shandon mount medium 
(ThermoSciences, UK).   
4.15 Statistics  
Unless explicitly stated, all data is presented as mean ± standard deviation. All 
values were analysed using Prism 7  (GraphPad Software, San Diego, CA, USA). 
Each data set is presented with details of the statistical analysis used, however, in 
summary; data were analysed for normality with Shapiro-Wilks testing. Non-normal 
data and those with unequal variances across groups were analysed using non-
parametric methods (Mann-Whitney for two-group comparisons and Kruskal-Wallis 
with Dunn’s correction for multiple groups). Data that were normally distributed 
were analysed using Student’s unpaired t-test for two-group comparisons (with 
Welch’s correction for unequal variance if required) and one-way ANOVA for 
multiple groups (with Bonferroni’s post-test correction). Discontinuous data 
(breeding outcomes) were analysed using a Chi-squared (χ2) test and contingency 
data (aneurysm development) using Fisher’s exact test of proportions. In all cases 
significance was accepted where the two-tailed probability was less than p=0.05. 
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Chapter 5: Results – Characterisation of Mouse Lines 
Using the transgenic methods, breeding programme and genotyping strategy as 
outlined, we were able to generate TG2-/-, FXIII-A-/- and TG2-/-.FXIII-A-/- (DKO) 
offspring on a defined C57Bl/6 background for use in further experiments. The DKO 
mice generated by this project are the first reported mice which lack both 
transglutaminases, without coexistent ApoE deficiency, and as such are an 
important tool for the investigation of the distinct and overlapping roles of TG2 and 
FXIII-A. This chapter will outline the results from the characterisation of the various 
transgenic lines in terms of their gross phenotype, growth, glucose homeostasis, 
and coagulation function.   
5.1 Maternal FXIII-A-/- phenotype 
As discussed in the methods section, we recognised that there were potential 
concerns related to breeding from FXIII-A deficient female mice given the 
observations from Koseki-Kuno et al (Koseki-Kuno et al., 2003) of overt genital 
bleeding at day 10 of gestation and increased maternal mortality. However, we felt 
it was important to confirm the maternal phenotype of our novel FXIII-A-/- mouse. A 
trial breeding programme was established whereby female FXIII-A-/- mice (with 
~75% C57Bl/6 background) were crossed with either male C57Bl/6 mice or male 
FXIII-A-/- mice. Unfortunately this breeding was unsuccessful, with recapitulation of 
the expected phenotype. Following this, all subsequent breeding (to generate both 
FXIII-A-/- and TG2-/-.FXIII-A-/- offspring) was carried out using female mice 
heterozygous for FXIII-A KO. 
 Details of Pregnancy / Complications 
#1 Found dead; obviously pregnant with evidence of bleeding in the cage 
#2 Uneventful pregnancy, found dead after delivery of two (non-viable) pups 
#3 Found dead; not obviously pregnant, no evidence of haemorrhage 
Table 5. Results from trial breeding with FXIII-A-/- females 
 
5.2 Frequency of breeding 
During the course of our breeding programme we observed what appeared to be a 
decreased frequency of FXIII-A-/- offspring in comparison to the numbers expected 
by Mendelian frequency. To assess the impact of TG2 and FXIII-A deficiency on 
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mouse fertility and breeding we analysed litter size and offspring genotype from the 
following breeding pairs (and trios where appropriate). 
1. TG2+/- male x TG2+/- female 
2. FXIII-AWT/flox male x FXIII-AWT/flox female 
3. FXIII-A-/- male x FXIII-A+/- female 
4. TG2-/-.FXIII-A-/- male x TG2-/-.FXIII-A+/- female 
Breeding of FXIII-A-/- male with FXIII-A+/- females generated numbers of offspring 
that were significantly different from expected values with 226 KO pups observed 
vs. the 325 KO expected (p=0.001). Likewise, DKO offspring were generated at a 
significantly lower rate than that predicted by Mendelian frequency (265 observed 
vs. 355 predicted, p=0.005). Heterozygous flox breeding generated 52 FXIII-Aflox/flox 
offspring, compared to an expected 66 pups, and likewise, heterozygous TG2 
breeding generated 80 knockout pups, when 88 were predicted by Mendelian 
frequency. Neither of these differences was statistically significant.  
The normal litter size from C57Bl/6 breeding is 6.2 pups per litter (Nagasawa et al., 
1973) and was 6.8 in our hands. There was no significant difference in average 
litter size between this and either the TG2 breeding (6.3 pups/litter) or the Flox 
breeding (6.9 pups/litter), however the FXIII-A breeding resulted in an average of 
only 5.4 pups/litter which was significantly different from Flox (p=0.023) and our 
C57Bl/6 (p=0.015) breeding. Likewise the DKO breeding resulted in smaller litter 
sizes (5.7 pups/litter). Female mice will release 6-10 oocytes per oestrus (Pinkert, 
2012) and a proportion will not survive due to failure of fertilisation, implantation or 
subsequent embryogenesis. Given that the frequency of FXIII-A+/- offspring did not 
differ from that predicted (388 observed vs. 399 expected, p=NS) it seems likely 
that it is FXIII-A deficiency in the oocyte that is the cause of an increased “failure to 
survive” of these cells. This is obviously an interesting observation and one worthy 
of future study.  
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Figure 22. Breeding frequency by genotype 
Frequency of genotype was retrospectively analysed for each heterozygous 
breeding pair/trio and the observed number of pups compared with the number 
expected by Mendelian frequency using the chi-squared statistic. Average litter size 
for each breeding line was also recorded and Kruksall Wallis test applied to assess 
difference from WT or Flox mice. *** p=0.001, ** p=0.005 
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5.3 Growth  
None of the transgenic mouse lines exhibited any gross phenotypic change and 
specifically no obvious defects in skeletal or vascular development were observed. 
Weekly weights were monitored in a subset of mice of each genotype (n=8, 
m:f=1:1) and no significant difference (on AUC AVOVA testing) between groups 
was seen to 16 weeks of age. Mice were also weighed prior to any intervention and 
a summary graph of all data is shown in Figure 23. A sub-group of mice (n=4-8 
male mice per genotype) were weighed weekly to 40 weeks of age. There was no 
statistically significant difference in weight between groups at 40 weeks (weight (g) 
± SD; C57 28.13 ± 5.91, TG2-/- 34.18 ± 7.32, FXIII-A-/- 33.01 ± 6.54, DKO 31.22 ± 
2.29, p=0.477) 
5.4 Blood pressure  
As part of an allied but separate study undertaken by our group, mice aged 24 
weeks (n=7-11 per group) were subject to right ventricular catheterisation and 
assessment of cardiac function via pressure-volume loop recording. Baseline 
(anaesthetised) systolic blood pressure (BP) measurements were recorded to 
enable comparison between the genotypes and these data were kindly provided by 
Dr Mark Drinkhill and are summarised in Figure 24. There was no difference in 
systolic blood pressure between the groups on ANOVA testing(mean BP (mmHg) ± 
SD; C57 73.67 ± 7.19, TG2-/- 73.73 ± 2.14, FXIII-A-/- 72.28 ± 10.93, DKO 73.36± 
10.72, p=0.984). 
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Figure 23. Growth of transgenic mice 
Figure shows average weight gain over time for each transgenic mouse line (n=>4 
at each time point). Data are only shown for mice that had not undergone any prior 
intervention or operative procedure. There is no statistical difference in weight gain 
between the experimental groups to 16 weeks of age and no statistical difference 
between genotypic groups in those mice investigated at specific later time points.  
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Figure 24. Systolic blood pressure 
Figure shows mean systolic (anaesthetised) blood pressure (with 95% CI) for each 
transgenic mouse line (n=7-11 per group). There is no statistical difference between 
the groups on ANOVA testing, p=0.984. 
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5.4 FXIII-A activity 
Plasma FXIII-A activity (velocity) was determined from murine plasma samples for 
n=10-18 mice per genotype. Each plate was run with one control WT sample and 
one human sample for which FXIII-A activity had previously been quantified. In 
each case the human sample was seen to have FXIII-A activity of 15% (± 5%) of 
that seen in the WT sample. 
For the purpose of comparison, the average activity in each experimental genotype 
was compared to the plasma activity of the FXIII-A “floxed” mouse (FXIII-AFlox/Flox) 
group to give a measure of relative FXIII-A activity (Figure 25). Data were analysed 
with one-way ANOVA testing with Bonferroni correction. The floxed mouse was 
taken as control because of an observed  small decrease in FXIII-A activity in the 
floxed mouse (mean activity (AU) ± SD; C57 2691 ± 558, Flox 2195 ± 632; 81.6% 
relative to C57Bl/6, p=0.013) which may be related to altered efficiency of gene 
splicing or subtle changes in gene expression. 
There was no statistically significant difference in plasma FXIII-A activity between 
the FXIII-AFlox/Flox mice and the TG2-/- mice, however heterozygosity for the FXIII-A 
gene decreased plasma activity levels to 74.3% of control (± 7.2%) and FXIII-A 
gene knockout resulted in a complete lack of plasma FXIII-A activity, as expected in 
both the FXIII-A-/- and DKO groups (***, p<0.0001). There was no statistically 
significant difference between FXIII-A-/- mice and the DKO mice group (p>0.99). 
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Figure 25. Relative plasma FXIII-A activity 
Plasma FXIII-A activity was determined from murine plasma samples for n=10-18 
mice per genotype. Each genotype was compared to the control (FXIII-AFlox/Flox) 
group to give a measure of relative FXIII-A activity which is shown above with 95% 
confidence intervals. NS = not significant, *** p<0.001 
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5.5 Metabolic testing  
TG2 has been reported to be involved in glucose homeostasis in a number of in 
vitro studies (Sener et al., 1985, Bungay et al., 1986) and Bernassola et al have 
published evidence of glucose intolerance, hyperglycaemia and impaired insulin 
secretion in their TG2-/- mouse line.(Bernassola et al., 2002) They also report a 
TGM2 gene mutation (Asn333Ser) located within the active site region of the gene 
which was present in 2 members of a family with MODY. No putative mechanism is 
given as to how this mutation causes hyperglycaemia and, as discussed in section 
2.1, these murine observations have not been recapitulated in the Graham TG2-/- 
mouse.  However given the conflicting evidence in the literature, we sought to 
characterise our own TG2-/-  line (generated from heterozygous founders provided 
by Prof Graham but back-crossed to a defined background) as well as the FXIII-A-/- 
and DKO lines in terms of their response to exogenous glucose or insulin 
challenge. The characterisation of the metabolic phenotype of the FXIII-A-/- mouse 
is vital in light of recent reports that FXIII-A has a role in adipogenesis (Myneni et 
al., 2014) and the development of obesity. 
There is some evidence to support an age-related decrease in insulin tolerance in 
laboratory mice (Lavine et al., 1971, Bailey and Flatt, 1982) and hence metabolic 
experiments were conducted in both young (10-12 week old) and aged (40-42 week 
old) mice. 
5.5.1 Glucose tolerance  
Glucose tolerance testing performed in 10-12 week old mice revealed no significant 
difference in glucose tolerance at any time point (Figure 26). Area-under-the-curve 
(AUC) analysis also showed no difference, either between the transgenic lines or 
when compared with the C57Bl/6 mice (C57 940.1 ± 133.4, TG2-/- 867.9 ± 97.2, 
FXIII-/- 1040.1 ± 254.2, DKO 919.9 ± 161.2; p=0.24). Likewise, glucose tolerance 
testing in old (40-42 week old) mice revealed no significant difference in blood 
glucose levels at any time point (Figure 28). AUC analysis was not significantly 
different between groups (C57 867.9 ± 97.2, TG2-/- 979.2 ± 299.0, FXIII-/- 834.3 ± 
97.0, DKO 1003.9 ± 128.1; p=0.29) with these results providing evidence that our 
lines are normoglycaemic and supporting the view that TG2 is not involved in 
glucose homeostasis. 
5.5.2 Insulin tolerance  
Insulin tolerance testing (ITT) measures the change in blood glucose level in 
response to an exogenous insulin challenge. ITTs performed in 10-12 week old 
mice revealed no significant difference in insulin tolerance at any time point (Figure 
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27). AUC analysis also showed no significant difference between groups in insulin 
tolerance across the whole 2-hour protocol (C57 631.7 ± 196.2, TG2-/- 497.8 
±203.2, FXIII-/- 760.1 ± 162.4, DKO 638.3 ± 197.6; p=0.06). In contrast, ITTs in 40-
42 week old mice (Figure 29) revealed a significant difference in blood glucose 
levels across the whole protocol (AUC: C57 810.3 ± 70.6, TG2-/- 743.6 ± 57.4, FXIII-
/- 527.6 ± 129.0, DKO 645.7 ± 159.4; p=0.0044) with the FXIII-A-/- mice have 
significantly lower AUC than the C57Bl/6 mice (p=0.0066). In this aged group of 
FXIII-A-/- mice, insulin sensitivity appeared to be increased (with a trend towards 
lower blood glucose levels seen at each time point). We had limited availability of 
aged FXIII-A mice because of reduced breeding numbers and hence we feel these 
results reflect insufficient mouse numbers (i.e. under-powering) rather than a true 
difference in glucose homeostasis. 
There was no significant difference in AUC analysis for ITTs, between 10-week old 
and 40-week old mice (all genotypes combined; p=0.623) (data not shown) hence 
our mice did not show any evidence of impaired insulin tolerance with increasing 
age, up to 40 weeks. 
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Figure 26. Glucose tolerance testing – young mice 
Mice (n=8-10 per genotype) aged 10-12 weeks underwent glucose tolerance testing 
as described in the text. Average (mean ± 95% CI) blood glucose tracings across 
the duration of the test are shown in panel A. ANOVA analysis of area-under-the-
curve (AUC) data (panel B) revealed no statistically significant difference in glucose 
tolerance between the four experimental genotypes in “young” mice. AUC data is 
presented as mean ± 95% confidence intervals. 
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Figure 27. Insulin tolerance testing – young mice 
Mice (n=8-9 per genotype) aged 10-12 weeks underwent insulin tolerance testing 
as described in the text. Average (mean ± 95% CI) blood glucose tracings across 
the duration of the test are shown in panel A. ANOVA analysis of area-under-the-
curve (AUC) data (panel B) revealed no statistically significant difference in insulin 
tolerance between the four experimental genotypes in “young” mice. AUC data is 
presented as mean ± 95% confidence intervals. 
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Figure 28. Glucose tolerance testing – old mice 
Mice (n=4-11 per genotype) aged 40-42 weeks underwent glucose tolerance testing 
as described in the text. Average (mean ± 95% CI) blood glucose tracings across 
the duration of the test are shown in panel A. ANOVA analysis of area-under-the-
curve (AUC) data (panel B) revealed no statistically significant difference in glucose 
tolerance between the four experimental genotypes in “old” mice. AUC data is 
presented as mean ± 95% confidence intervals. 
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Figure 29. Insulin tolerance testing – old mice 
Mice (n=4-11 per genotype) aged 40-42 weeks underwent insulin tolerance testing 
as described in the text. Average (mean ± 95% CI) blood glucose tracings across 
the duration of the test are shown in panel A. ANOVA analysis of area-under-the-
curve (AUC) data (panel B) revealed a statistically significant difference in insulin 
tolerance between the four experimental genotypes “old” mice. AUC data is 
presented as mean ± 95% confidence intervals. 
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5.6 Coagulation function 
ROTEM® analysis was performed on murine whole blood samples as a measure of 
overall coagulation function of the various experimental mouse lines. Each sample 
was analysed under conditions designed to replicate either the extrinsic (“extem”) or 
intrinsic (“intem”) coagulation pathway but results were not statistically different 
between conditions (data not shown) and hence only “extem” data is shown in 
Figure 30. Data were analysed by one-way ANOVA testing with Bonferroni 
correction.  
As expected from the known fibrin-crosslinking function of FXIII-A, samples from 
mice deficient in FXIII-A - both the FXIII-A-/- and the TG2-/-.FXIII-A-/- double deficient 
mice - form clots more slowly than those from other genotypes (α-angle (degrees); 
C57 74.8 ± 5.5, TG2-/- 70.3 ± 3.1, FXIII-A+/-  66.3 ± 4.7, FXIII-A-/- 43.0 ± 8.0, DKO 
44.2 ± 6.9, p<0.0001) and produce weaker blood clots (maximum clot firmness 
(MCF) (mm); C57 56.5 ± 2.4, TG2-/- 52.0 ± 7.0, FXIII-A+/-  51.0 ± 4.6, FXIII-A-/- 19.0 
± 4.0, DKO 15.2 ± 4.5, p<0.0001) which are easier to lyse (lysis index at 30 minutes 
(%); C57 100.0 ± 0.0, TG2-/- 100.0 ± 0.0, FXIII-A+/- 100.0 ± 0.0, FXIII-A-/- 50.0 ± 8.3, 
DKO 51.7 ± 7.5, p<0.0001).  
TG2 deficiency alone had no impact on clot formation time, clot strength or 
resistance to lysis and TG2 deficiency in addition to FXIII-A deficiency did not 
worsen the clotting abnormalities observed. Heterozygosity for the FXIII-A gene 
was not sufficient to result in a change in clot characteristics.  
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Figure 30. ROTEM analysis of murine whole blood samples 
Murine whole blood samples for each genotype (n=3-5) were analysed by rotational 
thromboelastography. Panel A shows representative traced from the four 
transgenic mouse lines. Panel B showsresults for α-angle (a surrogate of clot 
formation time) with larger values representing a longer time to form a clot of 20mm 
firmness. Panel C shows results for the maximum clot firmness (in mm) reached 
over the two-hour study period and panel D demonstrates the clot lysis index (% of 
the remaining clot stability in relation to maximum clot firmness, at 30 minutes). 
Data were analysed by ANOVA for multiple groups with Bonferroni correction for 
multiple testing.  
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5.7 Cardiac fibrosis 
As part of the characterisation of our mice and, in an attempt to verify the results 
seen by Newell et al in Bristol, we sought to investigate the potential role of TG2 
and FXIII-A in the development of cardiac fibrosis. This analysis of this work was 
carried out in conjunction with Dr Cora Beckers and is summarised in Figure 31. 
Myocardial fibrosis was determined by % collagen content from Sirius Red staining 
at 8 weeks of age (baseline, n=10-14) and at 21-weeks of age after feeding with 
chow diet (n=18-27). Figure 31 shows representative images from the three 
transgenic lines and Figure 32 presents data compared to the results seen in FXIII-
A-/- mice at 21 weeks. Data were analysed by Kruksal-Wallis testing with Dunn’s 
correction. 
Cardiac sections from C57Bl/6 and TG2-/- mice showed no evidence of myocardial 
fibrosis at either baseline or at 21-weeks. In contrast, the FXIII-A-/- group showed 
small amounts of fibrosis at baseline (0.80 ± 0.51%) which was significantly 
different from WT (p=0.0001) and which had increased by 21-weeks (2.39 ± 
2.25%), again to a level significantly different from WT or TG2-/- mice (p<0.0001). 
The DKO group showed significantly higher levels of fibrosis at baseline (3.25 ± 
5.14%) when compared to either the C57Bl/6 or TG2-/- (p<0.0001) groups and by 
21-weeks showed obvious fibrotic change (14.0 ± 8.25%) which was significantly 
different from C57Bl/6 and TG2-/- mice (p<0.0001) but not from FXIII-A-/- mice 
(p=0.456) at the same time-point.  
Haemosiderin deposition was quantified in adjacent paraffin sections using % 
Prussian Blue staining and results are presented in Figure 32. At 21-weeks of age, 
hearts from WT mice showed 0.14% haemosiderin content (SD 0.53%), as 
compared to 0.12 ± 0.28% in TG2-/- mice, 0.10 ± 0.26% in FXIII-A-/- mice and 0.76% 
± 0.35% in DKO mice. Haemosiderin deposition was significantly different across 
groups with the DKO mice showing more deposition when compared to that seen in 
WT (Dunn’s, p<0.001), TG2-/- (p=0.002) and FXIII-A-/- (p<0.001) mice.. Despite the 
obvious overall similarity in the above results with the DKO mice showing greater 
amounts of both fibrosis and haemosiderin deposition, there was only minimal 
correlation between these two parameters when either DKO alone, or all 
genotypes, were examined.  
 
- 127 - 
A. 
 
B. 
 
C. 
 
 
Figure 31. Representative images – myocardial fibrosis 
Panel A shows a representative cardiac section (with Sirius Red staining) 
from a TG2-/- mouse. Panel B is from a FXIII-A-/- mouse and shows sparse 
areas of fibrosis and panel C is from a DKO animal and shows definite 
strands of fibrosis within the myocardium. Collagen is stained red / dark 
pink.Scale bars represent 500µm in each image. 
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Figure 32. Myocardial fibrosis and haemosiderin deposition 
Panel A summarises relative fibrosis in each of the experimental mouse groups at 
baseline and after 21 weeks chow diet and are presented as relative fibrosis 
compared to that seen in the FXIII-A-/- mice at 21 weeks. P-values shown are for 
Kruksall Wallis testing (with Dunn’s correction) of all groups at baseline and 21-
weeks. Further statistical detail is provided in the main text. Panel B shows data for 
% haemosiderin deposition in cardiac sections from mice in each of the 
experimental groups at 21 weeks. Results are presented as mean ± 95% 
confidence intervals 
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Phenotypic 
Characteristic 
TG2
-/-
 FXIII-A
-/- 
DKO 
Breeding No phenotypic change 
observed 
Unable to breed from FXIII-
A
-/- 
KO females 
↓ litter size 
↓ no. of KO offspring 
Unable to breed from TG2
-/-
.FXIII-A
-/- 
KO females 
↓ litter size 
↓ no. of KO offspring 
Growth Normal Normal Normal 
Skeletal 
Development 
No phenotypic change 
observed 
No phenotypic change 
observed 
No phenotypic change 
observed 
Glucose 
homeostasis 
Normal ? ↑ insulin sensitivity with 
age (requires confirmation) 
Normal 
FXIII-A activity Normal Absent Absent 
Clotting Normal Clots; 
-take longer to form 
-are less stable 
-more easily lysed 
Clots; 
-take longer to form 
-are less stable 
-more easily lysed 
(no different from FXIII-A
-/-
 
KO) 
Cardiac Fibrosis None observed ↑ at baseline 
↑↑ at 21 weeks 
↑↑ at baseline 
↑↑↑ at 21 weeks 
Table 6. Summary results – characterisation of transgenic mouse lines 
The above table summarises the results presented in this chapter pertaining to the 
phenotypic characterisation of the three transgenic mouse lines utilised in this 
thesis. Where a characteristic is described as “normal”, we found no statistically 
significant difference in phenotype between the transgenic and the WT line. 
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5.8 Discussion  
This chapter presents results (summarised in Table 6) from the characterisation of 
the three transgenic mouse lines used in this thesis; the Graham TG2-/- mouse, 
which is a well-established model of TG2 deficiency (Nanda et al., 2001) that has 
been previously characterised on various strain backgrounds but which was utilised 
by us, in this work, on a known C57Bl/6 background; a FXIII-A-/- mouse line, 
generated from a novel “floxed” mouse using cre-lox recombination technology, 
again on a C57Bl/6 background, and finally; a double-deficient TG2-/-.FXIII-A-/- or 
DKO mouse line which is previously unreported and allows for investigation of the 
distinct and/or overlapping roles of TG2 and FXIII-A without the confounding 
influence of ApoE deficiency. 
As expected, our TG2-/- mice were viable, fertile and showed no gross phenotypic 
abnormality. The mice lacking FXIII-A also showed normal fertility (i.e. FXIII-A is not 
required for conception) but as in the human situation – where patients with FXIII-A 
deficiency experience recurrent 1st trimester losses – we were unable to breed from 
homozygote female mice due to bleeding and maternal death. This phenotype is as 
reported by Koseki-Kuno et al in 2003 (Koseki-Kuno et al., 2003) which was 
hypothesised to be due to rupture of placental vessels, but we have also seen 
reduced numbers of FXIII-A-/- offspring (from both FXIII-A-/- and DKO breeding) in 
the setting of smaller litter size.  
Various roles have been proposed for FXIII-A in the maintenance of a viable 
pregnancy and FXIII-A has been reported in histiocytes and macrophages within 
uterine implantation tissue and within the developing placenta.(Adany and 
Muszbek, 1989, Asahina et al., 2000) Muszbek et al (Muszbek et al., 2011b) report 
that ECM cross-linking by plasma FXIII-A is key to development of the Nitabuch’s 
fibrin layer within the placenta, which has an “immunological barrier” function 
(Schneider and Moser, 2016) as well as being crucial to placental integrity.  Whilst 
maternal FXIII-A activity is of key importance in pregnancy; our results, which show 
reduced FXIII-A-/- offspring with no evidence of pregnancy-associated bleeding or 
foetal loss, suggest that embryonic FXIII-A may also play a role in embryo survival 
or implantation. The significance of this is as yet unknown and clearly worthy of 
future study. 
Despite this breeding deficiency, FXIII-A-/- and DKO mice develop normally and, like 
the TG2-/- mice, show no impairment in terms of growth or gross skeletal 
development. This is in contrast to the work of Al Jallad et al (Al Jallad et al., 2006) 
and Tarantino et al,(Tarantino et al., 2009) who have suggested that there is 
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functional redundancy between FXIII-A and TG2 with regards bone deposition and 
mineralisation, and instead supports work from our group,(Cordell et al., 2015) 
which showed no gross deficit in bone mineralisation (on x-ray or DEXA scanning) 
in TG2−/−.FXIII-A−/− double knockout mice on an ApoE-deficient background. These 
findings highlight the caution that is required when extrapolating in vitro culture 
results to the in vivo situation. 
Hyperglycaemia (induced by streptozotocin injection) has been reported to limit 
aneurysm development in both the elastase and AngII aneurysm models.(Miyama 
et al., 2010) Although these findings have not been reported in the CaCl2 model, it 
is clear that any large differences in glucose homeostasis observed in the 
transgenic mouse lines would potentially complicate the results obtained from aortic 
injury. In line with the work of Iismaa et al (Iismaa et al., 2013) we have found no 
significant differences in glucose homeostasis in the mice deficient in TG2 in either 
“young”, or “aged” mice at 40-weeks of age. Likewise, despite analogous claims 
that FXIII-A is involved in the proliferation of pre-adipocytes (rather than their 
differentiation and deposition as fat),(Myneni et al., 2014) our FXIII-A-/- and DKO 
mice were not obese, demonstrated normal weight gain and had esssentially 
normal glucose homeostasis.  We saw no evidence of increased fat deposition in 
these mice during organ harvest, or at the time of aortic injury and hence have 
found no evidence of gross metabolic phenotype in any of these experimental mice 
that could potentially influence the response to vascular injury. 
Our anticipated findings were confirmed using a FXIII-A activity assay which 
showed that gene knockout resulted in a complete absence of plasma enzyme 
activity in the FXIII-A-/- and DKO mice. FXIII-A activity was reduced to approx. 75% 
of control in mice heterozygous for FXIII-A gene knockout and activity was (as 
expected) not affected by TG2 gene deficiency. These changes in FXIII-A activity 
had predictable effects on clot formation with FXIII-A-/- and DKO mice producing 
clots that took longer to form, were less stable and were more easily lysed than the 
clots formed by WT mice. TG2 deficiency has not been reported to affect clotting 
parameters and this was confirmed in our mice.  
Souri et al (Souri et al., 2008b) have previously reported on the development of 
spontaneous cardiac fibrosis in the hearts of older male mice with FXIII-A 
deficiency, leading to an increased mortality rate by 10 months of age. Likewise, 
Newell and colleagues in Bristol (in preparation) have shown cardiac fibrosis in both 
FXIII-A-/- and TG2-/-.FIII-A-/- male mice on an ApoE deficient background, subject to 
a high fat diet. In this work, and as part of ongoing studies into the role of FXIII-A in 
vessel stability and repair, we have shown that FXIII-A-/- mice of both sexes, subject 
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to a normal chow diet, develop spontaneous myocardial fibrosis by 21 weeks of 
age. This fibrotic change is exacerbated in mice which have concomitant TG2 
deficient and appears to be present as early as 8 weeks of age. Although male 
mice showed more fibrosis than female mice (in both FXIII-A-/- and DKO groups) 
this was not statistically significant hence we cannot comment on specific gender 
differences in predilection to fibrosis in this study.  
Cardiac fibrosis has also been reported in the hearts of mice lacking tissue factor 
(TF) and Factor VII in the work of Pawlinski et al.(Pawlinski et al., 2002) They, like 
Newell et al, and recapitulated by us, show deposition of haemosiderin at sites of 
fibrosis and conclude that fibrosis occurs as a response to impaired haemostasis 
and haemorrhage from cardiac vessels. The alternative theory, to one of impaired 
haemostasis, is that FXIII-A in this context is playing a role in vascular integrity and 
that impairment of this function leads to vessel “leakiness”, bleeding and 
haemosiderin deposition, and subsequent fibrosis. The role of FXIIII-A in the 
maintenance of endothelial barrier function has been discussed and it is feasible 
that TG2 activity could mitigate cardiac damage, either by compensating for FXIII-A 
in terms of vessel stability or by instigating tissue repair and thus limiting the fibrosis 
seen in FXIII-A single deficient mice. In DKO mice however, vessel integrity is 
either further compromised, or tissue damage goes unchecked, and hence fibrosis 
can proceed to the levels seen in our samples.  
We have observed increased haemosiderin deposition in the hearts of our DKO 
animals, which is localised to the areas of fibrotic change. We have not shown any 
correlation between haemosiderin and collagen content, however non-fibrotic 
hearts did not show any evidence of haemosiderin staining using the robust Perl’s 
Prussian Blue method. In many ways this result is unsurprising as there is likely to 
be a considerable time differential required between red blood cell leakage, 
macrophage uptake and production of haemosiderin (the presumed trigger for 
fibrosis) and the development of fibrosis itself.  
Further work is ongoing to assess whether the fibrosis observed at a histological 
level in our mice has an impact at the physiological level in terms of cardiac function 
and/or mortality. Certainly baseline investigations show that there is no difference in 
anaesthetised (unstressed) systolic blood pressure between the genotypes. If 
histological fibrosis is observed without significant myocardial impairment this would 
represent a useful, spontaneously occurring, model of fibrosis which could be 
utilised in future work to investigate the potential therapeutic role of FXIII-A.  
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Chapter 6: Results – TG2 and FXIII-A in Normal Vessel 
Structure and Function 
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Chapter 6: Results – TG2 and FXIII-A in Normal Vessel 
Structure and Function 
6.1 Aim  
We aim to elucidate the roles of TG2 and FXIII-A in basal vessel structure and 
function, and investigate the evidence for upregulation of other transglutaminases 
to compensate for single/dual deficiency. 
6.2 Transglutaminase compensation 
It has been suggested in the literature that TG2 and FXIII-A overlap functionally and 
that they can compensate for each other under conditions of deficiency. A full 
discussion of the arguments for and against this theory is given in section 2.2, 
however we sought to investigate whether there is upregulation of any of the 
transglutaminases in the aorta with single (TG2-/- or FXIII-A-/-) or double (TG2-/-
.FXIII-A-/-) gene deficiency. Levels of aortic mRNA were determined by qPCR. The 
expression levels of each transglutaminase are given relative to the level of that 
particular transglutaminase in C57Bl/6 control tissue and statistical significance of 
the change of expression was calculated using one-way ANOVA with Bonferroni 
correction for multiple testing. Statistical analysis was performed on raw ΔCt values 
rather than transformed (2-ΔCt) data and significance was assumed where p<0.05.  
Transglutaminase 2 is the most abundant transglutaminase expressed in the aorta 
(Figure 33, panel A) and expression levels of the other transglutaminases are low 
(FXIII-A and TG3) or negligible (TG1, TG4, TG5, TG6, TG7) in comparison. 
Absence of TG2 and/or FXIII-A does not significantly increase the expression of 
any of the other transglutaminases (Figure 33, panel B) and specifically, TG2 or 
FXIII-A deficiency does not appear to induce compensatory upregulation of mRNA 
expression of the reciprocal enzyme.  
Relative to WT mice, FXIII-A-/- mice actually showed a reduced level of mRNA 
expression of TG2 (approx. 3-fold reduction in expression; p<0.045); the reverse of 
what would be expected if reciprocal compensation was occurring in aortic tissue. 
There was a statistically significant difference in TG3 mRNA expression across the 
experimental groups (p=0.029) with both the TG2-/- and DKO experimental groups 
exhibiting reduced aortic expression of TG3 mRNA relative to WT (C57 vs TG2-/- 
p=0.037, C57 vs DKO p=0.031), a trend also shown by the FXIII-A-/- group (C57 vs 
FXIII-A-/- p=0.053). However, the absolute expression of TG3 in our WT samples 
- 135 - 
was extremely low and therefore it is unlikely that TG3 contributes to the overall 
TGase activity in the aorta and that these decreases are biologically relevant. 
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Figure 33. Expression levels of the transglutaminases in the aorta 
Panel A. Transglutaminase 2 is the most abundant transglutaminase expressed in 
the aorta. Expression levels of the other TGs are low (FXIII-A and TG3) or 
negligible (TG1, TG4, TG5, TG6, TG7). Values shown are TG expression (2-ΔCt) in 
C57Bl/6 control aortic tissue (Mean ± 95%CI). Panel B. Absence of TG2, and/or 
FXIII-A does not significantly increase the expression of the other TGs, however the 
FXIII-A-/- mice showed a reduced expression of TG2. Both the TG2-/- and DKO mice 
showed significantly reduced aortic expression of TG3 relative to WT. All values are 
expressed as fold change relative to the expression level of that particular 
transglutaminase in C57Bl/6 control aortic tissue. * = p<0.05, ** = p<0.001 
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6.3 Baseline biochemistry 
In order to identify any differences in the experimental genotypes in terms of vessel 
composition we sought to analyse baseline vessel biochemistry prior to injury in a 
cohort of mice. Important parameters were deemed to be elastin and collagen 
content as well as a measure of cellularity in the form of LDH and/or DNA levels 
(relative to protein content). The oxalic-acid extraction required for elastin 
quantification is not compatible with collagen extraction and hence it was not 
possible to quantify both elastin and collagen in the same sample. Given that the 
insoluble fraction was utilised for elastin or collagen measurement, LDH and DNA 
levels were instead compared to solubilised protein content, with a decrease in 
LDH:protein or DNA:protein ratio indicating a relative loss of cellularity. 
Data are summarised in Figure 34 and Figure 35 and are from n=25-28 mice per 
genotype for LDH and DNA measurements and from n=8-12 mice for elastin and 
collagen measurements . Statistical analysis was performed using one-way ANOVA 
with Bonferroni correction for multiple comparison. As elastin:collagen ratios are 
calculated from average elastin content per group compared to average collagen 
content per group and do not come from elastin and collagen data from the same 
sample, it is not straightforward to present an estimate of the error of these data 
and hence mean ratio data are presented. More sophisticated statistical options 
may be available and are being investigated for future work. 
Determination of LDH:solubilised protein ratios revealed a statistically significant 
difference between groups (mean ± SD) (C57 0.013 ± 0.005, TG2-/- 0.013 ± 0.006, 
FXIII-A-/- 0.011 ± 0.005, DKO 0.009 ± 0.004; p= 0.012) with the DKO group showing 
a decreased LDH:solubilised protein ratio (p=0.027), indicative of decreased 
cellularity. Quantification of DNA content was also undertaken with a statistically 
significant difference found between groups (mean ± SD) (C57 0.0030 ± 0.0014, 
TG2-/- 0.0028 ± 0.0010, FXIII-A-/- 0.0023 ± 0.0009, DKO 0.0022 ± 0.0006; 
p<0.0001). Both the FXIII-A-/- and DKO mice had lower DNA:solubilised protein 
ratios when compared to WT mice (p<0.001 in both cases) although there was no 
difference between those mice with single FXIII-A gene deficiency and the DKO 
group. Again, these findings would be in keeping with basal differences in 
biochemical composition between the genotypes with decreased cellularity in the 
aortas of mice lacking FXIII-A. 
Elastin content was determined using the FastinTM assay and standardised to 
solubilised protein and where sufficient sample available, also to LDH content. 
There was no significant difference in standardised elastin content between 
genotypes on ANOVA testing (Elastin:solubilised protein, p=0.872, Elastin:LDH 
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p=0.507). Collagen content was determined using the SircolTM assay and again 
standardised to solubilised protein +/- LDH. The DKO mice had a higher mean 
standardised collagen content than the other genotypes when standardised to 
solubilised protein content (C57 0.0135 ± 0.006, TG2-/- 0.0118 8 ± 0.006, FXIII-A-/- 
0.0133 ± 0.008, DKO 0.0171 ± 0.009, p=0.341) or to LDH content (C57 1.16 ± 0.48, 
TG2-/- 1.21 ± 0.67, FXIII-A-/- 1.48 ± 0.73, DKO 1.89 ± 1.23, p=0.176) however this 
was not statistically significant. 
Summary data for elastin:collagen ratios for each of the methodologies (solubilised 
protein: C57 25.1, TG2-/- 24.5, FXIII-A-/- 22.5, DKO 15.8; LDH: C57 20.2, TG2-/- 
18.2, FXIII-A-/- 18.3, DKO 15.8) are presented in Figure 35 and clearly show a trend 
towards a decreased ratio in the DKO group. This finding could either reflect a 
decreased vessel elastin content, which is not seen, or indicates a relative collagen 
increase i.e. fibrotic change within the aorta.  
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Figure 34. Baseline biochemical characteristics of un-operated aortas 
Data shown as mean ± 95% confidence intervals, n=25-28 in each group. Panel A. 
shows LDH levels in un-operated aortas, standardised to solubilised protein 
content. ANOVA testing revealed a statistically significant difference between 
groups with DKO aortas having a lower LDH:solubilised protein ratio than the other 
genotypes. Panel B. shows DNA content in un-operated aortas, standardised to 
solubilised protein content. ANOVA testing revealed a highly statistically significant 
difference between groups with FXIII-A-/- and DKO aortas having a lower 
DNA:solubilised protein ratio than the other genotypes. See text for further details. 
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Figure 35. Elastin and collagen content of un-operated aortas 
All results are presented as mean ± 95% confidence intervals, n=8-12 in each 
group. Panel A. shows elastin content in un-operated aortas, standardised to 
solubilised protein content. Panel B shows collagen content (standardised to 
solubilised protein). Panels C and D respectively show elastin and collagen content 
standardised to LDH content. Elastin:collagen ratios (mean elastin content / mean 
collagen content for each group) are presented in Panel E. with results from the 
solubilised protein methodology shown in filled bars and the results from the LDH 
methodology shown in patterned bars.  
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6.4 Expression data 
Given the role of TG2 as a cross-linking enzyme and its multiple “structural” protein 
substrates (including tropoelastin and fibrillin) we sought to investigate whether TG2 
deficiency (and/or FXIII-A deficiency) altered the mRNA expression of various 
structural proteins within the mouse aorta. Levels of mRNA expression were 
determined by qPCR and statistical analysis was performed on raw ΔCt data (i.e. 
Ctgene of interest – (0.5*(Ctβactin+CtRpl32)). Experimental groups were compared using 
one-way ANOVA with Bonferroni correction for multiple testing. As well as structural 
proteins, a number of other gene transcripts were investigated, including CD163 (an 
M2 macrophage marker), tPA and uPA (serine proteases which catalyse 
plasminogen activation and ECM breakdown), perilipin (a protein found on the 
surface of lipid droplets), PAI-1 (due to its role as an inhibitor of tPA and uPA) and 
TGF-β. These results are summarised in Figure 36. 
There was no statistically significant difference in expression of any of the 
“structural” proteins investigated across the experimental groups. Specifically there 
was no statistically significant difference in the expression of elastin in the TG2-/- 
group, despite levels being approximately 17% of that seen in the C57Bl/6 mouse 
aortas.  
Perilipin expression differed significantly across groups (p=0.0023) and expression 
was lower in both the TG2-/- (p=0.022) and FXIII-A-/- groups (p=0.001), although not 
significantly different from WT in the DKO group (p=0.373). Given that perilipin is 
associated with lipid droplet formation it may be that these results reflect a 
difference in the amount of fat collected at the time of aortic harvest, rather than a 
true difference in expression subsequent to gene deficiency. Certainly there was no 
marked increase in perilipin expression in FXIII-A deficient mice, despite claims that 
FXIII-A inhibits adipogenesis in culture. There was also no statistically significant, or 
systematic, difference in expression of PAI-1, uPA, tPA, or CD163, thus providing 
no evidence of differences in local inflammation between genotypes, at an mRNA 
level.  
Expression of TGF-β was significantly different across the groups (p=0.0044) due to 
a higher level of expression in the FXIII-A-/- group only (levels >2-fold increased 
compared to WT; p=0.002). Aortic expression levels of the other gene transcripts of 
interest were not significantly different in the transgenic mice compared with the WT 
group.  
  
- 142 - 
A. 
C
o
ll
a
g
e
n
 I
C
o
ll
a
g
e
n
 I
I I
E
la
s
t i
n
F
ib
r i
ll
in
 1
F
ib
r i
ll
in
 2
V
im
e
n
ti
n
a
S
M
A
H
O
-1
0 .0
0 .5
1 .0
1 .5
2 .0
F
o
ld
 c
h
a
n
g
e
 r
e
la
ti
v
e
 t
o
 e
x
p
r
e
s
s
io
n
 i
n
 W
T
 m
ic
e
 
B. 
C
D
1
6
3
tP
A
u
P
A
P
e
r i
li
p
in
P
A
I-
1
T
G
F
B
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
F
o
ld
 c
h
a
n
g
e
 r
e
la
ti
v
e
 t
o
 e
x
p
r
e
s
s
io
n
 i
n
 W
T
 m
ic
e
C 5 7  (n = 9 ) T G 2
- / -
 (n = 9 ) FXIII-A
- / -
(n = 1 0 )
D K O  (n = 1 0 )
*
**
**
 
 
Figure 36. Gene transcript expression levels in the un-operated aorta 
Data is expressed as fold change relative to the expression level of that particular 
gene transcript C57Bl/6 control aortic tissue. Panel A. shows mRNA expression of 
various “structural” proteins in the un-operated aorta with no significant differences 
between experimental groups. Panel B. shows expression of a number of other 
genes of interest. Statistical analysis was performed using one-way ANOVA with 
Bonferroni correction.  * = p<0.05. ** = p<0.01 
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6.5 MMPs 
Quantitative real-time PCR was performed to investigate the mRNA expression of 
various MMPs in aortic tissue from each of the experimental genotypes. In view of 
their reported importance in aneurysm development, we chose to look at MMP-2, -
9, -12, -14 (MT1-MMP), as well as TIMPs -1 and -2. These results are summarised 
in Figure 37 and data were analysed using ANOVA and Bonferroni testing. 
MMP-2 and TIMP-2 showed the highest levels of expression in the un-operated WT 
aorta (Figure 37, panel A), with very low levels of MMP-9, MT-MMP-1 and TIMP-2. 
There was no detectable expression of MMP-12 in the un-operated aorta in the 
C57Bl/6 group, as expected from its known release from macrophages in response 
to injury.  
Only expression of MMP-9 (p=0.025) and TIMP-1 (p=0.035) differed significantly 
across the experimental groups. Aortas from the TG2-/- mice had lower levels of 
MMP-9 expression (approx. 40% of WT expression, p=0.034), however given the 
very low expression of this gene transcript under normal circumstances, this 
additional decrease is unlikely to be biologically relevant.  
TIMP-1 expression was increased in aortas taken from FXIII-A-/- mice (nearly 3-fold 
increase compared to WT, p=0.013), a difference not seen in either the TG2-/- or 
DKO groups. All three transgenic groups showed detectable MMP-12 mRNA by q-
PCR however there was no statistically significant difference in MMP-12 expression 
between the WT mice and any of the transgenic mouse aortas on ANOVA testing.  
Attempts were made to validate the findings from qPCR using enzyme zymography 
with methodology as outlined in section 4, and currently in use in our lab utilising 
cell lysates. Unfortunately, we were unable to optimise this assay sufficiently to 
obtain useful data. Conditioned media from cultured HT-1080 cells (kindly supplied 
by Dr Emily Clarke on behalf of Dr Karen Porter) was successfully assayed as a 
control sample (see gel in Figure 38), and hence we proceeded to assess the 
optimum conditions to produce conditioned media from our aortic samples. 
Although we were able to assay “fresh”  conditioned media from our un-operated 
aorta samples (see Figure 38. panel B), subsequent samples, from both operated 
and non-operated vessels, generated absent or unclear digestion bands which we 
were unable to quantify meaningfully. We felt that at least some of the issues with 
this protocol may have been explained by the freezing of these media samples prior 
to subsequent assay in “batches” of samples. This was done for logistical reasons 
but may have impacted on enzyme activity in the small amount of aortic tissue 
harvested from each mouse. A trial zymography assay was undertaken in freshly 
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harvested operated aortic tissue but again we were unable to identify the presence 
of either pro- or activated forms of MMP-2 or -9 in gelatin zymography or MMP-12 
with casein zymography. We hypothesise that we are seeing proteolytic 
degradation of our samples and hence will need to extract the MMPs in an 
appropriate protease inhibitor, such as that used by Eliason et al,(Eliason et al., 
2005b) which would spare the zinc-dependent MMPs. Further work is planned to 
optimise this technique to enable quantification of differential MMP content and 
activity in un-operated vs. operated samples and across the experimental 
genotypes.  
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Figure 37. Expression levels of the MMPs in the un-operated aorta 
Panel A. Values shown are MMP expression (2-ΔCt) in C57Bl/6 control aortic tissue 
(Mean ± SD). MMP-2 is the most abundant MMP expressed in the aorta, and TIMP-
2 the most abundant TIMP of those investigated. Expression levels of the other 
MMP/TIMPs are low (MMP-9, MT-MMP-1, TIMP-1) or absent (MMP-12). Panel B. 
TG2-deficient mice showed a decrease in MMP-9 and FXIII-A mice an increase in 
TIMP-1 expression. MMP-12 expression was detectable in control aortas from all of 
the transgenic mouse lines. All values are expressed as fold change relative to the 
expression level of that particular transglutaminase in C57Bl/6 control aortic tissue. 
* = p<0.05.  
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A. 
 
B. 
 
Figure 38. MMP gelatin zymography 
Panel A. Gelatin zymography of conditioned media from cultured HT1080 cells. Gel 
clearly shows bands of enzymatic digestion at sizes consistent with both the pro- 
and active forms of both MMP-2 and MMP-9. Panel B. is a representative gel from 
a trial assay whereby un-operated WT aortic samples were incubated in reduced 
serum media for either 24-, 48-, or 96-hours prior to zymography. Although digested 
bands are visible they are unclear and difficult to quantify using densitometry. See 
text for more details.  
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6.6 Endothelial permeability  
Transglutaminases (and specifically FXIII-A) have been implicated in the 
maintenance of endothelial barrier function,(Sane et al., 2007) the loss of which 
plays a role in the early development of atherosclerosis and fibrosis. FXIII-A is 
thought to modify paracellular transport in endothelial cell culture (Noll et al., 1999b) 
and acquired, relative FXIII-A deficiency may contribute to the myocardial and 
pleural oedema seen after cardiopulmonary bypass.(Wozniak et al., 2001) The role 
of TG2 in endothelial barrier function is less well understood. To investigate this 
further we used a method described by Orr et al (Orr et al., 2007) to assess aortic 
vessel permeability in each of the four experimental genotypes (n=10-12). Data was 
analysed using one-way ANOVA testing with Bonferroni’s correction. 
Figure 39 summarises this data and shows mean Evans Blue concentration 
(amount (ng) per mg dry weight of aorta) for each of the genotypes. Account needs 
to be taken for the variation in this technique, however despite this we obtained 
results similar to Orr et al. Our C57Bl/6 mice showed low levels of Evans Blue 
(mean ± SD; 17.7 ± 10.6 ng/mg), indicating minimal leakage of dye into the aorta 
and “normal” vessel permeability.  
The TG2-/- group (7.7 ± 5.6 ng/mg, p=NS) was not significantly different from WT, 
whereas the FXIII-A-/- and DKO groups both showed increased Evans Blue 
concentration (34.9 ± 20.8 (p=0.045) and 34.6 ±14.9 (p=0.051) ng/mg respectively). 
There was no significant difference in Evans Blue concentration between the FXIII-
A-/- and DKO (p>0.99) indicating that it is FXIII-A that contributes to endothelial 
permeability and that additional TG2 loss does not worsen the observed deficit in 
barrier function. 
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Figure 39. Aortic endothelial permeability 
Data shown are mean Evans Blue concentration (amount by aorta weight (ng/mg)) 
with 95% CI. Evans Blue concentration is significantly increased in the FXIII-A-/- and 
DKO groups compared to wildtype (*, p<0.05) indicating an increased endothelial 
permeability in these mice. There was no significant difference on ANOVA testing 
between C57Bl/6 mice and those with TG2 deficiency, or between the FXIII-A-/- and 
DKO groups. Arrow indicates mean result (18 ± 4 ng/mg) obtained by Orr et al in 
(Orr et al., 2007).  
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6.7 Wire myography 
Biochemical assays on the DKO arteries at baseline indicate that they have an 
increased collagen:elastin ratio. Our initial results also suggest that the DKO 
vessels (and possibly also the FXIII-A-/- vessels) are less cellular, possibly due to a 
loss of aortic VSMCs. Wire myography provides a means of measuring aortic 
tension and contractility under controlled conditions and allows us to investigate the 
expected differences between the genotypes. This myography assay was 
established and optimised following the advice of Prof David Beech and then 
individual experiments were performed by Dr Lih Cheah  - I would like to 
acknowledge her skill and time with regards the generation of these data.  
The infrarenal aorta (n=4 per genotype) was harvested into cold Hanks solution and 
aortic rings (2 per sample) of 1mm length were mounted in a myography. The rings 
were then placed under normalised tension by increasing the separation distance of 
the mounting wires. The force (mN) generated at each separation distance (µm) 
was recorded and is shown graphically in panel B of Figure 40. This process 
provided initial evidence that the DKO vessels were different from those from other 
genotypes as they generated less force at each separation distance than vessels 
from mice of other genotypes, i.e. they have intrinsically lower vessel tension. After 
equilibration and assessment of contractile function to high concentration K+ and 
phenylephrine (PE) a concentration response curve of contraction (mN) vs. log [PE] 
was constructed.  
Mean dose-response curves for each genotype group are shown in panel D of 
Figure 40 along with calculated EC50 values (the concentration of PE required to 
produce 50% maximal response) in panel C. The EC50 values were not statistically 
different on Kruksal-Wallis testing across the groups (mean concentration (µM) ± 
SD; C57 0.125 ± 0.049, TG2-/- 0.179 ± 0.040, FXIII-A-/- 0.120 ± 0.052, DKO 0.158 ± 
0.061, p=0.129) and the maximum force generated was also not statistically 
different between groups although this value was lower in the DKO vessels (mean 
maximum force (mN) ± SD; C57 3.99 ± 1.95, TG2-/- 3.66 ± 1.61, FXIII-A-/- 3.50 ± 
1.96, DKO 2.58 ± 0.91, p=0.439). To attempt to assess tension as a whole – which 
appeared to be lower in the DKO vessels (mean curve shifted downwards and to 
the right) – we performed area-under-the-curve (AUC) analysis which has been 
advocated by some to be the most reliable metric to assess dose-response curves 
(Huang and Pang). DKO vessels showed a trend towards  lower AUC values than 
control vessels (mean AUC ± SD C57 11.55 ± 3.65, TG2-/- 10.65 ± 3.91, FXIII-A-/- 
10.16 ± 5.49, DKO 6.55 ± 2.09, p=0.118) however this did not  reach statistical 
significance (p=0.072) and requires further investigation.   
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Figure 40. Wire myography – un-operated aorta 
Panel A. is a representative myography trace from a WT mouse. For details of the 
full protocol see section 4.11. Panel B .shows the average force generated by the 
initial wire separation during myography set-up and highlights that the DKO vessels 
generated less force for each separation distance. Mean dose-response curves 
(n=4 per genotype with 2 repeats per vessel) showing the contraction response 
(force in mN) to increasing concentrations of PE are shown in panel D. with EC50 
data (presented as mean ± 95%CI) in panel C. Summary data for this dose-
response is presented in panel E. as AUC analysis with ANOVA testing, p=0.118. 
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6.8 Histology  
Normal, un-injured, aortas (n=2 per genotype) were harvested into 4% PFA and 2 x 
5µm sections cut at 200µm intervals throughout the vessel. Sections were stained 
with haematoxylin and eosin and imaged to assess any obvious histological 
differences in vessel structure between the four experimental genotypes. 
Representative images from each of the genotype groups are shown in Figure 41. 
No obvious differences were seen between the groups, however Newell et al 
(publication in preparation) reported histological differences between carotid 
arteries of ApoE-/- and ApoE-/-.TG2-/-.FXIII-/-mice subject to sham operation. The 
TKO cohort showed increased elastic lamellae number and a higher frequency of 
elastic breaks than the control animals.  
In light of these findings, the same sectioning protocol as above was undertaken in 
both un-operated (n=2 per group) and sham operated (NaCl application, n=2 per 
group) followed by staining with Miller Van Gieson to highlight elastin fibres (shown 
as purple in the image in Figure 41). The maximum lamellae number was recorded 
for each section and then the mean maximum number calculated for each vessel 
and compared across genotypes. These results are tabulated in panel E of figure 
39; there was no difference between the experimental groups in terms of lamellae 
number under either un-operated or sham-operated conditions. Likewise sham 
operation (the application of NaCl) had no effect on lamellae number in any of the 
experimental groups i.e sham-operation does not induce an increase in lamellae 
number, unlike the changes seen in the ligation protocol. No broken elastic fibres 
were observed in aortic sections from any of the genotypes at baseline, nor after 
sham-operation.  
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E. C57Bl/6 TG2-/- FXIII-A-/- DKO 
Normal “un-
operated” 
vessels 
4.82 ± 0.51 4.45 ± 0.51 4.55 ± 0.51 4.66 ± 0.55 
Sham (NaCl) 
operated 
vessels 
4.70 ± 0.56 4.31 ± 0.47 4.64 ± 0.49 4.62 ± 0.55 
 
 
Figure 41. Effect of TG2 and/or FXIII-A deficiency on “normal” aortic 
histology 
Panels A shows a representative section from a “normal” un-operated aorta from a 
C57Bl/6 mouse with inset to show lamellar structure. Panels B, C and D show 
representative sections from “normal”, un-operated vessels from a  TG2-/-, FXIII-A-/- 
and DKO mouse respectively. All images are from haematoxylin and eosin stained 
5µm sections imaged at 10X magnification. Scale bar represents 100µm in each 
image. Panel E. shows lamellar number (mean ± SD) for normal and sham 
operated aortas (n=2 per genotype) Statistical analysis was perfomed using 
Kruksall Wallis testing and showed no differences between genotype groups. 
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Figure 42. Summary diagram - the normal aorta 
This figure summarises the main findings from Chapter 6 pertaining to the structure and function of the the “normal” un-operated aorta in 
each of the transgenic mouse lines. Dark purple arrows highlight findings from this thesis whilst light purple arrows illustrate those findings 
that may be related to the overall conclusion that mice lacking FXIII_A appear to have generalised (aortic) cariovascular fibrosis. These 
results are discussed in full in section 6.9. 
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6.9 Discussion  
In this chapter we investigate the roles of TG2 and FXIII-A in basal structure and 
function and present the evidence for upregulation of other transglutaminases to 
compensate for single or double gene deficiency. These findings are summarised in 
Figure 42 and ultimately lead to the conclusion that mice lacking FXIII-A exhibit  
generalised cardiovascular fibrosis, which (we hypothesise) is secondary to 
increased vessel “leakiness”. 
Using qPCR we determined that (as previously shown by Cordell et al in cardiac 
tissue)(Cordell et al., 2015) TG2 is the most abundantly expressed 
transglutaminase in the mouse aorta. Similar levels of transglutaminase mRNA 
gene expression were seen in aortas harvested from the transgenic lines (with 
complete absence of TG2 in the TG2-/- line, FXIII-A in the FXIII-A-/- line and both 
TG2 and FXIII-A in the DKO line as expected). We found no evidence of a 
compensatory increase in mRNA expression of any of the other transglutaminases 
in the setting of gene deficiency and, specifically, there was no evidence of a 
compensatory increase in mRNA of the alternative enzyme in either the TG2 or 
FXIII-A KO animals. 
One obvious limitation of qPCR and the analysis of transcription levels of mRNA is 
that these levels do not necessarily correlate to enzyme activity within the tissue 
examined. Transcription may be increased, yet changes in translation or post-
translational modification may mean that protein levels are unchanged or even 
decreased. Likewise, changes in enzyme inhibition or activation may mean that 
increased amounts of a particular transglutaminase do not equate to increased 
activity. Even if a particular mRNA transcript (and subsequent protein product) is 
increased we are unable to predict the effect that this could have on the complex 
signalling networks and cascades that exist within the aorta. For example, a small 
rise in MMP expression could effect multiple targets, leading to cell infiltration, 
growth factor release and proteolytic degradation, or alternatively could be rapidly 
neutralised by already present inhibitors. Real-time PCR results must therefore be 
interpreted whilst taking account of the limits of the methodology, but they still 
provide an important means of identifying potential candidates for follow-up protein 
studies. 
If, as is reported, TG2 and FXIII-A are predominantly found in an inactive or latent 
state with regards their transamidating function, it may be that conditions that result 
in their activation (such as a rise in calcium concentration or reduction via 
thioredoxin) may be more important in functional compensation than upregulation 
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per se. Confirmation of this hypothesis would require in situ assay of isozyme-
specific transglutaminase activity in the aorta which could be undertaken using the 
methodology of Itoh et al who utilised fluorescence-labelled substrate peptides to 
localise TG2-ase activity in whole body sections from mice.(Itoh et al., 2011) 
However, certainly at an mRNA level, there is no evidence of reciprocal 
compensation between FXIII-A and TG2 in the aorta. 
We found no gross differences in levels of mRNA for various “structural” gene 
transcripts and no evidence of differences between the groups in those transcripts 
known to be involved in inflammation and proteolysis. Alpha-SMA was expressed at 
the highest levels in the aorta (far in excess of the levels of any of the other 
transcripts) and reflects the presence of VSMCs; collagen, elastin and vimentin 
were also expressed at high levels, although again, did not vary significantly 
between groups. A knowledge of transcription levels in the “normal” or WT tissue 
under study is obviously important when interpreting fold changes, for example 
TGF-β levels were 2-fold higher in FXIII-A-/- samples, a statistically significant 
change, however one which was not seen in DKO samples and correlates to a very 
small actual level of expression. 
Investigation of MMP mRNA levels revealed that  MMP-2 levels were highest in the 
baseline WT aorta and that these were unchanged in the transgenic lines. MMP-12 
expression could not be detected (below the threshold of Ct=40) in the WT samples 
which was as expected given the known release of this enzyme from infiltrating 
macrophages in response to injury. In contrast, we were able to detect MMP-12 
expression in the aortas of TG2-/-, FXIII-A-/- and DKO mice which may be reflective 
of low level vascular damage in these experimental animals.  
Of particular interest, in light of the cardiac fibrosis exhibited by our FXIII-A-/- and 
DKO animals, was the finding that aortas from these animals also showed evidence 
of decreased LDH (in DKO mice) and DNA (in FXIII-A-/- and DKO mice) content 
relative to solubilised protein levels. These results are indicative of decreased 
cellularity, perhaps indicating a loss of VSMCs in these vessels. Coupled with this is 
an observed increase in collagen content seen in the vessels of the DKO animals. 
This result suggests a degree of fibrotic change in the aortas of the DKO mice at 
baseline and is important when interpreting any subsequent differences in response 
to injury in these animals.  
Just as the myocardial sections of the mice with cardiac fibrosis also showed 
increased haemosiderin deposition (suggesting increased vessel “leakiness”) we 
have shown that the FXIII-A-/- and DKO aortas showed increased Evans Blue 
content reflecting an increased large vessel permeability. No significant difference 
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was observed between WT and TG2-/- mice or between FXIII-A-/- and DKO mice in 
this assay implying that it is FXIII-A that contributes to endothelial permeability and 
that additional TG2 deficiency does not worsen the observed deficit. We 
hypothesise that FXIII-A-/- mice have increased vessel “leakiness”, allowing 
extravasation of RBCs, and the production of haemosiderin by inflammatory 
macrophages. This persistent inflammatory stimulus prompts attempts at vessel 
repair (by TG2) which are partially successful in FXIII-A-/- mice (hence the reduced 
cardiac fibrosis and relatively “normal” aortic biochemistry) but are lacking in DKO 
mice giving rise to generalised cardiovascular fibrosis. 
Wire myography (with vessels held under isometric conditions) allows the 
examination of basic vessel properties such as length-tension relationships and 
vascular smooth muscle function whilst also providing a system for assessment of 
pharmacological reactivity. Although pressure myography (with vessels held under 
isobaric conditions) is felt by some to be more “physiological”, similar results for 
passive relationships can be obtained with both techniques (Buus et al., 1994) and 
agonist responses can be adequately compared between vessels when using either 
methodology. Although there is a theoretical risk of endothelial surface damage with 
the wire mounting, we screened for this by assessing vessel response to carbachol 
and this was not an issue in our hands. The wire myography protocol has been fully 
optimised by the Beech group in our Institute and we are grateful to Professor 
Beech for his input to this work.  
Using the wire myography protocol we have identified that the DKO aortas are 
functionally distinct from those in the other genotype groups. Less tension was 
developed in these vessels during the initial normalisation procedure, i.e for every 
µm of “stretch” applied to the vessel a lower force was recorded. Contractility as 
measured by dose-response to phenylephrine was not significantly different in the 
DKO aortas with equivalent EC50 and force range (maximum force – minimum 
force) values achieved across all genotypes. The reasons for the observed 
decreased vessel tension are not immediately obvious although these data could 
suggest that elastin function is in some way comprised in the DKO aorta. We have 
not seen evidence for a loss of elastin in these vessels (either biochemically or 
histologically) and no elastin breaks were observed in un-operated aortas. We 
hypothesise that the decreased vessel tension is a function of impaired elastin 
cross-linking (?by TG2) in the media; the fact that deficit is only seen in the DKO 
vessels implies that either 1) both TG2 and FXIII-A contribute to elastin x-linking 
basally and that function is only compromised with loss of both enzymes, 2) TG2 
cross-links elastin basally but deficit is compensated by FXIII-A activity or 3) loss of 
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TG2 cross-linking coupled with impaired vessel integrity (due to FXIII-A action on 
endothelial barrier function) is sufficient to cause functional impairment. Further 
work is required to elicit which of these possible mechanisms is physiologically 
relevant in vivo however (tropo)elastin has not previously been reported to be a 
substrate for FXIII-A .  
 
- 158 - 
Chapter 7: Results – TG2 and FXIII-A in Aneurysm Induction 
and Progression  
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Chapter 7: Results – TG2 and FXIII-A in Aneurysm Induction 
and Progression 
7.1 Aims  
We aim to establish the murine CaCl2 model of abdominal aortic aneurysms in our 
Institute and optimise the experimental conditions for its use. We then aim to 
investigate the roles of TG2 and FXIII-A in aneurysm induction and progression 
using the above experimental model. 
7.2 Carotid ligation model 
7.2.1 Survival and histology 
Carotid ligation has been widely used as a model of neointimal formation and 
inward vessel remodelling however, in ApoE-/-.TG2-/-.FXIII-A-/- (TKO) mice carotid 
ligation has been shown to result in elastin damage, vessel dilatation and rupture. 
To verify the results obtained by Drs Newell and Jackson in Bristol without the 
presence of a confounding ApoE-/- background, we carried out carotid ligation in a 
cohort of C57Bl/6 and DKO mice. Mice (n=10 per genotype) underwent right 
common carotid artery ligation under anaesthesia, were recovered, and harvested 
at 28 days. All C57Bl/6 mice (M:F=1:1) survived to harvest with no post-operative 
complications. Of the 10 DKO mice operated (M:F=3:2), one (female) mouse was 
found dead at 24 days post-op. A post-mortem analysis was carried out, which 
revealed findings consistent with vessel rupture with a large amount of blood and 
clots in the neck. There was no other gross pathology evident.  
In many ways these results replicate what was seen by Newell et al, in that WT 
mice tolerated the procedure well, with no associated morbidity or mortality. The 
only death in our hands occurred in the DKO group and was indicative of vessel 
rupture, however this mortality occurred much later than the deaths observed in the 
TKO mice (which occurred at 5-7 days) and at a much lower rate. This suggests 
that the additional ApoE-/- gene deficiency may influence outcome after surgery by 
means that are as yet unknown. 
Representative histology from these procedures (as shown in Figure 43) was 
obtained in n=2 mice per group with Miller van Gieson staining undertaken to show 
elastin fibres. The C57Bl/6 mice appeared to show elastin flattening but no clear 
evidence of either inward remodelling or elastin fibre breakage. In contrast, the 
DKO mice showed an increased lamellae number (as was seen in the TKO sham 
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operated group) but without elastin disruption. Further work is needed to fully 
characterise this model in our DKO mice but clearly the additional ApoE gene 
deficiency is detrimental to vessel integrity either before or following carotid ligation 
. 
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Figure 43. Representative histology – carotid ligation model 
Images are captured at 10x magnification from 5µm sections of mouse carotid 
arteries. All panels show staining with Miller staining to highlight vessel elastin 
fibres and scale bar represents 100µm in each image; panels A and B are co-
stained with Van Gieson stain whilst panel C is co-stained with Picosirius Red. 
Panel A is representative of a “normal”, unoperated C57Bl/6 carotid artery with 
typical wavy fibres and 3-5 clearly defined elastic lamellae. Panel B is from a 
C57Bl/6 mouse subjected to carotid artery ligation. Elastin flattening is seen in 
these vessels but with no loss of integrity. Panel C showd a DKO mouse carotid 
artery following ligation. Again, there is no evidence of elastic fibre disruption but an 
increased lamellae number was clearly observed (filled arrows) which is shown 
magnifid in panel D 
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7.3 CaCl2 aneurysm model 
7.3.1 Safety and feasibility of the model 
The CaCl2 model, as communicated by the Baxter lab at the University of Nebraska, 
was established in our Institute and piloted in a trial group of C57Bl/6 mice. The 
model was found to be reproducible with obvious gross differences between the 
vessels of those mice treated with NaCl and those treated with CaCl2 (see Figure 
44).  
Operations carried out in the first two months (n=21) after initiating the Nebraska 
protocol were undertaken in a mean of 38.4 ± 7.5 minutes, which is far below the 
duration of isofluorane anaesthesia deemed safe.(Szczesny et al., 2004) Those 
undertaken in the second two months (n=47) were undertaken in a mean of 32.6 ± 
3.0 minutes, which was not significantly different from the overall mean operating 
time (31.6 ± 3.9 minutes; p=0.09). This suggests that there is an initial learning 
curve to the model, during which operation time can be reduced, and beyond which 
operation time cannot be reduced further. Pilot work also revealed that laparotomy 
and aortic exposure could be achieved without significant intra-operative bleeding 
and that there were no obvious problems with wound healing.  
7.3.2 Effect of increasing CaCl2 concentration 
The specifics of the CaCl2 model (concentration of calcium, exposure time, time to 
harvest) vary between investigators.(Wang et al., 2013a) To determine the optimal 
concentration of CaCl2 to utilise in this work we undertook injury using NaCl (sham-
operated), 0.25M CaCl2 and 0.5M CaCl2 in C57Bl/6 mice before harvest at 6 weeks. 
Aggregated data from all control mice utilised in the data to be presented below is 
shown in Figure 44.  
Aortas treated with NaCl (n=4), showed no gross changes at 6 weeks with minimal 
inflammation, scarring or dilatation (% change in aortic diameter; 2.2 ± 6.1). In 
contrast, those exposed to 0.25M CaCl2 showed superficial inflammation with only 
mild dilatation (28.7 ± 17.5%) whereas exposure to 0.5M CaCl2 resulted in gross 
inflammation, scarring (with formation of adhesions) and obvious focal dilatation 
(60.0 ± 36.3%). The observed change in aortic diameter was significantly different 
between experimental conditions (p=0.0014) with differences observed between 
NaCl and 0.5M CaCl2 application (p=0.0047) and between 0.25M and 0.5M CaCl2 
application (p=0.0416). Similar results have been observed in TG2-/- mice (data not 
shown). 
Serial sectioning of harvested vessels (n=2 for C57Bl/6 and TG2-/-) was performed 
to assess the histological changes seen with increasing calcium concentration. 
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Representative images seen with each experimental condition are shown in Figure 
45. Sham operated vessels showed no obvious damage, with intact elastin fibres 
and minimal inflammation, whereas vessels injured with 0.25M CaCl2 exhibited 
early signs of aneurysm development with loss of elastin fibre waviness. The area 
of injury on the ventral aorta was clearly distinguishable from the normal, 
unexposed, dorsal vessel. Aortas subject to injury with 0.5M CaCl22 showed 
evidence of severe damage with elastin fibre loss and breakage. Again, the 
damaged and uninjured parts of the vessel were easily identified, confirming that 
each mouse could act as its own histological control if required. 
In our hands, the CaCl2 model represents a reproducible experimental protocol to 
induce vascular injury in the infra-renal aorta. This targeted and tuneable insult 
causes arterial damage and provides a mechanism by which the actions of 
transglutaminases in aneurysm development and arterial protection can be studied. 
CaCl2 concentrations ranging from 0.15 to 1.0M have been described, however 
strain specific differences in response have been reported (personal communication 
and (Wang et al., 2013a). Our preliminary images were reviewed by Dr Wanfen 
Xiong (University of Nebraska) who confirmed that they were what would be 
expected from the technique they developed. We therefore decided to use a CaCl2 
concentration of 0.5M for all future experiments as this consistently resulted in 
gross inflammatory changes after exposure in our WT control animals.  
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Figure 44. Effect of increasing calcium concentration 
All images and data are from C57Bl/6 mice and scale bar represents 1mm in all 
images.. Panel A shows a representative image from a non-operated aorta (i.e. a 
“pre-op” image). Panel B shows the same aorta after application of NaCl and 
harvest at 6 weeks. Panel C shows a representative image of the infra-renal aorta 
after exposure to 0.25M CaCl2 and harvest at 6 weeks and displays superficial 
inflammation but only very mild dilatation. Panel D is representative of the changes 
seen at 6 weeks after application of 0.5M CaCl2 and highlights the gross 
inflammation and focal vessel dilatation seen with this injury model. Panel E 
summarises the change in aortic diameter (given as % change from baseline) seen 
with each experimental condition.  
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C.  
 
Figure 45. Representative images – sham-operated and injured aortas 
All images are from haematoxylin and eosin stained 5µm sections imaged at 10X 
magnification. Scale bar represents 100µm in each case. Panel A is representative 
of images obtained after NaCl application (sham operation) in a C57Bl/6 mouse. 
Panel B shows a representative image following 0.25M CaCl2 injury in a TG2
-/- 
mouse and clearly shows elastin flattening (filled arrows and inset). Panel C shows 
a typical image following 0.5M CaCl2 exposure and harvest at 6 weeks (image from 
a C57Bl/6 mouse). There is an obvious distinction between the un-injured (dorsal) 
aorta (open arrows) vs. the injured (ventral) aorta (filled arrows) which displays 
characteristic elastin damage, breakage and fibre loss.  
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7.4 Short term aneurysms 
7.4.1 Survival and growth in operated mice 
The CaCl2 aneurysm model involves an anaesthetic time of ~30 minutes, a 
laparotomy, exposure of the aorta (through blunt dissection) and insult to the main 
vessel of the abdomen. Although initial pilot work had not shown any significant 
problems with the CaCl2 model in terms of bleeding, wound healing, abdominal 
complications or mortality, the majority of this work was undertaken in C57Bl/6 and 
TG2-/- mice because of delays in breeding the FXIII-A-/- and DKO transgenic mice. 
As further experiments were undertaken it became apparent that mice lacking FXIII-
A had an obviously decreased survival rate following apparently normal recovery 
from the injury procedure.  
In general, the mice appeared to recover normally but were then either found dead 
in the subsequent 1-5 days, or failed to gain weight post-operatively, became 
increasingly ill and were terminated (by a Schedule-1 approved method) as per 
Home Office guidelines. Overall the mortality rate for all operations (from which the 
mouse was recovered from anaesthetic) was 8.6% in the C57Bl/6 group, 6.8% in 
the TG2-/- group, 41.1% in the FXIII-A-/- group (p<0.0001) and 62.3% (p<0.0001) in 
the DKO mice.   
In response to this unexpected high mortality rate, we initiated closer monitoring of 
the post-op animals, held a low threshold for termination if there was evidence of 
suffering and undertook detailed recording of cause of death and post-mortem 
findings where possible. Table 7 outlines operating numbers, mortality rates and 
causes of death for the 6 week CaCl2 injury model and highlights that there is a low 
level of mortality (8.6%) associated with this model in C57Bl/6 mice. The causes of 
death in these mice included bleeding problems (presumably from unidentified  
injury at the time of dissection which resulted in continued bleeding) and bowel 
ischaemia (due to torsion of bowel loops on return to the abdominal cavity) as well 
as one case of post-op fighting. A similar mortality rate was seen in the TG2-/- mice 
(6.8%). It should be noted that the majority of these deaths occurred within the first 
few months of setting up the model and hence may reflect the initial “learning curve” 
of this technique.  
The FXIII-A-/- and DKO mice exhibited very different appearances post-mortem to 
those animals with normal FXIII-A gene function. These mice showed more 
episodes of bleeding (which might be expected from their impaired clot function) but 
also, a significant number of mice (approximately 30-40% of post-op deaths), 
showed features of cardiac pathology (with blackened, thrombus filled atria) as well 
as multiple, discrete areas of focal necrosis (for example in the bowel, spleen and 
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liver). This bowel ischaemia showed a different pattern to that seen with simple 
bowel torsion/injury and examples of the post-mortem pathology seen are shown in 
Figure 46. Although it is obviously difficult to conclusively determine cause of death 
in these mice, we hypothesise that these animals, deficient in FXIII-A, could be  
forming non-stable clots which are embolised to visceral arteries. The source of 
these clots may be the site of aortic injury (although this is unlikely given the 
observed sites of embolisation) or more likely the heart, secondary to some 
undetermined cardiac pathology. We have not seen additional deaths in our aged, 
un-operated FXIII-A and DKO mice when compared to WT, hence suggesting that 
the physiological stress of surgery is required to “trigger” this pathology. Deaths 
were also seen in sham operated DKO animals (but not in FXIII-A-/- sham operated 
mice) possibly hinting at a more severe phenotype in this group. 
Post-operative weight was measured in all animals as an adjunct to close 
monitoring of appearance and behaviour in the assessment of animal welfare. As 
can be seen from Figure 47, the FXIII-A-/- and DKO mice had a lower average 
weight over the 6 weeks between operation and harvest (AUC data; C57 871.4 ± 
235.2, TG2-/- 892.9 ± 239.1, FXIII-A-/- 576.2 ± 413.1, DKO 456.3 ± 408.7) which is 
attributable to a greater weight loss in the immediate post-op period. When only 
data from those animals that survived to harvest were analysed (panel C) there was 
no significant difference in weight between genotypes (p=0.265), suggesting that 
weight loss is a surrogate for probability of survival. Panel D shows the weight loss 
in the first 7-days after surgery in DKO mice, sub-grouped into surviving and non-
surviving animals. It is clear that as early as day 2, weight loss can be used to 
identify mice that are unlikely to survive and hence, in the future, we would suggest 
that weight loss on day 2 of >12% is an indication for termination by a Schedule 1 
approved method.  
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Genotype Operations Deaths Mortality Rate Causes of Death 
C57Bl/6 
Sham – 4 
0.25M – 9 
0.5M – 60 
Total – 70 
Sham – 0 
0.25M – 0 
0.5M – 6 (5M, 1 F) 
Total – 6  
8.6% 
- Bowel Ischaemia 
- Bleeding 
- Fighting post-op 
TG2 
-/-
 
Sham – 4 
0.25M – 29 
0.5M – 55 
Total – 88 
Sham – 0 
0.25M – 4 (1M, 3F) 
0.5M – 2 (2M) 
Total – 6 
6.8% 
- Bowel Ischaemia 
- Bleeding 
FXIII-A
 -/-
 
Sham – 2 
0.25M – 5 
0.5M – 49 
Total – 56 
Sham – 0 
0.25M – 4 (1M, 3F) 
0.5M – 19 (9M, 10F) 
Total - 23 
41.1% 
- Bleeding 9% 
- Cardiac +/- Ischaemia 35% 
- Other  
- Bowel Ischaemia 
- Wound Complication 
- Unknown 
DKO 
Sham – 4 
0.25M – 6 
0.5M – 67 
Total – 77 
Sham – 2 (1M, 1F) 
0.25M – 3 (1M, 2F) 
0.5M – 42 (18M, 24F) 
Total - 47 
62.3% 
- Bleeding 26% 
- Including late ? bleeding 
events  
- Cardiac +/- Ischaemia 34% 
- Other  
- Bowel Ischaemia 
- Wound Complication 
- Renal mass? cause 
- Fighting post-op 
- Unknown  
Table 7. Mortality Rates – CaCl2 Injury 
Table outlines operating numbers, mortality rates and causes of death for the CaCl2 injury model. The mortality rate for all operations (from 
which the mouse was recovered from anaesthetic) was 8.6% in the C57Bl/6 group, 6.8% in the TG2-/- group, 41.1% in the FXIII-A-/- group 
and 62.3% in the DKO mice. Causes of death are listed in the table and are discussed in detail in the main text. 
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Figure 46. Post-mortem pathology in DKO mice 
Representative images from post-mortem examination of DKO mice. Panel A. 
shows a DKO mouse found dead on day 5 post op and is typical of the 
appearances seen with post-op bleeding. There is bruising to the abdomen with 
blood and clots found in the abdomen and pelvis. The most common site of 
bleeding was from the pelvic vessels or along the posterolateral aspect of the aorta. 
Panel B. shows the heart of a DKO mouse that underwent sham operation and was 
found dead on day 2 post-op. There were no problems with the wound and no 
evidence of bleeding into the abdomen. Blood stained serous fluid was found in the 
thoracic cavity and the heart appeared as shown here with a black, clot filled atrium 
and dusky appearance to the anterior surface. Panels C and D are images taken of 
a DKO mouse found dead at day 5 post-op. Again, there was no evidence of 
bleeding however the abdominal contents had patchy areas of necrosis with 
discrete ischaemia shown here in the bowel (C) and stomach (D). 
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Figure 47. Weight change in mice post-injury 
All data is shown as mean % weight change (from pre-op) with 95% confidence 
intervals. Panel A shows weight change in all operated mice after 0.5M CaCl2 
injury. Panel B shows AUC data for the curves in panel A. One-way ANOVA testing 
revealed a significant difference in weight between groups (p<0.0001) due to lower 
weights in the FXIII-A-/- and DKO groups, however, when mice that died post-
operatively are excluded from analysis (C), there is no difference between groups 
(p=0.265). Panel D plots weight change in the first 7-days in surviving vs non-
surviving DKO mice and shows that by post-op day 2, weight loss can be used to 
predict survival. 
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7.4.2 Diameter change and aneurysm proportions  
Mice from each genotype (n=19-28) were subject to 0.5M CaCl2 injury to the ventral 
surface of the aorta as outlined (Figure 21). Aortas were harvested at 6 weeks and 
the % change in infra-renal aortic diameter calculated from images captured in vivo 
pre-and post-injury. Each experimental group showed a mean % increase in aortic 
diameter (mean % ± SD; C57 60.0 ± 36.3, TG2-/- 67.5 ± 30.2, FXIII-A-/- 59.4 ± 32.9, 
DKO 43.1 ± 27.5) although the DKO mice appeared to show smaller % changes in 
aortic diameter than the other groups. There was, however, a wide variation in 
response and no statistically significant difference was found between groups 
(p=0.097).  
In conjunction with this observed variation in results it also became apparent that 
vessels either appeared to be grossly dilated or showed a lack of obvious 
inflammation and evidence of injury. To investigate this further we used a 50% 
increase in diameter as a “cut-off” between those vessels classified as developing 
an “aneurysm” and those classified as not developing an “aneurysm”. This 
methodology has been utilised by other groups and is equivalent to the 3cm 
diameter cut-off in the national aneurysm screening programme which represents 
an increase in 50% from an average aortic diameter of 2cm.  
These results are summarised in Figure 49 and it can be seen that 17/28 (60.7%) 
mice developed an aneurysm in the C57Bl/6 group  as compared with 20/27 
(74.1%) in the TG2-/- group, 16/26 (61.5%) in the FXIII-A-/- group and 7/19 (36.8%) 
in the DKO group.  Fisher’s exact testing showed no significant different in outcome 
between groups when compared with WT however the DKO mice did develop a 
significantly lower proportion of aneurysms than the TG2-/- group (p=0.016). 
The data from Figure 48 are re-presented in panel C of Figure 49 with sub-group 
analysis of each genotype group into i) those mice that did reach >50% increase in 
diameter (developed an “aneurysm”) (mean % ± SD; C57 79.4 ± 33.1, TG2-/- 76.5 ± 
29.9, FXIII-A-/- 79.11 ± 23.88, DKO 70.0 ± 17.8) and ii) those that did not (C57 30.0 
± 13.4, TG2-/- 41.8 ± 8.4, FXIII-A-/- 27.9 ± 15.9, DKO 27.4 ± 18.3). Kruksal-Wallis 
testing of these sub-groups (with Dunn’s correction) again revealed no differences 
in % change in aortic diameter across the genotypes in either in those that did 
(p=0.814) or did not (p=0.160) develop an aneurysm. Overall this data suggests 
that the DKO mice have a lower propensity to aneurysm development (i.e. initiation 
is affected) rather than that they develop smaller aneurysms overall.  
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Figure 48. Summary results from the short-term CaCl2 injury model – % 
change in diameter 
Panel A. shows representative images from a TG2-/- mouse pre- and post- injury 
with 0.5M CaCl2. Scale bar represents 1mm in each image. This vessel increased 
in size by 70.7% in the 6 week study period. Panel B. shows summary data from all 
four genotypes with results shown as % change in infra-renal aortic diameter (mean 
± 95% confidence intervals) from baseline. There was no statistically significant 
difference seen between groups (ANOVA, p=0.097). 
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B. Aneurysm (n) No Aneurysm 
(n) 
Proportion Developing AAA 
(%) 
C57Bl/6 17 11 60.7 
TG2
-/-
 20 7 74.1 
FXIII-A
-/- 
16 11 61.5 
DKO 7 12 36.8 
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Figure 49. Summary results from the short-term CaCl2 injury model – 
proportion developing an aneurysm 
Panel A shows representative images from two DKO mice; the top images are from 
a DKO aorta which shows clear inflammation and dilatation (by 87.3%) after 0.5M 
CaCl2 exposure whilst the bottom images are from a DKO aorta showing very 
minimal inflammation and no dilatation (1.60%) following the same insult. Scale bar 
represents 1mm in all images. Panel B. shows summary data from all four 
genotypes with results shown as proportion (%) of mice developing an AAA (i.e. 
>50% increase in diameter). Fisher’s Exact testing revealed no difference between 
groups when compared to wildtype, however TG2-/- and DKO groups did differ 
significantly (p=0.016). Panel C. shows the data from the previous figure but with 
each genotype split into those mice that did reach >50% increase in aortic diameter 
and those that did not. There was no difference in % diameter change between 
genotypes when these subgroups where analysed separately. 
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7.4.3 Histology 
7.4.3.1 Elastin damage 
For each group (n=6) injured aortas were harvested, fixed, processed and 
sectioned. Slides were stained using the Miller Van Gieson protocol to enable 
visualisation of elastic fibres. The midpoint of the area of injury was identified and 
taken as the “zero-point”. Ten serial sections from this point and 5 each from 50µm 
proximal and 50µm distal to this zero-point were analysed for elastin damage. Each 
section was analysed blind and elastin fibres classified as either healthy, damaged 
but intact (i.e. showing mild degradation with flattening and thinning of fibres) or 
damaged and fragmented. This classification is based on that used by Watanabe et 
al in 2012 (Watanabe et al., 2012) (and shown in Figure 51). The proportion of each 
degree of damage was calculated relative to the whole vessel circumference and is 
given as a %. From this analysis we were also able to assess the correlation 
between outer aortic diameter (as measured from intra-operative photographs) and 
average inner circumference (as measured on histological sections). The results of 
this analysis are presented in Figure 50 and show that these two measures are 
reasonably well correlated (R2=0.522).  
Elastin damage data are shown in Figure 51. One-way ANOVA testing for each 
degree of elastin damage revealed no significant difference between groups in 
terms of proportion of healthy fibres (p=0.824), or in proportion of broken fibres 
(p=0.192) however the groups did vary significantly with regards the proportion of 
damaged but intact fibres present (p=0.028) with the DKO group showing a 
significantly higher proportion of damaged/intact fibres when compared with WT 
mice (p=0.028).  
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Figure 50. Correlation between "outer" diameter and "inner" 
circumference 
Figure shows the relationship between the post-operative “outer” aortic 
diameter (n=24), measured from photographs captured in vivo at the time of 
harvest (at 6 weeks) and the “inner” vessel circumference measured from 
histological sections from the area of injury (mean of 10 sections per vessel, 
n=24). The coefficient of determination (R2) is 0.522 with regression equation 
y=4.143x + 0.1975.  
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Figure 51. Elastin damage in the short-term CaCl2 injury model 
Panels A-F show representative sections of elastin damage from a DKO mouse 
aorta exposed to 0.5M CaCl2 and harvested at 6 weeks. Scale bar represents 
100µm in each case. Panel A is a schematic of the area of injury and highlights the 
location of panels B-F. Panels B and C show areas of gross elastin damage and 
breakage whilst elastin flattening and loss of fibre waviness are apparent in D and 
E. Panel F shows the iliac bifurcation with relatively normal elastin fibre appearance 
seen in both vessels. Panel G is taken from (Watanabe et al., 2012) and shows the 
grading system utilised for classification of elastin damage. Scale bar represents 
50µm in these images. Panel H summarises the findings in the four experimental 
genotypes (n=6 mice, 20 sections/vessel) with the mean proportion of healthy, 
damaged/intact and broken elastin fibres expressed as a % of the total 
circumference. 
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7.4.3.2 Collagen density 
For each group, (n=6) injured aortas were harvested, fixed, processed and serial 
sectioned. Every 10th slide was stained using the Sirius Red protocol and then 
imaged using the multiphoton microscope to enable visualisation of fibrillar 
collagen. Representative sections from each of the genotypes are shown in Figure 
52 and clearly show that collagen density is reduced at sites of elastin damage. 
Although total collagen content was not quantified, Figure 53 shows collagen 
density (as measured by Image J software) for each of the genotypes as it relates 
to the degree of elastin damage. Again, a clear relationship between these two 
parameters can be seen, with higher collagen densities present adjacent to areas of 
healthy medial elastin and more sparse fibrillar collagen at sites of elastin damage 
and breakage. No statistical differences was seen between genotype groups for 
each degree of elastin damage however when all groups were combined ANOVA 
testing revealed a statistically significant diffence in collagen density between sites 
of healthy elastin and sites of either damaged or broken elastin (p<0.001). 
7.4.3.3 Calcification 
For each group (n=6) injured aortas were harvested, fixed, processed and serial 
sectioned. Every 10th slide was stained using the Alizarin Red protocol to enable 
visualisation of calcification. In a subgroup of mice (n=2 per genotype) vessels were 
harvested 24 hours after injury and were handled as above. 
Analysis of calcification in the 6 week samples revealed that Alizarin Red staining 
was specifically localised to the site of injured and/or broken elastin fibres in each of 
the genotypes. Representative images are shown in Figure 54 and clearly 
demonstrate the correlation between elastin damage and calcification. No 
calcification was observed in vessels without elastin damage, although in areas 
where new, disorganised, elastin fibres were visible, calcification was also clearly 
present. Vessels harvested at 24-hours showed no Alizarin staining and hence no 
evidence of calcium deposition, thus indicating that the calcium applied to the aorta 
does not simply remain in situ but is removed and it is the injury and subsequent 
inflammation that induces calcification at sites of damage.  
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Figure 52. Collagen distribution  in the short-term CaCl2 model 
Panels A-D show representative matched sections stained with Miller Van Gieson stain (for elastin) on the left or stained with Sirius Red and 
scanned with the muliphoton microscope (for fibrillar collagen) on the right. Images are from 5µm sections, captured at 2.5x magnification and 
imaged at 10x magnification. Scale bars represent 100µm in each case. Samples are from each of the genotypes (A=C57Bl/6, B=TG2-/-, C=FXIII-
A-/- and D=DKO) and clearly show that collagen density is reduced at areas of elastin damage.  
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Figure 53. Collagen density in the short term CaCl2 model 
Sites of 1) healthy elastin, 2) damaged but intact elastin and 3) broken elastin were 
identified on n=20 sections per vessel for n=6 vessels per genotype. At each site a 
10x10 (AU2) area was analysed using ImageJ software to measure collagen 
density. No difference in collagen density was found between genotype groups 
within each degree of elastin damage. When all groups were combined ANOVA 
testing revealed a statistically significant diffence in collagen density between sites 
of healthy elastin and sites of either damaged or broken elastin (p<0.001). AU = 
Arbitrary units 
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Figure 54. Calcification in the short-term CaCl2 injury model 
Panels A-D show representative adjacent sections stained with either Miller Van 
Gieson stain (for elastin) on the left or Alizarin Red stain (for calcium) on the right. 
Images are from 5µm sections, captured at 2.5x magnification and imaged at 10x 
magnification. Samples are from each of the genotypes (A=C57Bl/6, B=TG2-/-, 
C=FXIII-A-/- and D=DKO) and clearly show that calcification (red) is localised 
specifically to areas of elastin damage and breakage. Panels  B and C appear to 
show attempts at new elastin deposition (outside the elastic media) but these fibres 
are disorganised and also show associated calcification (filled arrows). Panel E 
shows representative images from injured aortas (C67Bl/6 (left) and DKO (right) 
mice) harvested at 24 hours post-op. No calcification was observed in any of these 
samples (n=2 per genotype). Scale bars represent 100µm in each image 
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7.4.4 Transglutaminase compensation 
Although we found no evidence of upregulation of any of the transglutaminases in 
the aorta secondary to single (TG2-/- or FXIII-A-/-) or double (TG2-/-.FXIII-A-/-) gene 
deficiency, we sought to investigate whether injury in the form of the CaCl2 
aneurysm model was sufficient to cause compensatory upregulation. Levels of 
aortic mRNA were determined by qPCR in samples harvested into liquid nitrogen 6 
weeks after CaCl2 injury (n=9-10 per genotype). Actual expression levels (2
-ΔCt) in 
both un-operated and operated vessels from C57Bl/6 mice are shown (Figure 55), 
as well as expression levels relative to the level of that particular transglutaminase 
in C57Bl/6 operated tissue. Relative expression levels in un-operated vessels 
(compared to WT) are shown for comparison and a reference line representing a 4-
fold increase in expression is shown across all graphs to enable appraisal between 
panels. Statistical analysis was performed on raw ∆Ct values and significance of 
change of expression was analysed using one-way ANOVA with Bonferroni 
correction for multiple testing.  
As in the un-operated vessels, TG2 is the most abundant transglutaminase 
expressed in the WT injured aorta and there is a small but non-significant increase 
in TG2 levels between un-operated and operated samples (mean with 95% CI; un-
operated TG2 expression 1.40 (0.74-2.64), operated TG2 expression 1.77 (1.11-
2.82), p=0.602). Expression levels of the other transglutaminases are low (FXIII-A 
and TG3) or negligible. Therefore CaCl2 injury does not significantly change the 
expression of any of the transglutaminases in the WT aorta. 
Statistically significant differences in transglutaminase expression were seen in 
operated aortas across the four transgenic lines, however absence of TG2 and/or 
FXIII-A did not induce compensatory upregulation of mRNA expression of the 
reciprocal enzyme. TG1 expression was higher in DKO vessels relative to WT 
(p=0.0055) as was TG4 (p=0.0172) and TG7 (p=0.0017) expression. The FXIII-A-/- 
groups also showed a significantly increased TG7 expression (p=0.0021) and TG5 
expression was increased in DKO mice relative to either of the single KO groups 
but was not significantly different from in the WT condition. Despite these 
differences between groups, no transglutaminase was expressed at a level 
comparable to that of TG2 in WT tissue hence these increases are unlikely to 
provide any functional compensation for the absence of TG2 and FXIII-A in the 
setting of vessel injury. 
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Figure 55. Expression levels of the transglutaminases in the injured 
aorta 
Panel A. Transglutaminase 2 is the most abundant transglutaminase expressed in 
both the un-operated and operated aorta. Expression levels of the other TGs are 
low (FXIII-A and TG3) or negligible. Vessel injury does not significantly change the 
expression of any of the TGs in the WT situation. Values shown are TG expression 
(2-ΔCt) in C57Bl/6 un-operated and operated aortic tissue (Mean ± 95%CI). Panel B. 
Expression of TGs in un-operated vessels for comparison. All values are expressed 
as fold change relative to the expression level of that particular transglutaminase in 
C57Bl/6 control aortic tissue. Panel C. Transglutaminase mRNA expression in 
operated aortic tissue. All values are expressed as fold change relative to the 
expression level of that particular transglutaminase in C57Bl/6 operated aortic 
tissue. Significant differences were seen in TG1, TG4 and TG7 expression however 
increases were not systematic and were not to the level of TG2 expression and are 
therefore not likely to be sufficient for functional compensation. Dotted line reflects a 
4-fold increase in expression relative to WT * = p<0.05, ** = p<0.01, ***p<0.001.  
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7.4.5 Expression data 
We investigated whether aortic injury via the CaCl2 model resulted in significant up- 
or down-regulation of a number of gene transcripts of interest. These included 
various structural proteins including collagen (types I and III), elastin and vimentin, 
as well as gene transcripts known to be involved in inflammation and proteolysis. 
Levels of mRNA expression were determined by qPCR and, as previously, 
statistical analysis was performed on raw ΔCt values with either Student’s t-test or 
ANOVA and Bonferroni testing applied to the data. Expression levels were 
compared between the un-operated and operated conditions in WT aortic tissue 
(actual expression levels (2-ΔCt) shown) and then across the four experimental 
genotypes after CaCl2 injury (expression is shown relative to levels in WT operated 
vessels).  
Of the gene transcripts investigated, α-SMA was the most predominant in the WT 
control aorta with expression levels 7-8 times that of the next most highly expressed 
transcript (vimentin and collagen I). Only PAI-1 expression was significantly 
different in operated vs un-operated WT aortic tissue with mean expression ~2.5 
fold lower in vessels subject to CaCl2 injury (p=0.0022). 
Our results showed considerable variability between samples as well as a number 
of statistically “significant” results which are unlikely to represent biologically 
relevant findings. Despite these caveats, there were a number of key results from 
these data. Expression of fibrillin-2 varied greatly between experimental genotypes; 
FXIII-A-/- samples demonstrated a 6-fold increase in fibrillin-2 expression 
(p=0.0045) and levels were 7-fold increased (p=0.0014) in operated DKO aortas in 
comparison with those from C57Bl/6 mice. Likewise, uPA expression and 
expression of haem oxygenase-1 ((HO-1), an inducible isoform of the haem 
degradation enzyme which is produced in response to oxidative stress) were also 
greatly increased in operated samples from the transgenic mice groups when 
compared to those from the WT group. Expression of uPA showed a trend towards 
increase in  TG2-/-mice (3-fold greater, p=0.079), was 4-fold greater in FXIII-A-/- 
mice (p=0.023) and approximately 5.5-fold greater in DKO mice (p<0.001). 
Expression of HO-1 was also increased 11-fold in DKO mice compared to WT 
(p=0.045).  
In addition to the decreased expression of α-SMA seen in WT operated samples 
(vs. un-operated aortas) we saw a further decrease in expression levels in the DKO 
mice (~85-fold decrease, p<0.0001). There was no difference between α-SMA 
expression in FXIII-A-/- or TG2-/- mice as compared to the operated vessels from WT 
mice. A similar pattern of results was seen with expression of PAI-1 (with 
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decreased levels in operated vs un-operated WT vessels and further decreases in 
expression seen in DKO mice (>6-fold decrease, p=0.004)) and vimentin (~3.5-fold 
decrease in DKO operated vessels compared to WT operated, p=0.009). 
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Figure 56. Gene transcript expression levels in the injured aorta 
Panels A and B show expression levels in un-operated (n=9) and operated (n=10) 
vessels from WT mice. Data is presented as 2-ΔCt values (mean with 95% CI) and 
highlights that only PAI-1 expression was significantly altered following 0.5M CaCl2 
injury and harvest after 6 weeks. Panels C and D are provided for reference and 
show mRNA expression of various gene transcripts in the un-operated aorta (n=9-
10) across the experimental genotypes (for interpretation of this data see section 
6.3). Panels E and F show expression levels of the same transcripts in operated 
samples (n=9-10 per genotype) with data presented as fold change relative to the 
expression level of that particular gene transcript in operated vessels from WT 
mice. Statistical analysis was performed using Student’s t-test (for 2 groups) or one-
way ANOVA with Bonferroni correction (for multiple groups).  Dotted line reflects a 
4-fold increase in expression relative to WT. * = p<0.05. ** = p<0.01, *** = p<0.001 
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7.4.6 MMPs 
Quantitative real-time PCR was performed to investigate the mRNA expression of 
various MMPs in aortic tissue from mice (n=9-10) from each of the experimental 
genotypes subject to 0.5M CaCl2 exposure and harvested at 6 weeks. These data 
are shown in Figure 57. Panel A reflects expression levels (as 2-ΔCt values) of 
MMPs in un-operated and operated tissue from C57Bl/6 mice. A 17-fold increase in 
MMP-12 expression was seen in operated vessels relative to baseline (Student’s t-
test, p<0.001) and TIMP-1 expression was increased by 2-fold (p=0.0047). None of 
the other MMPs investigated were differentially expressed in WT vessels following 
injury.  
Comparison was made across the four experimental genotypes after CaCl2 injury 
(expression is shown relative to levels in WT operated vessels). The only MMP 
transcript to increase significantly across all genotypes was MMP-12. In addition to 
the 17-fold increase from basal to operated (in WT), levels showed a further 4.5-fold 
increase between operated WT and TG2-/- vessels (p=0.0127), a 13-fold increase 
between operated WT and FXIII-A-/- vessels (p<0.0001) and an 8-fold increase 
between operated WT and DKO vessels (p=0.0004). This equates to a huge 
upregulation of MMP-12 of >140-fold when comparing basal WT vessels to those 
harvested from DKO animals following CaCl2 injury. 
TIMP-1 expression was also found to be increased in FXIII-A-/- operated samples 
(~3-fold increase, p=0.0475) and MT-MMP expression was increased in both FXIII-
A-/- and DKO samples (5-fold increase, p=0.0004 and 4-fold increase, p=0.002 
respectively). TIMP-2 expression was decreased in DKO operated vessels (to 
approximately 17% of WT operated levels, p=0.0042) but similar decreases were 
not seen in either of the other transgenic groups. No significant changes were seen 
in mRNA expression levels of either MMP-2 or MMP-9, either between basal and 
operated conditions in WT mice, or between genotypes following operation 
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Figure 57. Expression levels of the MMPs in the injured aorta 
Panel A. shows expression levels in un-operated (n=9) and operated (n=10) 
vessels from WT mice. Data is presented as 2-ΔCt values (mean with 95% CI) 
and highlights that only MMP-12 and TIMP-1 expression were significantly 
altered following 0.5M CaCl2 injury and harvest after 6 weeks. Panel B. is 
provided for reference and shows mRNA expression of MMP gene 
transcripts in the un-operated aorta (n=9-10) across the experimental 
genotypes (for interpretation of this data see section 6.4). Panel C shows 
expression levels of the same transcripts in operated samples (n=9-10 per 
genotype) with data presented as fold change relative to the expression level 
of that particular MMP gene transcript in operated vessels from WT mice. 
Statistical analysis was performed using Student’s t-test (for 2 groups) or 
one-way ANOVA with Bonferroni correction (for multiple groups).  Dotted line 
reflects a 4-fold increase in expression relative to WT. *, p<0.05, **, p<0.01, 
***, p<0.001 
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7.4.7 Immunohistochemistry 
Immunohistochemical staining of selected aortic sections from injured vessels from 
each genotype (n=6 per group) was undertaken to assay for the presence of αSMA 
(a specific marker of smooth muscle cells) and MMP-12 in our samples.  
Anti-SMA antibody (ab184675, Abcam Plc, UK) was used for staining of αSMA, a 
highly conserved cytoskeletal protein which is expressed in all eukaryotic cells. This 
antibody is known to react with rat protein and is predicted to strongly cross-react 
with a variety of mammalian species including murine samples. The antibody has 
been tested in SV40LT-SMC cells which are rat aortic smooth muscle cells 
transfected with simian virus 40 large T antigen. These cells have been shown to 
main SMC characteristics over >200 population doublings by Reilly (Reilly, 1990) 
and have been utilised extensively in the literature as a model of SMC phenotype. 
Anti-MMP-12 antibody (ab200410, Abcam Plc, UK) was used for staiing of MMP-
12. This antibody has been raised against a synthetic peptide corresponding to the 
last 20 amino acids of the human protein but is predicted to react with both mouse 
and rat species. The antibody has been tested in the A549 cell line which is derived 
from human alveolar (lung) adenocarcinoma and in our work murine lung samples 
were used as a positive control for MMP-12 staining.  
Quantification of this work has not yet been undertaken however representative 
images are shown in Figure 58 and highlight the intense expression of αSMA 
around damaged and broken elastin fibres. MMP-12 staining appeared to differ 
between the genotypes and from preliminary analysis is more prevalent in vessels 
from DKO mice. All the sections examined showed MMP-12 within the adventitia 
and surrounding inflammatory tissue rather than in the media itself.    
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Figure 58. Representative sections – MMP-12 immunohistochemistry 
Representative sections (10X magnification) from operated aorta from each of a A. 
C57Bl/6, B. TG2-/, C. FXIII-A-/- and D. DKO mouse. Scale bar represents 100µm in 
these images. Immunohistochemistry was performed as outlined in methods to 
stain α-SMA (brown) and MMP-12 (pink). The vessel wall clearly demonstrates α-
SMA staining in each case, with intense staining around sites of broken/damaged 
elastin. MMP-12 staining is variable between genotypes but appears to be 
strongest in DKO vessels and is located in the surrounding adventitia and 
inflammatory tissue rather than in the elastic media itself. Panels E, F and G show 
murine lung tissue and represent our negative (E) control and positive control for 
MMP-12 (F) and α-SMA (G) staining. Scale bar represents 50µm in these images. 
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7.5 Long term aneurysms 
Many authors have reported a difference between experimental aneurysm initiation 
and progression and work from our group suggests a role for TG2 in vascular 
repair. Therefore, we decided to investigate whether there were any longer-term 
effects of TG2 deficiency in the setting of the CaCl2 aneurysm model. The other 
experimental genotypes were not investigated under these conditions because of a) 
ethical considerations regarding the high post-op mortality in these mice and b) the 
lack of strong evidence for the involvement of FXIII-A in vascular repair.   
7.6.1 Diameter change and aneurysm proportions 
Mice from C57Bl/6 (n=19) and TG2-/- (n=17) genotype groups were subject to 0.5M 
CaCl2 injury to the ventral surface of the aorta and results are summarised in Figure 
59. Aortas were harvested at 6 months and the % change in infra-renal aortic 
diameter calculated from images captured in vivo pre-and post-injury. Each 
experimental group showed a mean % increase in aortic diameter (C57 64.1 ± 30.7, 
TG2-/- 89.5 ± 34.5) with the TG2-deficient mice showing a statistically significant 
larger increase in diameter over the 6 month period (p=0.025). 
Comparison was also made between changes in diameter observed between 
genotypes at 6 weeks vs. those seen at 6 months. The C57Bl/6 group at 6 weeks 
showed a change in diameter of 60.0 ± 36.3% which was not statistically different 
from that seen at 6 months (64.1 ± 30.7), suggesting that these mice were able to 
halt aneurysm progression (or attempt vascular repair) following the initial injury. In 
contrast, the TG2-/- mice showed a change in diameter of 67.5 ± 30.2% at 6 weeks, 
which was significantly different (smaller) than that seen at 6 months (89.5 ± 34.5, 
p=0.031). This would indicate that the injury has continued to progress unchecked 
and that the TG2-/- mice are unable to halt aneurysm progression once it has been 
initiated, perhaps due to a failure of vascular repair. 
Vessels were classified as either “aneurysmal” (demonstrating a % change in 
diameter of >50%) or “non-aneurysmal”. Under conditions of long-term CaCl2 
exposure, 10/19 (52.6%) of C57Bl/6 mice studied developed an aneurysm as 
compared with 16/17 (94.1%) of TG2-/- mice subject to the same experimental 
conditions. This was statistically significant on analysis with Fisher’s Exact Test 
(p=0.0084). These data suggest that aneurysm initiation and progression are 
distinct processes and that TG2 may have a role in the latter, possibly through its 
arterial repair function.   
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Figure 59. Summary Results – long-term CaCl2 injury model 
Panel A. Representative images from “long-term” injury model from a C57B/l6 
mouse showing pre- and post-injury appearances. Scale bar represents 1mm. 
Panel B. Summary results from the aneurysm model in C57Bl/6 and TG2 mice 
under conditions of NaCl application (sham-operated), 0.25M CaCl2 application and 
0.5M CaCl2 application with harvest at either 6 weeks or 6 months. Data is shown 
as mean % change in aortic diameter (from baseline) with 95% confidence 
intervals. Panel C. summarises the proportion of mice of each genotype that 
develop and “aneurysm” (% diameter change >50%). Data were analysed using  
Fishers Exact Test (of proportions), p=0.0084 
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7.6.2 Histology  
7.6.2.1 Elastin damage 
For each group (n=6) elastin damage was classified as either healthy, damaged but 
intact or broken, as previously. Data are averaged for each aorta from analysis of 
20 sections from the middle 100µm of the area of injury, and then presented as an 
average for each genotype (either C57Bl/6 or TG2-/-). The proportion of each 
degree of damage was calculated relative to the whole vessel circumference and is 
given as a %. Results are shown in Figure 60. Student’s t-testing for each degree of 
elastin damage revealed no significant difference between C57Bl/6 and TG2-/- mice 
in terms of proportion of healthy fibres (p=0.304), damaged but intact fibres 
(p=0.734) or in the proportion of broken fibres (p=0.570).  
7.6.2.2 Collagen density 
Long-term injured aortas (n=6 per group)  were processed, stained and imaged to 
enable visualisation of fibrillar collagen. Results similar to those obtained with the 
short-term protocol were seen, with collagen density clearly reduced with increasing 
degree of elastin damage (p=0.0012 when data from both genotypes combined) . 
Figure 61 shows data relating to collagen density (arbitrary units) for each 
genotype, classified by the degree of elastin damage present at that site. Where 
elastin was classified as either “healthy” or “damaged but intact”, the TG2-/- vessels 
had a lower collagen density than those from WT mice (p=0.042 and p=0.026 
respectively).  
7.6.2.3 Calcification 
For each group (n=6) injured aortas were harvested, fixed, processed and serial 
sectioned. Every 10th slide was stained using the Alizarin Red protocol to enable 
visualisation of calcification.  
As seen in the 6 week samples, analysis of calcification revealed that Alizarin Red 
staining was specifically localised to the site of injured and/or broken elastin fibres 
in each of the genotypes. Representative images are shown in Figure 62.  
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Figure 60. Elastin damage in the long-term CaCl2 injury model 
Panel A shows representative sections of elastin damage from a C57Bl/6 and a 
TG2-/- mouse aorta exposed to 0.5M CaCl2 and harvested at 6 months. Scale bar 
represents 100µm. Panel B. summarises the findings in the two long-term 
experimental genotypes (n=6 mice, 20 sections/vessel) with the mean proportion of 
healthy, damaged/intact and broken elastin fibres expressed as a % of the total 
circumference. Student’s t-testing revealed no statistically significant differences 
between the 2 groups in any of the “degrees of elastin damage”. 
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Figure 61. Collagen density in the long-term CaCl2 injury model 
Collagen density was measured as described with areas of “healthy” elastin, 
“damaged but intact” elastin or “broken” elastin assessed separately. In both 
C57Bl/6 and TG2-/- mice, collagen density was reduced as the severity of elastin 
damage increased (ANOVA of combined data from both genotypes, p=0.0012). 
Pairwise Student’s t-testing (with Welch’s correction) revealed that the C57Bl/6 
vessels had increased collagen density when compared to TG2-/- vessels at sites of 
healthy elastin (*, p=0.042) and where fibres were damaged but intact (*, p=0.026) 
A. 
  
B. 
 
 
Figure 62. Calcification in the long-term CaCl2 injury model 
Panel A. shows representative images from a C57Bl/6 mouse aorta, harvested at 6 
months post calcium injury. Images are from 5µm sections, captured at 2.5X 
magnification and imaged at 10X magnification. Correlation between elastin fibre 
damage/breakage and calcification is clearly seen. Panel B. shows the same 
findings but are taken from a TG2-/- mouse aorta. Scale bars represent 100µm in all 
images. 
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7.6.3 Expression data 
Real-time PCR was performed to investigate mRNA expression of the 
transglutaminases as well as various other gene transcripts in aortic tissue 
harvested from WT (n=3) and TG2-/- (n=3) mice subject to 0.5M CaCl2 exposure 
and harvested after 6 months. These results are summarised in Figure 63 and 
Figure 64 and in both cases show actual expression levels (2-ΔCt) in un-operated, 
“short-term” operated and “long-term” operated vessels from C57Bl/6 mice. 
Statistical analysis was performed on raw delta Ct values. Due to the small number 
of samples per group normality could not be reliably assessed and hence 
significance of change of expression was analysed using Mann-Whitney testing (for 
two groups) and Kruksal-Wallis testing with Dunn’s  correction for multiple groups. 
 
There was no evidence of substantive transglutaminase upregulation in the long-
term CaCl2 model. In WT tissue there was a significant decrease in TG2 expression 
between aortas from the short-term model vs. those subject to the long-term model 
(p=0.020). A similarly decreased FXIII-A expression was also observed in aortas 
from WT mice harvested after 6 months (p=0.0129) vs those harvested from the 6 
week model. Expression of both TG1 and TG7 was increased in WT aortas from 
the 6 month model in comparison to those from the un-operated group (p=0.0074 
and p=0.0098 respectively). The expression level of TG1 was not significantly 
higher than that of TG2 (mean 2-ΔCt with 95% CI; TG1 0.24 (0.09-0.66), TG2 0.11 
(0.04-0.30), p=0.70) and despite a >80-fold increase on basal TG1 levels still did 
not reach the levels of TG2 expression seen in basal tissue samples (1.40 (0.74-
2.64)). Similarly, TG7 expression levels (0.18 (0.04-0.75)) were >200-fold increased 
compared to baseline levels but were not statistically greater than TG2 expression 
levels in either baseline or operated samples. 
 
When comparing expression between WT and TG2-/- samples the only gene 
transcript that varied significantly in this model was TG2 itself. No statistically 
significant differences were seen between expression levels of any of the other 
transglutaminases compared to expression in WT vessels subject to the same 
conditions. In terms of the gene transcripts investigated that are known to be 
involved in inflammation or are components of vessel structure, there was no 
significant difference between the two experimental genotypes with this model. 
Expression levels of α-SMA were dramatically decreased in WT aortas harvested at 
6 months (>13-fold decrease in expression compared to basal tissue levels, 
p=0.008) similar to the changes observed in the 6 week model, however α-SMA 
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expression was not different between WT and TG2-/- samples. Expression levels of 
many of the other “structural” transcripts were also decreased in the long-term 
model. Collagen I (11-fold decrease, p=0.0143), collagen III (33-fold decrease, 
p=0.0057), fibrillin I (8-fold decrease, p=0.0031), and vimentin (4-fold decrease, 
p=0.0074) expression levels were all decreased relative to basal levels.  
 
Although we did not observe significant differences in expression levels between 
WT and TG2-/- aortic samples, the long-term model did appear to affect expression 
levels of fibrillin II (26 fold increase, p=0.0475), HO-1 (14-fold increase, p=0.015), 
uPA (7-fold increase, p=0.0039) and PAI-1 (35-fold decrease, p=0.0092) when 
compared to baseline, un-operated, values. Of note, these are the transcripts that 
varied in the DKO transgenic mouse line in the 6week model, and each result 
showed the same trend (i.e. either increase or decrease) perhaps suggesting that 
the loss of FXIII-A and TG2 is an “injurious stimulus” similar to that of long term 
CaCl2 injury in WT/TG2
-/- mice.  
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Figure 63. Expression levels of the transglutaminases in the long-term 
CaCl2 injury model 
Panel A. Absolute expression levels (mean 2-ΔCt values ± 95% CI) of the 
transglutaminases in un-operated (n=9), “short-term” operated (n=9) and “long-
term” operated (n=10) vessels from C57Bl/6 mice  TG2 expression is reduced in 
the long-term model and both TG1 and TG7 expression is increased, but not to the 
levels of TG2 seen in basal tissue. Panel B. Transglutaminase mRNA expression in 
the 6 month operated aortic samples from C57Bl/6 (n=3) and TG2-/- (n=3) mice. All 
values are expressed as fold change relative to the expression level of that 
particular transglutaminase in C57Bl/6 6 month operated aortic tissue. Only TG2 
expression was significantly difference between groups. Dotted line reflects a 4-fold 
increase in expression relative to WT * = p<0.05, ** = p<0.01, ***p<0.001. 
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Figure 64. Gene transcript expression levels in the long-term CaCl2 
injury model 
Panel A shows expression levels in un-operated (n=9), “short-term” operated 
(n=10) and “long-term” operated vessels from C57Bl/6 mice. Data is presented as 
2-ΔCt values (mean ± 95% CI) and highlights those transcripts that are significantly 
altered in the long-term model (see text for details). Panel B shows expression 
levels of the same transcripts in long-term operated samples (n=3 per genotype) 
with data presented as fold change relative to the expression level of that particular 
gene transcript in long-term operated vessels from WT mice. No significant 
difference was seen between WT and TG2-/- mice in any of the transcripts studied. 
Statistical analysis was performed using Mann-Whitney testing (for 2 groups) or 
Kruksal-Wallis testing with Dunn’s correction (for multiple groups).  Dotted line 
reflects a 4-fold increase in expression relative to WT. * = p<0.05. ** = p<0.01, *** = 
p<0.001 
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7.6.4 MMPs 
As with the short-term model, qPCR was performed in samples harvested from the 
long-term model (n=3 per genotype) to investigate the expression of MMP-2,-9 and-
12, as well as MT-MMP and TIMPs 1 and 2. These data are summarised in Figure 
65. Panel A reflects expression levels (as 2-ΔCt values) of MMPs in un-operated, 
“short-term” (6 week) and “long-term” (6 month) operated tissue from C57Bl/6 mice. 
Expression levels of MMP-9 were unchanged relative to baseline or the 6 week 
model whilst MMP-2 (11-fold decrease, p=0.0074) and TIMP-2 (6-fold decrease, p-
0.0112) levels were decreased relative to basal expression. Similar to the 6 week 
model, expression levels of both MMP-12 and TIMP-1 were dramatically increased 
in aortic tissue harvested at 6 months. MMP-12 expression showed a >400-fold 
increase (p=0.0013) relative to baseline (c.f. 17-fold at 6 weeks) and TIMP-1 levels 
had increased by 30-fold (p=0.0019) relative to baseline as compared to the 
doubling in expression levels seen at 6 weeks. Clearly MMP-12 and TIMP-1 play an 
important role in progression of vessel dilatation in this model and warrant further 
study as to their potential interactions with the transglutaminases under 
investigation. 
Table 5. Expression levels of the MMPs in the long-term CaCl2 injury 
model 
 
Panel B of Figure 65 shows relative expression levels of MMPs in vessels from 
TG2-/-  mice (compared to WT) subject to the long-term CaCl2 model.  Although both 
MMP-12 and TIMP-1 showed increased levels in TG2-/- samples relative to those 
Gene Transcript C57Bl/6 (n=3) 
Mean 2-ΔCt (95% CI) 
TG2-/-(n=3) 
Mean 2-ΔCt (95% CI) 
MMP-2 0.02 (0.004 – 0.07) 0.01 (0.005 – 0.02) 
MMP-9 0.03 (0.01 – 0.07) 0.01 (0.005 – 0.02) 
MMP-12 2.37 (0.61 – 9.27) 7.04 (3.28 – 15.11) 
MT-MMP 0.60 (0.23 – 1.56) 1.68 (1.35 – 2.10) 
TIMP-1 2.03 (0.43 – 9.50) 3.33 (1.13 – 9.83) 
TIMP-2 0.11 (0.07 – 0.17) 0.06 (0.02 – 0.15) 
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from C57Bl/6 mice (see Table 6) no statistically significant difference was found 
between WT and TG2-/- mice in any of the MMPs/TIMPs investigated with the 6 
month model.  
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Figure 65. Expression of the MMPs in the long-term CaCl2 injury model 
Panel A. shows expression levels in un-operated (n=9), “short-term” (6 week) 
operated (n=10) and “long-term” (6 month) operated (n=3) vessels from WT mice. 
Data is presented as 2-ΔCt values (mean with 95% CI) and highlights that transcripts 
that were significantly changed in the long-term model (see text for detail). Panel B 
shows expression levels of the same transcripts in long-term operated samples 
(n=3 per genotype) with data presented as fold change relative to the expression 
level of that particular MMP in long-term operated vessels from WT mice. Statistical 
analysis was performed using Mann-Whitney testing (for 2 groups) or Kruksal-
Wallis testing with Dunn’s correction (for multiple groups).  Dotted line reflects a 4-
fold increase in expression relative to WT. * = p<0.05. ** = p<0.01, *** = p<0.001 
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7.7 Carotid aneurysm model 
7.7.1 Survival 
Due to the high mortality observed with the CaCl2 model of AAA in those mice 
deficient in the FXIII-A gene, we wanted to investigate whether a modified model 
could be established. This would need to allow vascular injury and repair to be 
investigated, without the high associated animal mortality. As carotid ligation 
experiments on DKO mice were well tolerated, and the original description of the 
CaCl2  model was in the (rabbit) carotid artery,(Gertz et al., 1988) we decided to trial 
the CaCl2 model in murine carotid arteries. This methodology is identical to that 
described in section 4.12 except that the right carotid artery is exposed to 0.5M 
CaCl2 after access through a midline anterior neck incision. This model has been 
utilised by Gallo et al (Gallo et al., 2012) to investigate the role of chemokine 
receptor 3 in aneurysm formation and likewise, Pimiento et al (Pimiento et al., 2008) 
have reported success with this model in aged mice subject to 0.5M CaCl2 
exposure and harvest at 5 weeks.  
 
Mice from C57Bl/6 (n=20) and DKO (n=9) genotype groups had 0.5M CaCl2 applied  
to the common carotid artery and vessels were harvested at 6 weeks in line with 
our previous work. Only one death was observed over the post-op period. This 
occurred in the DKO group but was due to fighting behaviours between male mice. 
Although substantial weight loss was observed in the mice in the immediate post-op 
period, there was no difference between genotypes in terms of % weight loss and 
no mouse lost >15% of their body weight. Intra-operative analgesia could not be 
administered with this model, because of the risk of local anaesthetic toxicity to the 
vagus nerve, however, no animal showed signs of post-op distress and there were 
no wound complications observed in this cohort. 
 
7.7.2 Diameter change and aneurysm proportions 
Vessels subject to 0.5M CaCl2 injury to the ventral surface of the right common 
carotid artery and vessels harvested under terminal anaesthesia at 6 weeks. The % 
change in vessel diameter was calculated from images captured in vivo pre-and 
post-injury. Each experimental group showed a mean % increase in carotid 
diameter (C57 43.1 ± 34.8, DKO 20.7 ± 15.9) with the DKO mice showing a 
statistically significant smaller increase in diameter over the 6 week period 
(p=0.028). 
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Under the conditions as described, 8/20 (40.0%) of C57Bl/6 mice studied 
developed an aneurysm (>50% dilatation) as compared with 0/8 of the surviving 
DKO mice. This showed a trend towards significance on analysis with Fisher’s 
Exact Test (p=0.063) but shows a similar pattern to the results obtained in the 
aorta, without the significant mortality. These data suggest that calcium chloride 
injury to the carotid artery may represent a feasible model for assessing vessel 
damage and repair in future studies. 
7.7.3 Histology 
Although formal qualitative and quantitative analysis of histology from the carotid 
artery model was not undertaken, representative images are shown in Figure 67. In 
general the injured vessels showed the characteristic elastic fibre flattening and 
loss of waviness, but without the elastic breaks that were seen in the aortic injury. 
Calcium deposition was not a prominent feature, in line with our observation that 
vessel calcification is closely correlated with elastic fibre damage. Further work is 
required to ensure that the carotid and aortic models are comparable in terms of 
histological features but initial findings suggest that this would be a viable 
alternative to aortic injury as a way to reduce operative mortality.  
  
- 206 - 
 
A. 
 
 
B. 
 
 
C.   D. 
C
57
 (n
=2
0)
D
K
O
 (n
=8
)
0
20
40
60
80
Genotype
%
 C
h
a
n
g
e
 i
n
 C
a
ro
ti
d
 D
ia
m
e
te
r
*
 
 C57Bl/6 DKO 
Mortality 0/20 1/9 
Proportion 
developing 
an AAA 
40% 0% 
   
   
Figure 66. Summary results – carotid CaCl2 injury model 
Panels A and B. Representative images from the carotid injury model from a 
C57Bl/6 (A) and DKO (B) mouse showing pre- and post-injury appearances. Scale 
bars represent 500µm. Panel C. summarises mortality rates and the proportion of 
mice of each genotype that develop an “aneurysm” (% diameter change >50%). 
Data were analysed using  Fishers Exact Test (of proportions), p=0.063. Panel D. 
Summary results from the carotid injury aneurysm model in C57Bl/6 and DKO mice. 
Data is shown as mean % change in aortic diameter (from baseline) with 95% 
confidence intervals. Student’s t-test (with Welch’s correction) revealed a 
statistically significant difference between the two groups (*, p=0.028) 
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Figure 67. Representative histology – carotid CaCl2 injury model 
Figure shows representative images from a C57Bl/6 carotid artery with sections 
from the area of injury following exposure to 0.5M CaCl2.  Images are from 5µm 
sections, captured at 2.5X magnification and imaged at 10X magnification. Scale 
bars represent 100µm. Panel A shows a section stained for haematoxylin and 
eosin and highlights (arrow) a relative loss of cellularity at the site of injury. Panel B 
is stained with Miller van Gieson stain (for elastin) and highlights elastin flattening 
and loss of normal fibre waviness. Panel C is a Sirius Red stained section (for 
collagen) and panel D is stained with Alizrin Red (for calcium) and shows a lack of 
calcium staining (consistent with the absence of elastin breaks in panel B). Similar 
images were obtained from the DKO carotid vessels.  
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Figure 68. Summary diagram - the injured aorta 
This figure summarises the main findings from Chapter 7 pertaining to the establishment of the CaCl2 model, the findings from the short (6-
week) and long (6-month) -term protocols and the main results from our mRNA expression studies. It also highlights that we have begun to 
investigate the carotid site as an alternative injury model and that our initial work has shown this to be feasible with similar results to those 
seen at the aorta. These results are discussed in full in section 7.8. 
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 7.8 Discussion  
This chapter summarises the process involved in establishing and optimising the 
CaCl2 model of AAA and presents the key findings (summarised in Figure 68) 
related to our hypothesis that TG2 is involved in the response to aneurysm 
induction, possibly through a vascular repair role. 
The CaCl2 model is technically challenging and requires a considerable time 
investment to ensure that a reproducible, targeted injury is being applied to the 
ventral aorta each time the model is undertaken. We have established this model 
and have determined that a CaCl2 concentration of 0.5M consistently results in 
gross inflammatory change +/- vessel dilatation. Through this work we have shown 
characteristic histopathological changes of elastin loss, damage and fibre breaks 
and have confirmed that our model results in true luminal dilatation and not simply 
external inflammatory tissue deposition as has previously been 
hypothesised.(Freestone et al., 1997)  
Unexpectedly, the CaCl2 model resulted in a high mortality rate in both the FXIII-A-
/- and DKO mice. We have not seen high mortality rates in our non-operated 
transgenic mice and deaths occur 1-5 days after surgery, hence deaths are 
occurring either secondary to CaCl2 application itself or because of the insult of the 
surgical procedure. Whilst it would be easy to assume that these deaths were 
simply due to impaired coagulation and bleeding, this was not the case and at least 
33% of deaths in these mice were associated with post-mortem findings suggestive 
of cardiac pathology +/- embolization. These mice showed no evidence of aortic 
dilatation, vessel rupture or bleeding nor any evidence of widespread intra-
abdominal inflammation or calcification from diffuse CaCl2 exposure. Although less 
dramatic, similar high mortality levels were also observed in ApoE-/-.FXIII-A-/- 
(~13%) and TKO (ApoE-/-.TG2-/-.FXIII-A-/-) (~20%) mice subject to a high fat 
feeding protocol. These mice had unclear causes of death but at least one showed 
evidence of intrathoracic haemorrhage and the surviving mice from the ApoE-/-
.FXIII-A-/- and TKO group showed evidence of cardiac fibrosis, as we have 
demonstrated in our FXIII-A-/- and DKO mice in this work. 
When considered together, this mortality data suggests that FXIII-A has a role in 
vessel integrity/stability and that deficiency results in “leaky” capillaries within the 
heart (resulting in fibrotic change) and increases likelihood of death (from a 
presumed cardiac cause) when the mouse is subject to physiological stress – either  
operative or dietary in the form of high fat feeding. TG2 deficiency worsens the 
observed FXIII-A-/- phenotype and DKO animals exhibit greater levels of cardiac 
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fibrosis and higher mortality rates. One possible mechanism is that the incipient 
cardiac fibrosis could predispose to cardiac arrhythmias leading to sudden death, 
heart failure and/or the formation of atrial thrombus which could subsequently 
embolise to distal sites as was observed in our post-op mice. 
Given that the TKO mice show worse outcomes after carotid ligation than our DKO 
animals, we hypothesise that additional ApoE deficiency again worsens the 
observed vascular phenotype. ApoE deficient mice have been shown to have 
increased large vessel permeability with greater Evans Blue leakage in areas of the 
aorta normally prone to atherosclerosis.(Methia et al., 2001, Hafezi-Moghadam et 
al., 2007) Studies to investigate the combined effects of ApoE and FXIII-A on 
endothelial barrier function, and how this is affected by physiological stress have 
not yet been reported   
It should, of course, be considered that the high mortality rate seen in our FXIII-A-
deficient and DKO mice could be biasing the results obtained using the CaCl2  
model and we are in some way “selecting out” a DKO population with less 
propensity to vessel injury. We believe this is unlikely as the FXIII-A-/- mice, which 
also exhibited a high post-op mortality rate, showed similar changes in aortic 
diameter to WT mice, both in terms of mean % change in diameter and with regards 
the proportion of mice showing aneurysm development. Likewise, the application of 
CaCl2 to the carotid artery, which did not result in high mortality rates in the DKO 
group, generated similar results in terms of diameter change as those achieved with 
the aortic model. Finally, the embolic pathology observed at post-mortem occurred 
at anatomical sites with blood supply proximal to the infra-renal abdominal aorta, 
thus suggesting that the cause of death in these mice is distinct from the site of 
vascular injury. 
The “short-term” (6 week) aneurysm protocol has revealed that CaCl2 application 
results in an increase in aortic diameter of 60-70% in WT mice, which is similar to 
that seen in TG2- and FXIII-A deficient animals. In contrast to our expectations, the 
DKO animals surviving to harvest showed a smaller average increase in aortic 
diameter of just 40%, below the 50% threshold of “aneurysm” development. Sub-
group analysis has determined that this lower % diameter change may reflect a 
lesser propensity to develop aneurysms in the DKO group, i.e. more mice are in the 
“non-AAA group” than in the “AAA” group. The average size of vessel in each sub-
group does not differ significantly across genotypes although the TG2-/- mice did 
show a trend towards developing bigger “non-aneurysms” at 6 weeks. If propensity 
to aneurysm development really is different in the DKO mice this could reflect an 
intrinsic difference in baseline structure, for example a greater elastin content or a 
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resistance of elastin to injury. Given that elastin is a known substrate of TG2, one 
might hypothesize that TG2-deficiency would result in elastin that is less well cross-
linked and hence more vulnerable to degradation and loss. Our baseline studies 
suggest that aortas from the DKO mice have “normal” amounts of elastin but 
instead have decreased cellularity and show low-level fibrotic change. Histological 
analysis has shown that the DKO injured vessels have a higher proportion of 
“damaged but intact” elastin fibres than vessels from the other genotypes and 
hence we believe that the DKO mice are relatively resistant to aneurysm 
development secondary to a relative resistance of elastin fibres to breakage. This 
may be due to aortic fibrosis or because of an as yet undetermined change in 
elastin fibre structure. 
We had anticipated that collagen deposition would be increased in our post-injury 
vessels as a compensatory response to elastin damage. Although we have not 
quantified collagen content post-operatively, our initial analysis shows that collagen 
density actually decreases as the degree of elastin damage increases. 
Mechanistically this loss of collagen could facilitate inflammatory cell infiltration 
leading to elastin fibre damage. Alternatively, collagen loss could occur secondary 
to the recruitment of invading macrophages attracted by the presence of elastin 
degradation products.   
In our work we have shown a clear correlation between elastin damage and medial 
calcification in the CaCl2 model. This relationship has been investigated previously 
by Basalyga et al (Basalyga et al., 2004) in rats. They showed that mural 
calcification occurred within one week of injury and that Ca2+ deposits associated 
with elastic fibres grew over time and resulted in connection of adjacent structures, 
elastic flattening and damage. They hypothesised that the increase in permeability 
seen in this model (measured using Evan’s Blue leakage) could be responsible for 
Ca2+ influx into the vessel wall. If this was the case then we might expect to see a 
greater degree of calcification (and elastin damage) in our FXIII-A-/- and DKO mice, 
which have higher basal endothelial permeability, but this was not observed, 
suggesting that calcification occurs prior to an increase in permeability. 
Of significance is the fact that we have seen evidence of medial calcification in all of 
our transgenic lines at 6 weeks and in WT and TG2-/- groups at 6 months. Vascular 
calcification is seen in aging, in Diabetes Mellitus and in renal failure, yet remains 
poorly understood. TG2-/- has been reported to be a key regulator of vascular 
calcification, acting via β-catenin signalling to mediate osteoblastic transformation 
of VSMCs.(Faverman et al., 2008) TG2 inhibitors have been shown to prevent 
vascular calcification (Beazley et al., 2013, Beazley et al., 2012) and NIH-funded 
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projects are in progress to investigate the role of TG2 in vascular calcification in 
chronic kidney disease (CKD). Likewise, TG2 and/or FXIII-A activity has been 
implicated in the ectopic calcification seen in atherosclerotic lesions,(Johnson et al., 
2008a, Matlung et al., 2009) with parallels drawn with their postulated roles in bone 
development and mineralisation. Work from our group (and supported by this 
thesis) has shown that bone development is normal in mice lacking both TG2 and 
FXIII-A (Cordell et al., 2015) and that chondrocytic metaplasia (the precursor of 
plaque calcification) of atherosclerotic lesions can occur in TKO animals (although 
they develop smaller brachiocephalic lesions than either WT or single-TG deficient 
mice – paper in preparation). The results presented here clearly demonstrate that 
in-vivo vascular calcification in response to arterial injury can also occur “normally” 
in the face of dual TG-deficiency.  
We have not found any evidence that the short-term CaCl2 model significantly 
changes transglutaminase expression in the WT aorta and specifically we have not 
seen evidence of TG2 upregulation as previously reported by Munezane et al in a 
combined elastase/CaCl2 model.(Munezane et al., 2010) Likewise the absence of 
TG2 or FXIII-A did not induce upregulation of the alternate enzyme in the context of 
vessel injury. Quantitative real-time PCR did reveal that expression of TG7 was 
increased in injured vessels from FXIII-A-/- and DKO vessels (by ~18-fold) which 
may reflect attempts at compensation. Increases in TG7 were also seen in both WT 
and TG2-/- mice subject to the 6 month CaCl2 protocol and although expression was 
not at the level of TG2 expression, may provide evidence for cooperative action of 
these enzymes which has not been previously reported. Further assays, including 
Western blotting, are needed to confirm the presence of increased TG7 protein 
(rather than just mRNA) in the aorta, as well as the presence of transglutaminase 
activity, which would be required for functional compensation.  
Other expression data has shown that fibrillin-2, HO-1 and uPA expression are 
increased in all of the transgenic groups following injury, although not in the WT 
injured vessels when compared to baseline. Increased fibrillin-2 may reflect 
attempts at stabilising or repairing the damaged elastin media, whilst upregulation 
of (macrophage) HO-1 expression has been reported to have a protective anti-
inflammatory action against AAA in both humans (Schillinger et al., 2002) and in a 
rat elastase model. (Nakahashi et al., 2002) Alternatively, the higher levels of 
expression of HO-1 (particularly in DKO mice) could reflect upregulation due to the 
presence of haem from “leaky” vessels. This process is known to occur in heart 
failure, when increased pulmonary vascular permeability leads to haemosiderin 
accumulation in siderophages or “heart-failure cells”. HO-1 expression and activity 
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has been shown to be increased in the lungs of rats exposed to a volume overload 
model of heart failure.(Lam et al., 2005)  Although we did not see differential HO-1 
expression in baseline vessels, the CaCl2 model is known to increase aortic 
endothelial permeabiity (Basalyga et al., 2004) and hence DKO mice might be seen 
to have a “double hit” in terms of vessel permeability which could increase haem 
leakage and promote HO-1 expression.  
Interestingly, the gene transcripts that were changed in the DKO mice in the short-
term model were also those that were altered in the WT (and TG2-/-) mice in the 6 
month protocol. Hence, for example, α-SMA was decreased (along with structural 
proteins such as collagen (I and II) and vimentin, whilst fibrillin-2, HO-1 and uPA 
were again all increased. It appears, therefore, that the gene expression profile of 
the DKO mice at 6 weeks seems to be reflecting an insult similar to that 
experienced by the WT mice at 6 months; as if they are having an accelerated 
response to injury, or are more “injured” basally. Despite this, the DKO mice do not 
show greater aneurysmal dilatation; we hypothesise that the fibrotic change of the 
vessels in these animals is masking the normal inflammation and dilatation that 
might be expected. 
We found no change in expression of MMP-2 and -9, either between un-operated 
and operated samples in WT mice or between genotypes in the short-term model. 
MMP-2 levels were decreased in the long-term model, although again there was no 
difference between WT and TG2-/- mice. MMP-9 levels did not differ across any of 
the experimental conditions or genotypes investigated. Whilst this appears to 
conflict previous work which has shown that MMP-2 or -9 deficient mice have 
attenuated or absent aneurysm formation (Longo et al., 2002, Pyo et al., 2000a) it 
might be that these enzymes are required for initiation of aneurysm formation 
and/or early growth, but that once established do not play a role in this model. 
Alternatively, given that the source of MMP-9 is probably due to both increased 
production by VSMCs and release from infiltrating macrophages, this model, which 
appears to cause VSMC apoptosis/de-differentiation) may not result in the 
increased MMP-9 expression that has been reported in human samples.(McMillan 
and Pearce, 1999) 
Interestingly, MMP-12 expression was detectable in the aortas of the transgenic 
mice (but not WT), was increased in WT mice in the short-term model, and was 
greatly increased in the injured aortas of TG2-/-(4.5-fold), FXIII-A-/-(13-fold) and DKO 
(8-fold) mice at 6 weeks. Likewise, the 6 month model resulted in dramatic 
increases (400-fold) in MMP-12 expression compared to baseline in both WT and 
TG2-deficient animals. Infiltrating macrophages, the source of MMP-12, are known 
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to respond to the presence of elastin fragments and/or degradation products which 
act as a chemoattractant to these inflammatory cells. The cross-linking role of TG2 
could hypothetically stabilise elastin and inhibit this chemokinesis and therefore 
could reduce MMP-12 production (and further ECM breakdown) as shown in Figure 
69. However, we have not seen large differences in MMP-12 expression between 
the WT and TG2-/- mice at 6 months and have seen equally large increases in 
MMP-12 expression in the single deficient FXIII-A-/- mice. This implies that there are 
multiple mechanisms resulting in macrophage infiltration (and MMP-12 release). 
Equally, this model may represent too severe an insult and thus the normal 
protective role of TG2 is overwhelmed. We have immunohistochemical data which 
has not yet been fully quantified but which appears to show increased staining for 
MMP-12 in the DKO injured vessels in the adventitia and surrounding inflammatory 
tissue. Clearly more work is needed to tease out the role of MMP-12 in this animal 
model, its relevance to the human situation and the relationship between MMP-12 
and the transglutaminases. 
The CaCl2 model is poorly characterised in terms of its longer-term effects. This, 
combined with an increasingly widespread view that aneurysm initiation and 
progression occur by different mechanisms, has prompted us to investigate the 
histological and mRNA changes that occur in the CaCl2 model after a 6 month 
period. Ideally we would have liked to study this protocol in all four experimental 
groups however when this was established we had not determined that the DKO 
mice show a decreased propensity to aneurysm development (which may or may 
not persist with increased exposure). Also, the high mortality of the FXIII-A-/- and 
DKO mice would have meant that prohibitively large numbers of mice would have 
been required to generate meaningful data. The results from this extended protocol 
show that the C57Bl/6 mice appeared to remain static between 6 weeks and 6 
months, both in terms of % diameter change and aneurysm proportion. In contrast, 
the TG2-/- mice developed larger aneurysms and almost all animals developed an 
“aneurysm” as defined previously. This is unusual as the CaCl2 model usually only 
generates an aneurysm in 50-60% of control mice (using 0.25M or 0.5M CaCl2 
(personal communication, Baxter group, Nebraska)) and suggests that the TG2-
deficient mice are different in terms of their propensity to develop aneurysms. The 
larger average diameter of the TG2-/- “aneurysm” group, may also reflect a 
difference in terms of progression of disease, or a failure of the ability to repair 
damage in these mice.  
As yet we have not been able to fully identify the mechanism behind why the TG2-
deficient mice show increased aneurysm development – expression data is not 
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statistically different between the genotypes, and histology – as assessed by elastin 
breakage scoring – is also not different between the groups. This suggests that the 
results observed in the long term model in the TG2-/- and C57Bl/6 mice are 
occurring via a different mechanism to that observed in the DKO mice in the short-
term model. This is predictable, as if the CaCl2 injury is sufficient to cause elastin 
breakage (which it does in all genotypes) then it would seem unlikely that TG2 
could cause complete repair of these fibres. If TG2 is facilitating repair, or vascular 
remodelling, then it would seem likely that this would occur through mechanisms 
outside of the vessel media, similar to those seen in the inward remodelling 
response to reduced blood flow.(Bakker et al., 2005, Bakker et al., 2006) 
Interestingly, the TG2-/- vessels exposed to CaCl2 and harvested at 6 months do 
appear to show lower collagen density, this requires formal quantification but may 
contribute to the continued expansion and larger aortic diameters seen in this 
group. 
Of primary importance for future work is the finding that the carotid aneurysm model 
generates similar differences in vessel diameter between the WT and DKO groups 
as are seen in the aortic model, but without the associated high mortality. We plan 
to validate our histological and mRNA expression findings at this alternative 
anatomical site so that planned future work can be carried out in the carotid artery 
and can be easily compared with the findings presented here. 
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Figure 69. Proposed relationship between TG2 and MMP-12 in AAA formation 
Schematic highlighting the potential relationship between TG2 and MMP-12 in AAA formation. The CaCl2  injury model promotes 
elastin damage and ECM degradation which results in the generation of elastin fibres and EDPs which are known to be chemotactic to 
inflammatory macrophages. Through up-regulation of TG2, the production of elastin fragments could be reduced and hence 
macrophage  infiltration could be limited with a subsequent reduction in MMP-12 release. This mechanism could potentially reduce  
further ECM degradation and could stabilise the  vascular injury induced by this experimental model.
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Chapter 8: Discussion and Future Work 
8.1 Original research question  
The aim of this project was to elucidate the roles of TG2 and FXIII-A in basal vessel 
structure and function, and secondly, to study the contribution of these enzymes to 
aneurysm progression and development.  
There is a wealth of literature proposing the involvement of TG2 in cardiovascular 
pathology with suggested roles in arterial remodelling,(Bakker et al., 2005) 
atherosclerosis (Haroon et al., 2001) and arterial calcification,(Faverman et al., 
2008) amongst others. Equally, FXIII-A has been purported to have roles in vessel 
remodelling,(Bakker et al., 2006) repair after myocardial infarction (Nahrendorf et 
al., 2006) and in the maintenance of vascular permeability,(Noll et al., 1999b, 
Wozniak et al., 2001) in addition to its well established clotting function. Many 
authors suggest that these two enzymes are complementary and that one enzyme 
can compensate for the other in the face of deficiency. Essential functions for this 
transglutaminase pair have been proposed in the skeletal system (in bone 
development and calcification (Tarantino et al., 2009)) and in the cardiovascular 
system (in atherosclerotic plaque calcification (Van Herck et al., 2010) and inward 
arterial remodelling (Bakker et al., 2006)). Despite these assertions, we found that 
mice deficient in TG2 show no difference in atherosclerotic plaque formation or 
composition (Williams et al., 2010) and that those lacking both enzymes 
demonstrate no gross phenotypic change and normal bone development.(Cordell et 
al., 2015) Work currently in preparation has also revealed that although double-
deficient mice (on an ApoE-/- background) develop smaller atherosclerotic lesions in 
the brachiocephalic artery, these plaques show cartilaginous metaplasia (the 
precursor stage to plaque calcification) at a rate similar to WT lesions of a 
comparable size.  
As an alternative to fat-feeding, these TKO (TG2-/-.FXIII-A-/-.ApoE-/-) mice were, in 
previous studies, subject to carotid ligation as a model for atherosclerosis, local 
vessel remodelling and neointimal formation. This unexpectedly gave rise to fatal 
carotid artery rupture, suggesting an intrinsic vessel weakness in TKO animals. 
Histological analysis of ligated vessels from mice lacking either ApoE and TG2 or 
Apo E and FXIII-A and from sham-operated vessels in the TKO mice suggests that 
under basal conditions both TG2 and FXIII-A contribute to arterial integrity but that 
TG2 is more important under conditions of vascular stress or injury. Given that the 
vessels from TG2-deficient mice in this study showed medial elastin breaks and 
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luminal area expansion – both features of aneurysm development – we sought to 
investigate the role of these enzymes in the CaCl2 model of aneurysm 
development. 
Various animal models have been developed to allow study of the early stages of 
aneurysm development and evaluation of potential therapeutic targets. The relative 
advantages and disadvantages of the three main murine models have been 
discussed in the Introduction but briefly, we chose the CaCl2 model because it can 
be undertaken in both male and female mice, does not require a hyperlipidaemic 
background (which had concerned reviewers of our original funding application) and 
more accurately represents the human situation in terms of anatomical site, elastin 
breakdown, and vascular inflammation.(Wang et al., 2013a) Over the course of this 
project we have established and optimised this model and it has already been used 
by other groups in our Institute in work investigating the role of the Orai1 calcium 
channel in AAA development.(Bailey et al.) 
This thesis has shown that, despite reservations in the literature,(Freestone et al., 
1997) the calcium chloride model results in true luminal expansion (and not just 
peri-adventitial inflammation and thickening) and, surprisingly, demonstrated that 
collagen density is reduced at sites of elastin damage. We were expecting to find 
that the model induced collagen deposition at areas of elastin loss/damage, to 
reinforce the arterial wall, however this was not the case on histological analysis. 
Collagen loss could precede inflammatory cell infiltration, facilitating cell migration, 
or could occur subsequent to macrophage recruitment triggered by the presence of 
elastin degradation products.  
Given the essential role that has been proposed for TG2 in ectopic calcification, an 
important finding from this work is that TG2-/-, FXIII-A-/- and DKO mice all show 
calcification of the aortic media in association with elastin fibre damage. This 
calcification is not present at 24 hours post injury, and hence is not due to CaCl2 
exposure directly, but occurs as a consequence of the inflammatory response 
generated by the injury model. Whether this process reflects the human situation is 
unclear, however this model represents a reproducible injury which should, if the 
literature is correct, induce transglutaminase activity. The results presented here 
demonstrate that in-vivo vascular calcification in response to arterial injury occurs 
“normally” in the face of dual TG-deficiency and thus challenges a view held by 
several influential papers within the field of transglutaminase research.  
Despite the distinct mechanisms of activation of FXIII-A and TG2 – plasma FXIII-A 
is activated by thrombin cleavage whereas extracellular TG2 becomes catalytically 
active on reduction of key residues – many have suggested that these enzymes 
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can act interchangeably or can compensate for each other. Whilst our previous 
work has not shown any evidence of reciprocal mRNA upregulation between TG2 
and FXIII-A (Cordell et al., 2015) this, and other findings, were complicated by the 
presence of additional ApoE deficiency. An important outcome from this thesis is 
the generation of a TG2-/-.FXIII-A-/- KO mouse on a defined C57Bl/6 background 
which will enable further study of the relative contributions of these two enzymes to 
normal physiology as well as to the development of disease.  
As expected, this DKO mouse had a grossly normal cardiovascular phenotype and 
this work has demonstrated no evidence for TG2/FXIII-A upregulation in the aorta, 
either at baseline, or after short- or long-term injury. Interestingly we have observed 
upregulated transcription of TG7 (which is relatively unstudied) in the injured 
vessels of FXIII-A-/- and DKO mice at 6 weeks, and in TG2-/- and WT mice at 6 
months. These findings require additional confirmatory work but may provide 
evidence of a previously unreported role for TG7 in vascular  injury. 
Our previous work has suggested that FXIII-A is important in the maintenance of 
arterial integrity. Lack of FXIII-A leads to impaired vessel integrity or increased 
“leakiness” that results in insipient haemorrhage and haemosiderin deposition. This 
in turn triggers an inflammatory response that ultimately results in cardiovascular 
fibrosis. We hypothesised that TG2 can compensate for FXIII-A deficiency under 
basal conditions, either through a vascular stabilising function or through a 
subsequent repair function. The findings from this thesis supoort this and DKO mice 
show more cardiac fibrosis (and higher surgical mortality) than single-FXIII-A-
deficient animals, although deficiency of FXIII-A alone is sufficient to result in 
increased endothelial permeability in the aorta. 
This finding has three important consequences; firstly the observation that FXIII-A-/- 
and DKO mice spontaneously develop mild cardiac fibrosis without the need for a 
hypercholesterolamic background or high-fat feeding means that we have identified 
a potential pre-clinical model of fibrosis which can be used in future studies. 
Secondly, FXIII-A is currently considered to be a viable anti-thrombotic target 
because of its role in fibrin-cross-linking and clot stabilisation. Whilst the literature 
emphasises the need for any FXIII-A inhibitor therapy to be “specific and targeted” 
to prevent bleeding complications,(Richardson et al., 2013) our work highlights a 
potential side-effect of FXIII-A inhibition that has not previously been considered. 
Thirdly, TG2 has been proposed to be involved in the development of fibrosis in 
response to injury in various organs.(Johnson et al., 2003b, Olsen et al., 2011a, 
Grenard et al., 2001) Despite this, we have found that mice lacking TG2 in addition 
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to FXIII-A show increased fibrotic change rather than the relative improvement in 
pathology that might be expected from reading of the literature. 
Under conditions of carotid artery ligation, the TG2-/-.ApoE-/- mice showed increased 
elastic lamellar number, increased elastin breaks and increased medial area. 
Likewise, our DKO mice showed increased elastic lamellar number and a lack of 
the expected inward vessel remodelling. These findings could be due to a baseline 
deficiency in medial elastin (and an attempt to increase tropoelastin formation as 
compensation), or could be secondary to a failure of the normal vascular repair or 
remodelling functions which have been attributed to TG2.(Bakker et al., 2005, 
Bakker et al., 2008)  We have not found evidence of basal deficiencies in elastin 
content, structure or function in the aortas of our TG2-deficient mice, but our long-
term aneurysm model results suggests that TG2 knock-out results in a failure to 
stabilise the injured aorta and progression of arterial dilatation.  
Surprisingly, we have found that our DKO mice were less susceptible to aneurysm 
formation. From the carotid artery rupture and mortality seen in the TKO mice, we 
had assumed that these mice would have weaker vessels that were more liable to 
show aneurysmal change. Whilst there are certainly intrinsic differences in the 
aortas from these mice (as shown by their decreased tension on myographic 
testing) they appear to be relatively resistant to elastin breakage and subsequent 
dilatation. We hypothesise that this is due to basal fibrotic change in these vessels 
which occurs as shown in Figure 70. This relative “protection” is outweighed by the 
increased mortality in these animals which seems to occur with the addition of any 
additional cardiovascular stress (e.g. fat feeding, ApoE deficiency, ligation or 
prolonged surgery) and may be due to unmasking of an as yet unqualified cardiac 
phenotype secondary to vascular or myocardial fibrosis.  
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Figure 70. Cardiac fibrosis and increased mortality 
Schematic of possible pathway linking FXIII-A deficiency, observed cardiovascular 
fibrosis and increased mortality rate. 
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8.2 Limitations 
Although this work has generated several key findings related to the role of 
transglutaminases in vascular integrity and repair and aneurysm formation; there 
are a number of limitations which need to be considered.  
As with any transgenic mouse model these results need to be interpreted with 
caution. The literature is littered with examples of gene knockouts which have 
widely varying effects in humans when compare to their murine counterparts. For 
example, PAI-1 deficiency in humans is rare and causes severe bleeding whereas 
serpine-1 (the mouse ortholog) knock-out mice are viable and able to reproduce 
with no increased tendency to bleed.(Iwaki et al., 2012, Iwaki et al., 2011) Likewise, 
Shapiro has discussed some of the pitfalls of the use of transgenic mice in research 
into emphysema and COPD,(Shapiro, 2007) where complexities in the genetic 
locus for mouse α-1-AT are such that mice have either 4 or 5 genes depending on 
their strain. These examples highlight that murine models can only ever represent 
the human situation and not reflect it entirely.  
An important example here, which may be very relevant to our work, is that of 
elafin, an inhibitor of neutrophil elastase (NE), that is present in humans but lacking 
in mice. NE can promote ECM degradation, has potential roles in aneurysm 
formation as well as atherosclerotic plaque disruption and has recently been 
proposed to be the link between inflammation and insulin resistance.(Mansuy-
Aubert et al., 2013, Talukdar et al., 2012) Clearly the ability to inhibit NE has huge 
therapeutic potential and in retrospect it seems surprising that so many murine 
atherosclerosis studies have been undertaken without acknowledgement of the lack 
of elafin and attempts to extrapolate to the human situation. Our plan to study this 
further is outlined below. 
The unexpectedly high mortality of the CaCl2 aneurysm model in mice lacking the 
FXIII-A gene has obvious implications in terms of mouse numbers, time, and 
associated breeding, husbandry and operating costs. However, operating on these 
mice still provided important data, both in terms of their propensity to aneurysm 
development and their causes of death. Although we were able to examine the 
majority of mice post-mortem there were a small number found dead by animal 
house staff, and in some cases mice were examined but no obvious pathology 
could be found. This highlights some of the difficulties of murine work, but >1/3 of 
deaths were able to be attributed to cardiac causes and/or distal thromboembolic 
events. It would be valuable to be able to establish whether these events are the 
result of primary atrial thrombus and one could imagine that continuous cardiac 
monitoring could identify problems with cardiac physiology that are as yet unknown. 
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We have previously attempted to insert intra-vascular telemetry devices into our 
DKO animals but they are prone to acute, fatal, cardiac dysfunction and alternative 
methods would need to be sought for this to be a viable avenue of future study.  
The application of CaCl2 to the ventral surface of the abdominal aorta promotes 
significant inflammation and scarring. Whilst this is to be expected, and can be 
dissected to allow vessel diameter measurements and vessel harvesting for mRNA 
analysis etc., it is difficult to ensure that only the vessel itself is harvested and that 
variable amounts of fibrotic/inflammatory tissue are not processed at the same time. 
This has implications for the analysis of post-operative aortic collagen and elastin 
content and means that we will need to adopt a morphological approach to obtain 
meaningful data because of the potential heterogeneity of samples.  
8.3 Future directions 
We have identified that the application of CaCl2 to the common carotid artery is a 
viable alternative injury model which appears to be well tolerated in our DKO mouse 
line. Although we have characterised this model in terms of morphological and 
histological outcomes we also made attempts to extract mRNA from un-operated 
and post-injury carotid vessels using the methodology as previously outlined. 
Insufficient mRNA was obtained from single vessels using the Trizol extraction 
process to allow reverse transcription to cDNA and hence in the future, multiple 
samples will need to be pooled to allow changes in gene expression to be 
quantified.  
Such mRNA data is difficult to interpret without supporting evidence of changes in 
protein levels, however, we have identified some important trends in aortic mRNA 
expression across the genotype groups. Alpha-smooth muscle actin expression 
was decreased in all groups following calcium chloride injury, presumably as a 
result of VSMC loss or de-differentiation, but was more decreased in FXIII-A-/- mice 
and further still in DKO animals. This could suggest that the calcium chloride model 
causes a greater degree of VSMC apoptosis in these lines or that they have 
decreased cellularity prior to injury (as is suggested from our basal biochemistry 
data). Work to confirm these findings and investigate them further is currently in 
progress and we are attempting to optimise a TUNEL assay of apoptosis to allow 
quantification of cell death in our aneurysm histological samples. 
The finding that TG2-/- mice develop larger aneurysms than control animals in a 6 
month model of injury could be explained by 1) an intrinsic vessel weakness only 
manifest after prolonged injury, i.e. a protective role for TG2, 2) a lack of vascular 
repair  normally present, i.e. a reparative role for TG2 or 3) both of these 
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mechanisms. Further work is necessary to elucidate the mechanisms by which TG2 
appears able to effect stabilisation in this model but could include the cross-linking 
of collagen and other structural proteins, or interaction with fibronectin and other 
integrins. The ability to assay collagen density in our samples would be useful in 
this work – at present we are able to qualitatively assess collagen distribution but 
hard calibration of our multiphoton microscopy would be required for quantification. 
Alternatively, use of the periadventitial elastase model may provide complementary 
results if it results in less scar tissue and allows for direct post-injury measurement 
of collagen (and elastin) content in harvested vessels.   
There is an increasingly prevalent view that TG2 functions predominantly as a 
structural protein and is usually inactive in terms of its transamidating activity. The 
work presented here assumes that murine extracellular TG2 can be (and is) 
activated in response to vessel injury, which may not be the case in mice. 
Constitutive activation of TG2 would allow assessment of the intrinsic vascular 
repair activity of TG2, if present. The transgenic TG2R579A/R579A mouse does not 
require GDP binding for activation and hence shows constitutive transamidating 
activity intracellularly (and presumably extracellularly if it can be secreted/released). 
This line has been utilised in the study of the role of TG2 in glucose homeostasis 
(Iismaa et al., 2013) but full characterisation has not been reported. Its use in 
studies similar to ours may prove crucial to attempts to delineate the 
transglutaminase function of TG2 from its other pleiotropic roles in the setting of 
vascular repair. 
Our FXIII-A-/- mice (both male and female) develop spontaneous myocardial fibrosis 
without the need for high fat-feeding or background hyperlipidaemia. If, as 
suspected from their normal unstressed phenotype, these mice lack any limiting 
cardiac pathology, this would represent a useful model to assess potential novel 
therapies. Although the morphology of fibrotic change in our mice is similar to that 
seen in virally-induced fibrosis, cardiac fibrosis is seen in hypertensive heart 
disease, secondary to diabetes and in the response to myocardial ischaemia. If 
FXIII-A deficiency results in spontaneous fibrosis, exogenous FXIII-A administration 
may be a viable option for treating fibrosis in a number of disease states. Further 
work is planned to assess the relative contributions of plasma vs. cellular FXIII-A to 
this process, whilst also extending our work investigating the cellular source of 
plasma FXIII-A, which we hypothesise to be a resident macrophage located with 
the cardiovascular system.   
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Although many of these research streams will be devloped in parallel, we initially 
plan to investigate the role of elafin in vascular repair and a full discussion of this 
work is outlined below. 
8.3.1 Elafin/trappin-2 
MMP-12, or macrophage elastase, produced by infiltrating macrophages is key to 
the later stages of aneurysm development and progression and our 
immunohistochemical data provides evidence of MMP-12 in inflammatory tissue 
surrounding injured vessels. However, some authors suggest that neutrophils may 
play a prominent role in the early phase of aneurysmal development (Tilson, 2005, 
Eliason et al., 2005a, Hannawa et al., 2005) and hence it would seem likely that 
neutrophil elastase is a viable target for study and therapeutic inhibition. 
Neutrophil elastase is covalently inactivated by serpins and, in addition, is non-
covalently inhibited by trappin-2 (pro-elafin). Trappin-2 has a repeated cementoin 
domain that enables it to be covalently cross-linked by transglutaminases to ECM 
proteins including collagen IV, fibronectin and elastin.(Guyot et al., 2005) Cross-
linking confers localised protection against proteolysis, most obviously at the site of 
synthesis and secretion but possibly also following circulation in the bloodstream 
and capture at distal sites. Cleavage of the cementoin domain from trappin-2 yields 
elafin, an anti-protease that has a single potential cross-linking site.(Tsunemi et al., 
1996) This may allow it to be covalently retained in the ECM but presumably with a 
reduced efficiency relative to trappin-2.   
Elafin expression has been reported in T-lymphocytes, and in inflammatory cells in 
atherosclerotic plaques. Elafin/trappin-2 has considerable therapeutic potential, 
(Shaw and Wiedow, 2011) has narrow anti-protease specificity and diffuses well 
into affected tissues.(Doucet et al., 2007, Sallenave, 2010)  A single clinical trial has 
been undertaken to assess the capacity of elafin to reduce inflammation following 
coronary artery bypass grafting (Alam et al., 2015) and further Phase II trials are 
investigating its use in kidney transplantation and following oesophagectomy.  
Mice lack an ortholog of trappin-2, i.e. they do not have an elastase inhibitor that is 
retained in tissues.(Williams et al., 2006) In some studies, mice (and larger species) 
have been locally infected with trappin-2 expressing adenoviruses and these have 
been shown to protect against lung (Simpson et al., 2001) and genital 
infections,(Drannik et al., 2013) or with trappin-2 expressing lactobacilli that protect 
against inflammatory bowel diseases.(Motta et al., 2012) In addition, transgenic 
mice have been constructed where trappin-2 expression is driven by the CMV 
promoter and these animals express strongly in epithelial tissues similar to the 
- 227 - 
expression of the endogenous human gene.(Sallenave et al., 2003) Collaborations 
are already in place to utilise these mice in our planned work. 
Mice have also been constructed that express trappin-2 in vascular tissues under 
the control of the pre-proendothelin promoter, and these mice are protected against 
myocardial fibrosis following viral myocarditis (Zaidi et al., 1999) or coronary 
ligation.(Ohta et al., 2004) However, while localized over-production of elafin can 
provide cardiovascular protection, it is not clear whether (i) endogenously 
synthesized elafin, from epithelial tissues or exogenously administered trappin-2 
can be captured and retained in cardiovascular lesions, or (ii) production by 
macrophages in cardiovascular lesions affords local protection.   
Whilst this work, and that published by our group relating to atherosclerosis in the 
TKO mice (Williams et al., 2010) suggest that TG2 cross-linking of the ECM per se 
has little effect on mouse models of early aneurysm and atherosclerosis, it may be 
that the protective effect of TGs will only be adequately reproduced where trappin-2 
is present, i.e. that a major role of induced and activated TGs in response to injury 
is to capture and retain circulating trappin-2. We are planning a programme of work 
in which trappin-2  will be administered to TG2 expressing and TG2 knockout mice 
and aneurysm development will be assessed. Atherosclerosis and the possible role 
of FXIII-A in trappin-2 retention will be assessed in subsequent projects if trappin-2 
proves protective against aneurysm development.   
8.4 Clinical and translational implications 
This work adds to the understanding of the pathobiology of aneurysm development 
and crucially provides additional knowledge about one of the key animal models in 
use in aneurysm research. We have not found clear evidence of a vascular 
protective effect of TG2, however important evidence supporting its role in vascular 
repair is presented. The clinical implications of this work more likely pertain to the 
use of TG2 and FXIII-A inhibitors which are currently under investigation for a 
variety of conditions. A better understanding of the potential side-effects of these 
inhibitors (for example in terms of cardiac fibrosis or vessel integrity) is important if 
future treatments are to be safe and effective. 
8.8 Conclusions  
In summary, there are several main conclusions to be drawn from this thesis. Both 
FXIII-A-/- and TG2 have roles in the maintenance of basal vessel integrity. Whilst 
endothelial permeability is increased in both FXIII-A-/- and DKO mice, and both 
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groups show evidence of decreased aortic cellularity, the DKO group shows more 
cardiac (and likely aortic) fibrosis and the DKO mice show a functional deficit which 
is not seen with single gene deficiency. We have not seen evidence of a clear 
protective effect of TG2 in the response to aneurysm development however our 
DKO animals showed an unexpected decreased propensity to aneurysm 
development at 6 weeks. These data may be explained by increased basal fibrosis, 
however both FXIII-A and DKO mice are at risk of increased mortality through a 
presumed cardiac mechanism. This finding has important implications given that 
inhibition of one or both enzymes has been proposed as a potential target for 
conditions as diverse as thrombosis, neurodegeneration and cancer. 
In an extended aneurysm model there is evidence that aneurysm initiation and 
progression occur by different mechanisms and that TG2 is involved in vessel 
repair or stabilisation of injury. This project has provided evidence that vascular 
calcification can progress normally in the presence of dual TG2 and FXIII-A 
deficiency and we have seen no evidence for reciprocal enzyme compensation 
although TG7 may be upregulated under conditions of vascular injury.  
Finally, we have established the CaCl2 model of aneurysm formation, a novel TG2
-/-
.FXIII-A-/- mouse line has been generated and initial characterisation of this line has 
been undertaken. The ability to study the distinct and overlapping roles of TG2 and 
FXIII-A in the cardiovascular system, without associated ApoE deficiency, is now 
possible, and these mice represent an important, previously unpublished, research 
tool in the field of transglutaminase study. 
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List of Abbreviations 
5-LO  Lipoxygenase-5 
α-1-AT  α-1-antitrypsin 
α-2-PI  α-2-plasmin inhibitor  
AAA  Abdominal aortic aneurysm 
AAAP  Aortic aneurysm associated protein 
ACEi  Angiotensin converting enzyme inhibitor 
ADAM  A disintegrin and metalloproteinase 
ADAMTS A disintegrin and metalloproteinase with thrombospondin motifs 
AGEs  Advance glycated end-products 
AGM  Aorto-gonadal mesonephros 
AIE  Anion exchanger 
AIF  Apoptosis inducing factor 
ALS  Amyotrophic lateral sclerosis 
Ang II  Angiotensin II 
ApoE  Apolipoprotein E 
APSS  Acral peeling skin syndrome 
ARB  Angiotensin-II receptor blocker 
AT  Angiotensin (receptor) 
AU  Arbitrary units 
AUC  Area-under-the-curve 
BAX  Apoptosis regulator BAX, also known as Bcl-2-like protein 4 
BBB  Blood-brain barrier 
BMP  Bone morphogenic protein 
BP  Blood pressure 
BSA  Bovine serum albumin 
CaCl2  Calcium chloride 
CCR2  C-C chemokine receptor type-2 
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CD  Coeliac disease 
cDNA  Complementary DNA 
CE  Cell envelope  
CI  Confidence intervals 
CKD  Chronic Kidney Disease 
CMP  Common myeloid precursor 
CMV  Cytomegalovirus 
COPD  Chronic obstructive pulmonary disease 
Co-Smad Common mediator Smad 
CREB  Cyclic AMP (cAMP) response element binding protein 
CTAD  Citrate theophylline adenine dipyridamol buffer  
CV  Cardiovascular 
DKO  Double knock-out (in relation to transgenic mice) 
DM  Diabetes Mellitus 
DNA  Deoxyribonucleic acid 
EBP  Elastin binding protein 
ECM  Extracellular matrix 
EDP  Elastin degradation product / Elastin derived peptides 
EDS  Ehlers Danlos Syndrome 
EDTA  Ethylenediaminetetraacetic acid 
EEL  External elastic lamina 
EF  Elastin fragment 
EGF  Epidermal growth factor 
ELISA  Enzyme-linked immunosorbent assay 
EMILIN Elastin microfibril interface located protein 
ESVS  European Society for Vascular Surgery 
Flt-3  FMS-like tyrosine kinase 3 
FXIII-A  Factor XIII-A 
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GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GMP  Granulocyte / macrophage precursor 
GTT  Glucose tolerance test 
GWAS  Genome-wide association study 
H&E  Haematoxylin and eosin 
HCl  Hydrochloric acid 
HIF  Hypoxia inducible factor 
HSC  Haematopoietic stem cell 
IEL  Internal elastic lamina 
IFN-γ  Interferon-gamma 
Ig  Immunoglobulin  
IGF-1  Insulin-like grwoth factor 1 
IL  Interleukin 
ILT  Intraluminal thrombus 
ITT  Insulin tolerance test 
IVC  Inferior vena cava 
JNK  cJun N-terminal kinase 
KO  Knock out 
LAP  Latency associated peptide 
LDL(R) Low-density lipoprotein (receptor) 
MAGP  Microfibril associated glycoprotein 
MANDP Metaphyseal anadysplasia  
MAPK  Mitogen activated protein kinase 
MDC  Monodansylcadaverine 
MEF  Mouse embryonic fibroblast 
MEP  Megakaryocyte / erythrocyte progenitor 
MI  Myocardial infarction 
miRNA/miR MicroRNA 
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MMP  Matrix metalloproteinase 
MODY  Maturity-onset diabetes of the young 
MP  Megakaryocyte precursor 
mRNA  Messenger RNA 
MyD88  Myeloid differentiation factor-88 
NAAASP National AAA screening programme 
NaCl  Sodium chloride (“normal saline solution”) 
NaOH  Sodium hydroxide 
NE  Neutrophil elastase 
NFκB  Nuclear factor kappa B 
NICE  The National Institute for Health and Care Excellence 
NOS  Nitric oxide synthase 
OR  Odds ratio 
PAI  Plasminogen activator inhibitor 
PAR-1  Protease/Proteinase activated receptor-1 
PBS  Phosphate buffered saline 
PCR  Polymerase chain reaction 
PDGF  Platelet derived growth factor 
Pf4  Platelet-factor 4 
PFA  Paraformaldehyde 
PGK  Phosphoglycerate kinase 
PI3K  Phosphatidyl-inositol 3 kinase 
PPE  Porcine pancreatic elastase 
pRb  Retinoblastoma protein 
PWV  Pulse wave velocity 
q-PCR  (quantitative) Real-time polymerase chain reaction 
RBC  Red blood cell 
RECK  Reversion-inducing cysteine rich protein with Kazal motifs 
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ROS  Reactive oxygen species 
Rpl-32            Ribosomal protein L-32 
R-Smad Receptor associated Smad 
SAS  Supravalvular aortic stenosis 
SDS  Sodium dodecyl sulphate 
SFA  Superficial femoral artery 
SLPI  Secretory leucocyte protease inhibitor 
SMA  Smooth muscle actin 
SMC  Smooth muscle cell 
SNP  Single nucleotide polymorphism 
SP1  Transcription factor SP1, also known as Specificity Protein 1 
TAA(D) Thoracic aortic aneurysm (+/- dissection) 
TAFI  Thrombin activatable fibrinolysis inhibitor 
TAK-1  TGF-β activated kinase 1 
TBS  Tris-buffered saline 
TF  Tissue factor 
TG  Transglutaminase 
TGF-β  Transforming growth factor-beta 
TGFβR TGF-β Receptor (types I and II) 
TIMP  Tissue inhibitor of metalloproteinases 
TKO  Triple knock-out (in relation to transgenic mice) 
TNF-α  Tumour necrosis factor-alpha 
TSP  Thrombospondin 
tPA  Tissue plasminogen activator 
tTG  Tissue transglutaminase (TG2) 
uPA  Urokinase plasminogen activator 
VEGF  Vascular endothelial growth factor 
VEGFR VEGF Receptor (types 1, 2 and 3) 
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VSMC  Vascular smooth muscle cell  
WT  Wild-type 
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Appendix A: Murine ear code identification system 
Mice within the CEU at the University of Leeds undergo ear notching to enable 
identification of individual animals housed within the same cage 
● = site of ear notching 
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Appendix B: Standard Solutions 
FXIII-A Activity Assay Reaction Mix 
Pre-diluted DTT (1mM stock) (Sigma, UK)    2.2mls 
Pre-diluted Biotin (3mM stock) (Pierce, Thermofisher, UK)  2.2mls 
100mM CaCl2        2.2mls 
Thrombin (250U/ml) (Calbiochem, UK)    87µl 
TBS (pH 8.3)        13.113mls 
Total Volume        19.8mls 
 
10X Tris-buffered saline (TBS), pH 8.3 
Tris         96g 
NaCl         163.6g 
Make up to 2 litres with dH2O and adjust pH to 8.3. Dilute 1 in 10 to give 1X stock 
solution with 40mM Tris and 140mM NaCl 
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Appendix C: Wire myography solutions 
Hanks pH7.4 (filter sterilise) 
Component Mw 
(g/mol) 
Conc. 
(mM) 
g/L g/500ml g/200ml 
NaCl 58.44 137 8.0063 4.0031 1.6012 
NaH2PO4
-2H2O 156.01 0.34 0.05304 0.02652 0.01061 
KCl 74.56 5.4 0.4026 0.2013 0.08052 
KH2PO4 136.09 0.44 0.05988 0.02994 0.01198 
Glucose 180.16 8 1.4413 0.7206 0.28824 
HEPES 238.3 5 1.1915 0.5957 0.2383 
CaCl2 110.98 0.01 0.00111 0.00055 0.00022 
 
Krebs pH7.4 (filter sterilise) 
Component Mw 
(g/mol) 
Conc. 
(mM) 
g/L g/500ml g/200ml 
NaCl 58.44 125 7.3050 3.6525 1.461 
KCl 74.56 3.8 0.2833 0.1416 0.05664 
NaHCO3 84.01 25 2.1002 1.0501 0.42004 
MgSO4
-7H2O 246.47 1.5 0.3697 0.1849 0.07394 
KH2PO4 136.09 1.2 0.1633 0.08165 0.03266 
Glucose 180.16 8 1.4412 0.7206 0.28824 
CaCl2 110.98 1.2 0.1332 0.0666 0.02664 
EDTA 292.24 0.02 0.0058 0.0029 0.00117 
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60K Krebs pH7.4 (filter sterilise) 
Component Mw 
(g/mol) 
Conc. 
(mM) 
g/L g/500ml g/200ml 
NaCl 58.44 68.8 4.02 2.01 0.804 
KCl 74.56 60 4.47 2.23 0.892 
NaHCO3 84.01 25 2.1002 1.0501 0.42004 
MgSO4
-7H2O 246.47 1.5 0.3697 0.1849 0.07394 
KH2PO4 136.09 1.2 0.1633 0.0817 0.03266 
Glucose 180.16 8 1.4412 0.7206 0.28824 
CaCl2 110.98 1.2 0.1332 0.0666 0.02664 
EDTA 292.24 0.02 0.00584 0.00292 0.00117 
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Appendix D: Histology – additional methodological detail 
4% Paraformaldehyde (for tissue fixation) 
Heat 800mls of distilled water to 40-45ºC, add 5 tablets of PBS and dissolve, 
keeping the solution at temperature. Add 40g of PFA and 6ml of NaOH and observe 
the solution clearing. Once clear, remove the solution from the hot plate and filter 
through filter paper. Allow the temperature to fall to approximately 22ºC and then 
top-up to 1litre final volume with water and adjust pH to 7.02-7.05 with HCl.  
 
Histology processing 
PFA-fixed samples were stored in 4% PFA for a minimum of 24 hours and then 
dehydrated using the Leica TP1020 tissue processing carousel (Leica 
Microsystems, UK) before paraffin embedding. All samples were subject to a 17 
hour processing programme as detailed below. 
1 70% Ethanol 30 minutes 
2 70% Ethanol 30 minutes 
3 70% Ethanol 30 minutes 
4 90% Ethanol 1 hour 
5 100% Ethanol 2 hours 
6 100% Ethanol 2 hours 
7 100% Ethanol 2 hours 30 minutes 
8 Histoclear 30 minutes 
9 Histoclear 1 hour 30 minutes 
10 Histoclear 1 hour 30 minutes 
11 Paraffin 1 hour 30 minutes 
12 Paraffin 2 hours 
 
 
Slide coating 
All microscopy slides were pre-coated prior to use. Briefly, slides were immersed in 
10% HCl in 100% ethanol for 1 minute, followed by 2 washes in distilled water, 
followed by immersion in 100% ethanol for 1 minute. The slides were then dried at 
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80ºC for 5 minutes before immersion in 2% TEPSA-acetone (for 20 seconds), 
100% acetone (for 1 minute) and then 2 washes in distilled water. Slides were then 
dried overnight at 60ºC and then left to cool prior to storage.  
 
Sirius Red solution 
Add 0.5g Sirius Red (Sigma Aldrich, UK) to 500ml of saturated aqueous solution of 
picric acid (Sigma Aldrich, UK).  
 
Aldehyde Fuchsin solution 
Add 1.35g of pararosanilin (Sigma Aldrich, UK) to 250ml of 60% EtOH and mix well. 
Add 2.4ml of paraldehyde and 3.75ml of HCl, mix well and set aside for 3 days. 
Filter solution and use only if metallic sheen present. Solution should be used within 
10 days. 
 
Alizarin Red solution 
Add 2g of Alizarin Red S (Sigma Aldrich, UK) to 100ml of distilled water and adjust 
pH to 4.1-4.3 with 10% ammonium hydroxide 
 
Potassium Ferrocyanide solution 
Add 12.5g of potassium hexacyanoferrate (II) 3-hydrate (PHF) (Sigma Aldrich, UK) 
to 250ml distilled water and stir. Add 237.5ml of distilled water to 12.5ml (40%) HCl 
and mix slowly; combine with PHF solution and leave overnight until solution has 
turned green. 
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Appendix E: Quantitative real time PCR primer sequences 
Gene 
Transcript 
Forward Primer Sequence Reverse Primer Sequence 
Elastin AAAGCCTGGGAAAGTTCCTG TACACCTGGAAGACCAACAC 
Collagen I ATGGATTCCCGTTCGAGTACG TCAGCTGGATAGCGACATCG 
Collagen III CACCCTTCTTCATCCCACTCTTA ACCAAGGTGGCTGCATCC 
Vimentin CGGAAAGTGGAATCCTTGCA CACATCGATCTGGACATGCTGT 
aSMA ACTGGGACGACATGGAAAAG GTTCAGTGGTGCCTCTGTCA 
MMP2 CTGATAACCTGGATGCCGTCGT TGCTTCCAAACTTCACGCTCTT 
MMP9 GTCTCGGGAAGGCTCTGCTGTT CTCTGGGGATCCACCTTCTGAG 
FXIII-A TGCTGGTGTCTTTAACACATTTTTAA TGGGCCGAGAATGAATTGGT 
TG1 TTCGCTACCCGTACCGTCA CTTCATCCAGCAGTCGTT 
TG2 ATTGGCAGTGTGGACATTC TCGTGGGCGGAGTTGTA 
TG3 AAGAAGCTGACCATGAGTGCTTT TGCGCCCTTCGATTCATAG 
TG4 CCCATCTATTTGACCATAACTTTGAA GCGAGAAACACCCTTGATT 
TG5 AGGCAGGATTCTGGAGAATATG GGGCCACAGCCACAGCAGTAGAG 
TG6 TCCGAGTCAATGTGAGCG GTCTTCTGTCAGGTCTCCTTTGTA 
TG7 ATGTGCACGGTAATGAGATGCT TGTGTGCAGAATGGAAATTGG 
CD163 ATGGGTGGACACAGAATGGTT CAGGAGCGTTAGTGACAGCAG 
tPA CAACAGCGGCCTGGTACAA CCCCATTGAAGCATCTTGGTT 
uPA GAAACCCTACAATGCCCACAGA GACAAACTGCCTTAGGCCAATC 
Perilipin CTGTGTGCAATGCCTATGAGA CTGGAGGGTATTGAAGAGCCG 
PAI-1 ACGGTGATGCGATATAATGTAAACG CATTCCTGAGAAACACAGCATTG 
Fibrillin 1 CCTGTGCTATGATGGGTTCA AGGTCCCACTAAGGCAGATG 
Fibrillin 2 CCACTCCTATTGCTGCCCAG TTGGGGCGGGAACAGAATC 
MT-MMP CCCAAGGCAGCAACTTCA CAATGGCAGCTGAGAGTGAC 
B-Actin CGTGAAAAGATGACCCAGATCA TCGTACGACCAGAGGCATACAG 
HO-1 AACAAGCAGAACCCAGTCTATG TGAGCAGGAAGGCGGTCTTA 
MMP12 GCTAGAAGCAACTGGGCAAC ACCGCTTCATCCATCTTGAC 
TIMP1 GTGGGAAATGCCGCAGAT GGGCATATCCACAGAGGCTTT 
TIMP2 CCAGAAGAAGAGCCTGAACCA GTCCATCCAGAGGCACTCATC 
TGFB CACCGGAGAGCCCTGGATA TGTACAGCTGCCGCACACA 
rpl32 AAAATTAAGCGAAACTGGCGG TGTTGCTCCCATAACCGATG 
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